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Figure legends 
 
Figure 1.8 Immunoglobulin G (IgG) antibodies, the most abundant of the 
immunoglobulins, are large molecules of about 150 kDa composed of 4 peptide chains.  
 
Figure 3.1.2 Cartoon models of CRP (ZD Net Healthcare, Accessed 18 January, 2009) 
and its homologous Serum Amyloid P (SAP) protein.  
 
Figure 3.1.4 SDS-PAGE gel of fractions from Protein A purification of rabbit anti-CRP 
pAb.  
 
Figure 3.1.5 (a) Checkerboard ELISA using purified rabbit anti-CRP polyclonal antibody 
(pAb).  
 
Figure 3.1.5 (b) Assay format used for checkerboard ELISA. 
 
Figure 3.1.6 (a) Assay format used for both fluorescent sandwich ELISA. 
 
Figure 3.1.6 (b) Fluorescent sandwich ELISA using purified unlabelled rabbit anti-CRP 
pAb as capture antibody and fluorescently-labelled rabbit anti-CRP pAb as detection 
antibody.  
 
Figure 3.1.6 (c) shows the plotted averaged data from part two of the fluorescent 
sandwich ELISA optimization, performed in triplicate.  
 
Figure 3.1.7 (a) shows a plot of the average CRP-binding response measured in response 
units (RU) on the Biacore 3000 system.  
 
Figure 3.1.7 (b) shows a 4-parameter calibration curve of inter-assay Biacore 3000 
analysis of a direct capture assay, involving purified rabbit anti-CRP pAb.  
 
Figure 3.2.3 The optimisation of the variable heavy (VH) and variable light (VL) chain 
amplifications using the cDNA from a CRP-immunised Balb/c mouse. 
 
Figure 3.2.4 SOE-PCR using different DMSO concentrations to optimise the product 
yield. 
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Figure 3.2.6 Polyclonal phage ELISA involving the phage pools of the unpanned library 
and the phage outputs from each of the successive rounds of panning.  
 
Figure 3.2.7 ‘Colony-pick’ PCR showing amplification of scFv gene inserts from 10 
randomly selected clones from the murine library subjected to 4 rounds of bio-enrichment 
against CRP. 
 
Figure 3.2.8 Direct ELISA using scFv-enriched lysate of 96 murine anti-CRP scFv clones. 
 
Figure 3.2.9 (a) An inhibition ELISA using the scFv-enriched lysate expressed from the 
murine anti-CRP scFv clone C11(2). 
 
Figure 3.2.9 (b) Assay format used for inhibition ELISA. 
 
Figure 3.2.10 Sequence alignment of functional variable domains of 10 murine anti-CRP 
scFv fragments.  
 
Figure 3.2.11 (a) Sensogram of C11-2 lysate (pAK 400 format) following passage across 
a CM5 chip immobilized with an anti-FLAG M1 mAb. 
 
Figure 3.2.11 (b) Sensogram of C11-2 lysate (pAK 400 format) being passed across CM5 
chip immobilized mCRP. 
 
Figure 3.2.12 Optimisation of part 1 of the ‘nested’ PCR using various annealing 
temperatures.  
 
Figure 3.2.13 (a) Direct ELISA using scFv-enriched lysate from 20 candidate scFv 
clones.  
 
Figure 3.2.13 (b) An inhibition ELISA using the scFv-enriched lysate expressed from the 
murine anti-CRP scFv C11(2) subcloned into the pComb3X vector. 
 
Figure 3.2.14 Sequences of the mouse anti-CRP C11-2 scFv clone in its original pAK 
format and its engineered pComb format. 
 
Figure 3.2.15 (a) Cross reactivity analysis of mouse C11-2 scFv subclone, avian H2 scFv 
and rabbit pAb via direct ELISA. 
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Figure 3.2.15 (b) Cross reactivity analysis of C11-2 scFv subclone lysate using an anti-
HA capture method on the Biacore 3000. 
 
Figure 3.2.16 (a) Analysis of reactivity of the C11-2 scFv subclone with mCRP using an 
anti-HA capture method on the Biacore 3000. 
 
Figure 3.2.16 (b) Kinetic analysis fit of the mouse C11-2 scFv subclone using the Biacore 
3000 system. 
 
Figure 3.3.3 (a) Cross reactivity analysis of 4 avian scFv’s and commercial mAb using 
direct ELISA. 
 
Figure 3.3.3 (b) Cross reactivity analysis of scFv-enriched H2 clone lysate using an anti-
HA capture method on the Biacore 3000. 
 
Figure 3.3.4 (a) Capture assay format used on the Biacore A100 instrument. Biotinylated 
anti-HA antibody was immobilised on spots 1, 2, 4 and 5 of a series S SAchip. 
 
Figure 3.3.4 (b) Typical kinetic analysis fit of avian anti-CRP scFv clone (F8) using the 
Biacore A100 system. 
 
Figure 3.3.5 Crude scFv-enriched lysate (L) and purified scFv (S) for all 4 avian anti-CRP 
scFv antibodies. 
 
Figure 3.3.6 (a) Illustration of a scAb fragment, composed of an scFv fused to a constant 
chain (kappa or lambda). 
 
Figure 3.3.6 (b) PCR amplification of the Cλcys chain from chicken cDNA using ‘in-
house’ designed primers (Lane 2). 
 
Figure 3.3.6 (c) Schematic diagram of the expression cassettes employed by the pMoPac 
series of vectors (Hayhurst et al., 2003), a modification of the pAK series (see section 
3.2.17). 
 
Figure 3.3.6 (d) Direct ELISA using scAb-enriched lysate from 60 PSA-specific scAb 
clones. 
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Figure 3.3.6 (e) PCR amplification of the H2 scFv gene using ‘in-house’ designed primers 
for incorporation of pAK format Sfi1 sites. 
 
Figure 3.3.6 (f) Direct ELISA using scAb-enriched lysate from 60 CRP-specific scAb 
clones. 
 
Figure 3.3.7 SDS-PAGE gel of each fractions of the IMAC purification of the CRP-
specific D9 scAb fragment. 
 
Figure 3.3.8 (a) Left - SDS-PAGE gel containing protein marker ladder (Fermentas) in 
lane 1 and purified D9 scAb in lane 2. Right - A developed nitrocellulose membrane of an 
identical gel showing protein marker ladder (Lane 1) and CRP-reacting bands of purified 
D9 scAb (Lane 2). 
 
Figure 3.3.8 (b) Left - SDS-PAGE gel containing purified D9 scAb (Lane 1), protein 
marker ladder (Lane 2) and purified H2 scFv (Lane 3). Right – The corresponding 
nitrocellulose membrane probed with the HRP labeled HA-specific mAb. 
 
Figure 3.4.2 Ribbon representation of the MPO dimer structure (left) (Anonymous Last 
Accessed January, 2009). 
 
Figure 3.4.3 Titration curve illustrating the MPO-specific response of serum taken from 
the final bleeds (red and blue) for chickens A and B, respectively.  
 
Figure 3.4.6 Polyclonal phage ELISA involving both the pre-panned and pan 4 phage 
pools from panning of the chicken scFv library. 
 
Figure 3.4.7 Direct soluble ELISA involving scFv-enriched lysate expressed from 120 
chicken anti-MPO scFv clones from pan 4. 
 
Figure 3.4.8 Capture assay format used on the Biacore 3000 instrument. 
 
Figure 3.4.9 Analysis of the percentage antibody/antigen complex remaining after 5 min 
dissociation in buffer for 25 of the MPO-specific scFv clones.  
 
 
v
 Figure 3.4.10 Sequence of the selected avian anti-MPO scFv clone. 
 
Figure 3.4.11 SDS-PAGE analysis of the various fractions of an IMAC purification of a 
MPO-specific scFv fragment. 
 
Figure 3.4.12 (a) Titration curve of purified avian anti-MPO B10B scFv against MPO in a 
direct ELISA format. 
 
Figure 3.4.12 (b) Assay format used for inhibition ELISA. 
 
Figure 3.4.12 (c) Inhibition curve of purified avian anti-MPO scFv against several 
selected concentrations of MPO. 
 
Figure 3.4.13 Kinetic analysis fit of the avian B10B anti-MPO scFv using the Biacore 
3000 system. 
 
Figure 3.4.14 (a) Assay format used for direct detection of MPO with TMB/OPD. 
 
Figure 3.4.14 (b) Use of reactive substrates TMB and OPD as direct detection agents of 
MPO in an ELISA-based assay.  
 
Figure 3.4.15 (a) Developed nitrocellulose membrane strips from the hybrid LFIA-
western blot assay. 
 
Figure 3.4.15 (b) Developed nitrocellulose membrane strips from LFIA optimisation 
experiments.  
 
Figure 3.4.15 (c) Developed nitrocellulose membrane strips from LFIA optimisation 
experiments. 
 
Figure 3.5.2 Developed LFIA strips from the fully optimized assay, performed in both 
MPO-depleted human serum (A) and 50 mM sodium phosphate, pH 7.5, containing 0.05% 
(v/v) Tween (B). 
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 Figure 3.5.3 (a) The Open lateral flow 4 castchip ™ (left) and a magnified image of the 
micro-pillar structures (right). 
 
Figure 3.5.3 (b) Assay format for competitive CRP assay on Open lateral flow 
4castchip™ chip. 
 
Figure 3.5.3 (c) Plotted competition ELISA data for all four purified avian anti-CRP scFv 
clones and two commercial CRP specific mAb’s (Fitzgerald). 
 
Figure 3.5.4 (a) Parabolic array format of biochip together with microfluidic channel for 
sample delivery (left). 
 
Figure 3.5.4 (b) Optically engineered biosensor platform (left) that focuses collimated 
light onto surface above critical angle to produce surface-confined TIRF excitation and the 
same platform exclusively collects SAF fluorescence above the critical angle (right). 
 
Figure 3.5.4 (c) Calibration curve for the determination of CRP levels from depleted 
human serum using a sandwich-based assay on a paraboloid chip. 
 
Figure 3.5.4 (d) Calibration curve for determination of CRP levels using a sandwich-
based assay on the parabolic chip. 
 
Figure 3.5.5 (a) Most widely used configurations of SPR sensors: (a) prism coupler-based 
SPR system - Attenuated Total Reflection (ATR) method; (b) grating coupler-based SPR 
system and (c) optical waveguide-based SPR system. 
 
Figure 3.3.5 (b) Plotted data for a direct binding assay using a novel CRP-specific scAb 
fragment on the SPRSpectral® platform. 
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TAE  - Tris-acetate-EDTA 
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TAT  - turn-around-time 
TB  - terrific broth 
TEMED - tetramethylethylenediamine 
TIMI  - Thromobolysis in Myocardial Infarction 
TIRF  - total internal reflection fluorescence 
TMB  - tetramethylbenzidine dihydrochloride 
TRI  - trizol 
VH  - variable heavy 
VK  - variable kappa 
VL  - variable light 
v/v  - volume per volume 
w/v  - weight per volume 
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Abstract 
 
The principal objective of this research was the production, characterisation and application 
of antibodies for the detection of both C-reactive protein (CRP) and Myeloperoxidase 
(MPO), two promising candidates in the field of cardiac diagnostics. CRP is a highly stable 
acute phase reactant, produced in the liver in response to interleukin (IL)-6. In January 2003 
both the Centres for Disease Control and Prevention (CDC) and the American Heart 
Association (AHA) recommended CRP as the inflammatory marker of choice for assessment 
of cardiovascular risk. The other biomarker under investigation was MPO, a mediator 
enzyme secreted by inflammatory cells such as activated neutrophils and monocytes. High 
levels of MPO have been reported in atherosclerotic plaques and accumulating evidence 
indicates that MPO may have a causative role in plaque vulnerability. It has been suggested 
that these markers may even be complementary in the assessment of patient cardiac risk. As a 
marker of disease activity and vascular inflammation, CRP detection is associated with long-
term risk stratification while MPO, being a marker of plaque instability and neutrophil 
activation, may be prove to be a key marker for short term stratification. 
A key feature of this work was to ensure the isolated antibodies had a sufficient level of both 
functional affinity and specificity for the development of novel diagnostic formats and assay 
platforms. Both classic polyclonal antibody generation and ‘state-of-the-art’ phage display 
technology were employed for the generation of CRP- and MPO-specific antibodies and 
recombinant fragments. The immune systems of mice, rabbits and chickens were investigated 
in this work, which allowed for the identification of the main advantages and disadvantages 
associated with each of the host immune systems and their capacity for generating specific 
and sensitive antibodies. It was observed that the avian immune system was found to be the 
most effective system for the generation of functional and soluble antibodies. 
The CRP-specific antibodies were incorporated into three novel biosensor platforms for their 
final characterisation. In addition, a novel lateral flow immunoassay (LFIA) for the rapid 
detection of MPO was developed, using a recombinant antibody isolated from a MPO-
immune library. Spiked samples of depleted human serum were employed in both the 
biosensor and LFIA systems, thus validating the detection of the analytes in a realistic sample 
matrix. 
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Aims and objectives: 
 
The primary goal of this work was the generation of both highly sensitive and specific 
recombinant antibodies towards the cardiac markers CRP and MPO. CRP has been 
consistently flagged as having great potential, particularly in the field of cardiac risk 
assessment. However, as a marker of disease activity and vascular inflammation, CRP 
detection has been associated with long-term risk stratification. Therefore, the 
implementation of a more comprehensive risk assessment strategy should also include a 
cardiac marker capable of identifying short-term risk cardiac patients. As an indicator of 
plaque instability and neutrophil activation, MPO, may prove to be a key marker for short-
term stratification. It was also suggested that both markers may even be complementary in 
the assessment of patient cardiac risk (Loria et al., 2008). This formed the basis for selection 
of both of these markers as targets for antibody production in this research.  
Initially, polyclonal antibody was generated from rabbits immunised with the chosen targets. 
The heterogenous nature of polyclonal antibody pools can restrict their use as target-specific 
reagents. However, polyclonal antibody is a relatively cheap and robust source of control 
antibody and, furthermore, can provide a highly sensitive capture reagent when combined 
with a target specific monoclonal antibody in a sandwich-based format. For the generation of 
the target-specific monoclonal antibodies, phage display-based recombinant antibody 
technology was employed. Although, hybridoma technology can also be used for monoclonal 
antibody generation, the direct link of phenotype to genotype in recombinant antibody 
technology, provides a key attribute for downstream manipulation or re-engineering of 
isolated antibodies. 
Combining an immunised host with phage display technology for the production of 
recombinant antibodies is well-documented (Berry and Popkov, 2005) and has provided 
significant breakthroughs in the fields of both diagnostics and therapeutics. However, 
conflicting opinions persist regarding the choice of immune host used (Andris-Widhopf et al., 
2000; O'Brien and Aitken, 2002; Finlay et al., 2005,). Consequently, this work will also 
investigate this issue by comparatively examining the use of several species in the production 
of recombinant antibodies against a select antigen, namely CRP. Mice, rabbits and chickens 
were chosen as the immune hosts for the study, with each species bringing its own unique 
characteristics and advantages to the antibody production process. Each of the immune host 
systems will be thoroughly discussed in the introduction of each of their respective sections 
and also the selection of each of the systems will be validated. It is envisaged this study will 
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shed some light on the issue of immune host selection and hopefully present some useful 
findings.  
In each case, optimised ‘state-of-the-art’ phage display systems combined with high-
throughput screening and characterisation platforms such as Biacore were employed. These 
systems will hopefully ensure that the full capacity of the immune systems of each of the 
species under investigation will be achieved. The ease of construction of the libraries, their 
characterisation and the final outputs from each of the species will be critically examined. 
Finally, the developed CRP - and MPO - specific antibodies will be used to validate novel 
point-of-care (POC) diagnostic platforms. A diverse range of platform technologies will be 
employed for the final application of the isolated antibodies from this research, ranging from 
basic yet robust technologies such as standard lateral flow to complex microfluidic chip-
based platforms. In each case, the reasoning behind each of the selected platforms will be 
discussed in the introduction section for each of the respective platforms. In addition, some of 
the limitations of existing antibody technologies are highlighted and how these may be 
overcome by employing some of the assay platforms investigated in this research. The 
performance of these platforms will be analysed using data evaluation packages to identify 
their ability in providing potential life-saving information in the fight against cardiovascular 
disease. 
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  Introduction 
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1. Introduction:  
 
1.1. Prevalence of cardiovascular disease 
 
Cardiovascular disease (CVD) is the cause of nearly half of all deaths in the western world 
(49%) (Allender et al., 2008). In addition, up to 50% of patients referred to cardiologists from 
primary care physicians have been originally misdiagnosed with conditions other than heart 
failure (HF). Thus, more accurate diagnosis is of paramount importance for improvements in 
clinical assessments. Furthermore, in the region of 5% of myocardial infarction (MI) patients 
are discharged from emergency departments (ED) without adequate treatment, as 
approximately one quarter of these patients present with atypical symptoms and about one 
third have non-diagnostic electrocardiogram (ECG) changes (Char, Israel and Ladenson, 
1998). Failure to diagnose MI in the ED is also a significant contributor towards payments of 
malpractice for ED physicians (Vukmir, 2004; White et al., 2004; Schull et al., 2006). In 
addition, the overall financial burden of CVD in the EU is believed to be 192 billion euro per 
year (Allender et al., 2008). 
 
1.2. Pathophysiology of acute coronary syndromes (ACS) 
 
The vast array of clinical symptoms evident after coronary plaque disruption are often 
cumulatively referred to as ACS (Braunwald et al., 2002). Initially, rupture of unstable 
coronary plaques results in intracoronary thrombosis, where the thrombus (bloodclot) leads to 
a reduction in blood flow (cardiac ischemia), thereby restricting the supply of oxygen to the 
myocardium. The continuum of this myocardial ischemia is ‘acute coronary syndrome’, 
which ranges from unstable angina (associated with reversible myocardial injury) to MI with 
large areas of irreversible damage (cardiac necrosis). Acute coronary syndromes are mainly 
separated into two categories based on changes seen in the electrocardiograms at 
presentation: ‘ST-segment elevation myocardial infarction’ (STEMI) and ‘non-ST-segment 
elevation ACS’ (NSTEACS). The therapeutic approach associated with each of these 
categories varies substantially. Consequently, it is essential to accurately categorise patients 
prior to treatment. NSTEACS are also further sub-categorised into unstable angina and non-
STEMI. A common pathogenesis is shared by both of these subgroups, as well as similar 
clinical presentation. However, ischemia in non-STEMI is more severe in intensity and 
duration and causes irreversible myocardial damage. 
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1.3. The first use of cardiac markers 
 
The earliest documented use of biochemical markers in the study of myocardial infarction 
was in 1954, which reported that glutamate oxaloacetic transaminase activity in serum 
increased above the reference range a few hours after acute myocardial infarction (AMI), 
reaching a peak after 2 to 3 days (Ladue et al., 1954). Biochemical markers now play a 
fundamental role in the diagnosis, prognosis, monitoring and risk stratification of patients 
with acute coronary syndromes (ACS) and the redefinition of myocardial infarction is 
dependent on markers such as cardiac troponin (Alpert et al., 2000; Apple et al., 2007; 
Morrow and de Lemos, 2007,). 
 
1.4. The ideal characteristics of a cardiac marker 
 
To obtain a high diagnostic sensitivity, cardiac biomarkers need to be easily accessible. 
Hence, smaller soluble molecules with faster release kinetics and rapid clearance from 
injured tissue are regarded as the most suitable markers for early diagnosis. However, in the 
case of late diagnosis a highly stable marker with a long plasma half-life is essential. 
Consequently, peak levels should be reached relatively quickly and persist in circulation for a 
few hours, as is the case with the cardiac troponins. Conversely, a rapid clearance of the 
marker from plasma is a crucial feature of markers of recurrent injury. The kinetics of release 
exhibited by the markers should have a clear relationship with the extent of the injury i.e. 
infarct sizing. The cardiac marker ideally should be highly specific for cardiac tissue and 
absent from non-myocardial tissue. It should also have the ability to differentiate between 
reversible (ischemia) and irreversible (necrosis) damage. The marker has to be thoroughly 
evaluated by large statistically designed clinical studies before its acceptance into routine 
clinical use. Finally, it must have the ability to influence therapy, such as providing additional 
information for existing risk scores or being one of the parameters of a new risk score. 
Despite the hugely significant developments in the field, there still is considerable 
controversy surrounding the use of cardiac biomarkers, as no single biomarker fulfils all the 
criteria of an ‘ideal’ cardiac biomarker. Presently, the cardiac troponins appear to be the most 
sensitive and specific biomarkers among all other diagnostic biomarkers for ACS. However, 
there is a consensus that a single measurement of the cardiac troponins at patient admission is 
insufficient because a single measurement will not detect 10% to 15% of at-risk patients 
(Hamm, 2001). Table 7.3.1 (Appendix section) shows some of the existing cardiac markers 
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currently used and their primary utility in the clinical setting. The two markers focused on in 
this research thesis were CRP and MPO, both inflammatory markers. 
 
1.5. Markers of inflammation 
 
Up to half of the events associated with cardiovascular disease (CVD) occur in asymptomatic 
individuals (Ridker et al., 2005), thus, emphasising the need for true ‘early’ biomarkers. 
Consequently, intense research has focused on markers of inflammation (Ross, 1999). 
Inflammatory processes play a prominent role in the development of both the intermediate 
and mature atheromatous plaque and also contribute to the destabilisation of vulnerable 
plaques resulting in ACS (Libby, 2002). Established and novel inflammatory markers such as 
C-reactive protein (CRP) and myeloperoxidase (MPO) may be elevated before the onset of 
irreversible damage. Accordingly, several inflammatory mediators have been evaluated as 
prognostic indicators of the risk of initial ACS, adverse sequalae and recurrent complications. 
 
1.6. C-reactive protein 
 
CRP is an acute phase reactant, produced in the liver in response to interleukin (IL)-6. CRP is 
a pattern recognition molecule made up of five identical subunits (Shrive et al., 1996). Its 
normal physiological role involves binding to phosphocholine expressed on the surface of 
dead or dying cells (and some types of bacteria) in order to activate the complement system 
via the C1Q complex (Thompson et al., 1999). In the presence of Ca2+, each subunit binds 
with high affinity to phosphocholine (PC) (Anderson et al., 1978). As the five ligand-binding 
sites are all on the same face of the pentamer (Shrive et al., 1996), CRP binds with high 
avidity to ligand-decorated targets such as bacteria. On the opposite side of each subunit is an 
effector molecule-binding site that mediates the protein's interaction with C1q, (Agrawal and 
Volanakis, 1994), FcγRI (Marnell et al., 1995) and FcγRII (Bharadwaj et al., 1999). 
It is a highly stable pentameric protein and its serum concentration can increase 10,000-fold 
during the acute phase response (Pepys and Berger, 2001; Black et al., 2004; Labarrere and 
Zaloga, 2004). Investigative data suggests that CRP may play an active role in atherogenesis. 
It has been shown that CRP co-localises with the membrane attack complex in early 
atheromatous lesions (Yasojima et al., 2001). Two more recent studies reported the detection 
of CRP in the early stages of plaque development and also stated a possible involvement in 
facilitating processes ranging from the initial recruitment of leukocytes to the arterial wall to 
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the eventual rupture of the plaque itself (Blake and Ridker, 2003; Azzazy et al., 2006). 
Another interesting study observed the loss of the pentameric symmetry of CRP resulting in a 
modified or monomeric CRP form (mCRP), which may be the major CRP isoform promoting 
the proinflammatory response in coronary arteries (Khreiss et al., 2004a). 
In January 2003 both the Centres for Disease Control and Prevention (CDC) and the 
American Heart Association (AHA) recommended CRP as the inflammatory marker of 
choice for assessment of cardiovascular risk (Pearson et al., 2004). The high sensitivity CRP 
assay (hs-CRP) was originally developed to aid evaluation of conditions associated with 
inflammation, in otherwise healthy individuals. Cardiac CRP (cCRP) assays are indicated for 
use in the clinical identification and stratification of patients at risk of future CVD-associated 
events. The hs-CRP assay is frequently quoted in a cardiac context and indeed both hs-CRP 
and cCRP assays have equivalent clinical cut-off and measuring ranges. Nonetheless, the 
additional performance validation demanded to support the expanded intended use of CRP in 
indications related to CVD dictates that a clear distinction be made (U.S. Department of 
Health and Human Services, Food and Drug Administration, Center for Devices and 
Radiological Health, Office of In Vitro Diagnostic Device Evaluation and Safety, Division of 
Chemistry and Toxicology Devices, 2005). The recommended guidelines for primary 
prevention set cut-off points according to relative risk categories: low risk (<1 mg/L), average 
risk (1-3 mg/L) and high risk (>3 mg/L) for patients with an intermediate 10-year CVD risk 
(10% to 20% Framingham Risk Score/ATP III guidelines). Recently, hs-CRP has also been 
incorporated into a cardiac risk score for women, the ‘Reynolds risk score’, based on a 
comprehensive study involving nearly 25,000 women over 10 years (Ridker et al., 2007), 
thus fulfilling one of the key criteria of an ‘ideal’ marker. 
Several large-scale epidemiological studies examining apparently healthy populations have 
found CRP to be a strong independent predictor of future cardiovascular events, including 
myocardial infarction, ischemic stroke, peripheral vascular disease and sudden cardiac death 
(Ross, 1999; Blake and Ridker, 2003; Calabro et al., 2003; Ridker, 2003; Ridker et al., 2005;) 
and this is evident in the growing number of commercially available hs-CRP tests, one 
example being the Pathfast® POC test supplied by Mitsubishi Chemical Europe GmbH. The 
emerging consensus is that subjects in the top quartile of hs-CRP levels are at 2-3 times 
greater risk of future coronary events than those in the bottom quartile. cCRP levels have 
been shown to be associated with coronary events as early as 5 years and as late as 15 years 
into follow up (Sakkinen et al., 2002). Numerous studies like TIMI, CAPTURE and FRISC 
(Morrow et al., 1998; Heeschen et al., 2000; Lindahl et al., 2000) have examined the 
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predictive value of CRP and have found it to contribute both independent and additive value 
to cardiac troponin levels. Furthermore, hs-CRP has been found to have prognostic value 
among patients without evidence of myocyte necrosis, notably even among patients with 
normal levels of troponin T (Morrow et al., 1998; Heeschen et al., 2000; Lindahl et al., 
2000). The optimal cut-off point for defining ‘high’ c-CRP levels among patients remains 
contentious, possibly due to heightened vascular inflammation or subtle undiagnosed 
inflammatory state at the time of presentation with ACS. For example, the CAPTURE study 
(Heeschen et al., 2000) found a threshold of 10 mg/L maximised the predictive value of hs-
CRP, whereas numerous other studies (Ridker et al., 1997; Ridker et al., 2000; Ridker et al., 
2001) have proposed a cut-off point of 3 mg/L to be most suitable. However, a clinical cut-
off concentration of ≤ 1.0 mg/mL has been recommended by the 2005 ‘Industry and FDA 
staff guidelines’ (U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Devices and Radiological Health, Office of In Vitro Diagnostic 
Device Evaluation and Safety, Division of Chemistry and Toxicology Devices, 2005). To 
date, there is insufficient evidence to substantiate the ability of hs-CRP to identify ACS 
patients who will benefit from a particular treatment (Heeschen et al., 2000; Solomon et al., 
2001). This is further confounded by estimates that more than 30% of patients with severe 
unstable angina do not present with elevated hs-CRP levels (Ridker and Cook, 2004).  
Notwithstanding the fact that CRP is the most extensively studied inflammatory marker, 
several other markers of inflammation exist with particular promise in the field of cardiac risk 
assessment. 
 
1.7. Myeloperoxidase 
 
MPO is a mediator enzyme secreted by inflammatory cells e.g. activated neutrophils and 
monocytes. MPO produces hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and 
chloride anion (Cl-) (or the equivalent from a non-chlorine halide) during the neutrophil's 
respiratory burst, requiring heme as a cofactor. Furthermore, it oxidizes tyrosine to tyrosyl 
radical using hydrogen peroxide as an oxidizing agent (Heinecke et al., 1993). Both 
hypochlorous acid and tyrosyl radical are cytotoxic and are used by neutrophils to kill 
bacteria and other pathogens. High levels of MPO have been reported in atherosclerotic 
plaques (Blake and Ridker, 2003) and accumulating evidence indicates that MPO may also 
have a causative role in plaque vulnerability (Hazen, 2004). MPO can generate several 
reactive oxidised intermediates, concomitantly inducing oxidative damage of cells and tissues 
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(Brennan et al., 2003). Such reactive intermediates have been found at increased levels in low 
density lipoprotein (LDL) isolated from artherosclerotic lesions (Hazen and Heinecke, 1997). 
Moreover, high MPO expression levels have been reported in patients with sudden cardiac 
death, at sites of plaque rupture, superficial erosions and in the lipid core, whereas less 
harmful fatty streaks were observed to exhibit little MPO expression (Sugiyama et al., 2001).  
Several recent clinical studies have suggested that MPO levels may play a potentially 
important diagnostic and prognostic role in endothelial function, CAD and ACS. The role of 
MPO as an independent predictor of endothelial dysfunction has been demonstrated (Vita et 
al., 2004) and further studies have underlined the value of MPO as a predictor of cardiac risk 
in populations with different incidences of ACS (Baldus et al., 2003; Brennan et al., 2003). 
Both studies concluded that a single measurement of plasma MPO at hospital admission 
predicted the risk of major adverse cardiac events for both a 30-day and six month period. 
Baseline levels of MPO were determinants of patient risk stratification, even in patients with 
consistently negative cTnT levels. The predictive power of MPO was also found to be 
independent of soluble fragment CD40 ligand (sCD40L), CRP and BNP in ACS patients with 
undetectable cTnT concentrations and sCD40L concentrations below their threshold values. 
MPO levels, in contrast to cTnT, CK-MB and CRP levels, identified patients at risk for 
cardiac events in the absence of myocardial necrosis. It has subsequently been suggested that 
MPO may play an important role in identifying short-term risk of recurrent ischemic events, 
again, independent of clinical risk factors like cTnI and other novel biomarkers (Morrow et 
al., 2008). A case control study highlighted that increasing levels of leukocyte-MPO and 
blood-MPO were significant predictors of CAD (Zhang et al., 2001). Individuals in the 
highest quartile of blood-MPO had a 20-fold higher risk of CAD than individuals in the 
lowest quartile, following adjustment for white blood cell count and Framingham risk score. 
In August 2005, the FDA approved the first MPO assay, CardioMPO™, developed by 
PrognostiX, Inc. The test is a sandwich enzyme immunoassay cleared for use in conjunction 
with clinical history, ECG and other cardiac biomarkers to evaluate patients with chest pain 
at risk of major adverse cardiac events.  
MPO appears to be one of the most promising contemporary candidates, yet due to its 
relatively recent emergence, there is still uncertainty about the additional benefits of MPO 
over standard ischemic biomarkers. Therefore, further supporting evidence is required to 
clarify this issue before it achieves widespread clinical acceptance. Moreover, almost all data 
for MPO is in the setting of ACS or established CAD and, thus, it remains unclear whether 
 
 
15
MPO can provide additional information to conventional atherothrombotic risk factors used 
in the Framingham Risk Score. 
 
1.8. Antibody production 
 
The traditional approach for the production of monoclonal antibodies (mAbs) was dominated 
by the use of hybridoma fusion techniques, first introduced by Kohler and Milstein in 1975 
(Köhler and Milstein, 1975). This technique commences with the immunisation of a relevant 
animal host (e.g. mouse) with a specific immunogen (the antigen against which antibodies are 
required). An adjuvant such as Freunds complete adjuvant is commonly administered in 
combination with the immunogen so as to augment a desired immune response (i.e. 
production of antibodies). The level of antibody, specific for the immunised antigen, is 
periodically calculated using a serum titre from the immunised animal. When a sufficient 
serum antibody titer is achieved (1/100,000 or higher), the immunised animal is sacrificed 
and its spleen removed. The spleen provides a rich source of antibody-producing B cells, 
which possess a hypoxanthine guanine phosphoribosyl transferase (HGPRT) gene, a crucial 
gene in the hybridoma process. These B cells are isolated and fused with myeloma cells (lack 
HGPRT), resulting in their immortalisation as hybridoma cells. A commonly used agent in 
the fusion process is polyethylene glycol (PEG), which promotes cell permeability and 
exchange of nuclei. The resultant hybridomas are cultured in Hypoxanthine Aminopterin 
Thymidine (HAT) medium, a selective medium in which only the fused hybrid cells may 
survive. Its selectivity is achieved via the presence of aminopterin in the medium, which 
blocks the pathway that allows for nucleotide synthesis. Hence, unfused myeloma cells die 
due to their inability to produce nucleotides by the de novo or salvage pathways (lack the 
HGPRT gene). In addition, unfused B cells die due to their limited life-span. Therefore, the 
only-surviving cells are the B cell-myeloma hybrids, as a consequence of their immortality 
combined with the possession of the essential HGPRT gene. Hybridoma cells secreting the 
antigen-specific monoclonal antibodies are then identified via screening of the cells media 
supernatant by techniques such as enzyme-linked immunosorbent assay (ELISA). Enrichment 
of these positively identified hybridomas is achieved by limiting dilution, to obtain a 
homogeneous cell clone secreting the desired mAb (Little et al., 2000). 
Since the culmination of hybridoma technology, the production of antibodies was 
revolutionised by the development of modern molecular biology methods for the expression 
of recombinant DNA. Among the various strategies developed for the in vitro production and 
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selection of recombinant antibodies, phage display has proven to be a robust and versatile 
technology. Phage display allows for the generation of billions of phage particles expressing 
an antibody fragment at their surface that has the potential to bind to the desired antigen.  
Phage display encompasses the four key components of selection platforms: genotypic 
diversity, genotype/phenotype coupling, selection pressure and amplification (Bradbury and 
Marks, 2004). A schematic representation of the phage selection cycle can be found in 
section 7.2.1 (Appendix section) has led to the ability to produce antibodies with affinities 
unobtainable in the immune system. A crucial advantage of this technology is the direct link 
that exists between the experimental phenotype and its encapsulated genotype, which allows 
the evolution of the selected binders into optimised molecules. 
The enrichment of phage presenting the desired binding protein (or peptide) is achieved by 
affinity selection of a phage library against a specific target molecule. In this “panning” 
process, binding phage are captured whereas non-binding phage are washed off. The bound 
phage are eluted (usually low pH or trypsin elution) and amplified by reinfection into E. coli 
cells. Put simply, the selection from phage display libraries is a cyclic process of selective 
enrichment and amplification. Typically, affinity is enriched (matured) through multiple 
rounds of biopanning, a process that involves binding to reducing concentrations of the ligand 
of interest. Four to six rounds of this process is usually sufficient to select for phage 
displaying high-affinity antibody fragments.  
 
Phage display systems can be grouped into two classes on the basis of the vector system used 
for the production of phages: 
1. True phage vectors – directly derived from the genome of filamentous phage (M13, 
f1, or fd) and encode all the proteins needed for the replication and assembly of the 
filamentous phage. 
2. Phagemid vectors – produce the fusion coat protein. A phagemid is a plasmid that 
bears a phage-derived origin of replication in addition to its plasmid origin of 
replication. The phage-derived origin of replication is also known as the intergenic 
region. 
In general, the two kinds of libraries that can be used are either naïve or immune libraries. 
Naive or semi-synthetic established libraries possessing greater than 1010 individual clones 
offer the possibility of selection of antibodies of any desired specificity without the need for 
immunisation. Nevertheless, the combination of an immunised host with phage display 
technology was shown to produce superior antibodies with both high affinity and specificity 
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towards cognate antigens (Krebber et al., 1997; Barbas et al., 2001). In addition to the vast 
array of potential library sources, huge advances in molecular biology have led to the ability 
to construct custom recombinant antibody formats (Figure 1.8). The two predominant formats 
chosen are either the single chain Fv (scFv) or Fab antibody fragment format. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Immunoglobulin G (IgG) antibodies, the most abundant of the immunoglobulins, 
are large molecules of about 150 kDa composed of 4 peptide chains. It contains 2 identical 
heavy chains (blue and red) of about 50 kDa and 2 identical light chains (green and grey) of 
about 25 kDa in molecular weight. The two heavy chains are linked to each other and to a 
light chain each by disulphide bonds. The building block that is most frequently used to 
create novel antibody formats is the single-chain variable (V)-domain antibody fragment 
(scFv), which comprises V domains from the heavy and light chain (VH and VL domain) 
joined by a peptide linker of up to 15 amino-acid residues. The Fab fragment is a 
modification of this format, which also contains a constant heavy and light chain for 
increased stability. The diabody format is comprised of the heavy and light-chain variable 
regions joined by a flexible peptide linker. The linker is long enough to allow separation of 
the domains so that two of the polypeptides can assemble into a dimer, making the antibody 
divalent.  
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2.0 Materials and Methods 
 
2.1 Equipment 
 
Biometra TGRADIENT PCR machine   - LABREPCO, 
        101 Witmer Road, Suite 700,  
Horsham, PA19044, USA. 
 
Nanodrop™ ND-1000    - NanoDrop Technologies, Inc., 
3411 Silverside Rd 100BC,  
Wilmington, DE19810-4803, 
USA. 
  
Gene Pulser Xcell ™ electroporation system  - Bio-Rad Laboratories, Inc., 
2000 Alfred Nobel Drive,  
Hercules, California 94547, 
USA. 
 
ORBI-safe TS Netwise orbital shaking incubator - Sanyo Europe Ltd., 
        18 Colonial Way, 
       Watford, WD24 4PT, 
United Kingdom. 
 
Trans-Blot® Semi-dry Transfer cell   - Bio-Rad Laboratories, Inc., 
2000 Alfred Nobel Drive,  
Hercules, California 94547, 
USA. 
 
Roller mixer SRT1     - Sciencelab, Inc., 
14025 Smith Rd. 
Houston, Texas 77396, USA. 
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Safire 2 plate reader     - Tecan Group Ltd.,  
Seestrasse 103, 
CH-8708 Männedorf, 
Switzerland. 
       
PX2 thermal cycler     - Thermo Electron Corporation,  
        81 Wyman Street, Waltham,  
Massachusetts (MA), 02454, 
USA. 
 
Biacore 3000 and A100    - GE Healthcare Bio-Sciences AB, 
        SE-751 84 Uppsala 
Sweden.  
 
Vibra Cell™ sonicator    - Sonics and Materials Inc., 
53 Church Hill Road, 
Newtown, CT 06470-1614,  
USA.   
  
sciFLEXARRAYER ™ S3    - Scienion AG, 
Otto-Hahn-Straße 15, 
D-44227 Dortmund, 
Germany. 
 
Linomat 5      - CAMAG,  
        Sonnenmattstrasse 11, 
P.O. Box 216, 
CH-4132 Muttenz 1, 
Switzerland. 
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2.2 Bacterial culture compositions 
 
2 x TY Media Tryptone 16 g/L 
      Yeast Extract  10 g/L 
      NaCl    5 g/L 
 
Super Broth (SB) Media   MOPS  10 g/L 
      Yeast Extract 30 g/L 
      Yeast Extract 20 g/L 
 
Terrific Broth (TB)    Tryptone 12 g/L 
      Yeast Extract 24 g/L 
      Glycerol        4 mL/L 
      KH2PO4       2.31 g/L 
      K2HPO4     12.54 g/L 
 
Super Optimal Catabolite (SOC) Media Tryptone 20 g/L 
      Yeast Extract   5 g/L 
      NaCl            0.5 g/L 
      KCl            2.5 mM 
      MgCl2  20 mM 
      Glucose 20 mM 
 
2.3 Bacterial cells for cloning and expression 
 
E. coli TOP10 F′ strain: {lacIq, Tn10(TetR)} mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 
lacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
 
E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB 
lacIqZ∆M15 Tn10 (TetR)]. 
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2.4 Buffer Composition 
 
Phosphate buffered saline (PBS) 0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4
18 mM KH2PO4
pH 7.4 
 
 
PBS-Tween 20 (0.05% (v/v) PBST) 0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4
18 mM KH2PO4
0.05% (v/v) Tween 20 
pH 7.4 
 
 
Milk-PBST (MPBST)   0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4
18 mM KH2PO4
0.05% (v/v) Tween 20 
Specified % (w/v) milk marvel powder 
pH 7.4 
 
 
Hepes buffered saline (HBS)  HEPES 2.38 g/L 
     NaCl  8.77 g/L 
     EDTA  1.27 g/L 
     Tween           0.5 mL/L 
     pH 7.4 
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2.5 SDS PAGE and Western Blotting 
 
12.5% Separation gel      1gel (6mL)  
1 M TrisHCl, pH 8.8      1.5 mL 
30% (w/v) acrylamide (Acrylagel)    2.5 mL 
2% (w/v) methylamine bisacrylamide (Bis-Acrylagel) 1.0 mL   
Distilled water                  934 μL   
10% (w/v) sodium dodecyl sulfate (SDS)     30 μL  
10% (w/v) APS      30 μL  
TEMED          6 μL   
 
 
4.5% Stacking gel      1gel (2.5mL)  
1 M TrisHCl, pH 6.8      300 μL  
30% (w/v) acrylamide (Acrylagel)    375 μL   
2% (w/v) methylamine bisacrylamide (Bis-Acrylagel) 150 μL   
Distilled water              1.74 mL   
10% (w/v) SDS       24 μL   
10% (w/v) APS       24 μL   
TEMED       2.5 μL   
 
 
10 X electrophoresis buffer 
50mM Tris, pH 8.3      30 g 
196mM Glycine      144 g 
0.1% (w/v) SDS      10 g 
Distilled water  to 1 L 
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Loading buffer (4 X) 
Tris 0.5M, pH 6.8   2.5 mL 
Glycerol    2.0 mL 
2 mercaptoethanol   0.5 mL 
20% SDS (w/v)   2.5 mL 
Bromophenol blue   20 ppm 
Distilled water    2.5 mL 
 
Coomassie stain dye/ 500mL  
Coomassie blue R-250       1 g 
Methanol                        225 mL 
Distilled water                          225 mL 
Acetic acid                        50 mL 
 
Coomassie destain/L
Acetic acid    250 mL 
Methanol    250 mL 
Distilled water    650 mL 
 
Transfer Buffer/L
1 X SDS electrophoresis buffer 800 mL 
Methanol    200 mL 
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2.6 Commercial kits 
 
Superscript III reverse transcriptase kit - Invitrogen Corporation, 
5791 Van Allen Way, 
Carlsbad, CA 92008, USA . 
 
Perfectprep Gel Cleanup Kit   - Eppendorf AG, 
       Barkhausenweg 1, 
Hamburg 22339, 
Germany. 
 
Wizard Plus SV Miniprep™ kit  - Promega, 
       2800 Woods Hollow Road, 
Madison, WI 53711, 
United States. 
 
Commercial DyLight 647™ kit  - Fisher Thermo Scientific, 
       47341 Bayside Pkwy.,  
Fremont, CA 94538, USA. 
 
QIAquick™ gel extraction Kit  - Qiagen, 
       28159 Avenue Stanford, 
Valencia, CA 91355, USA. 
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2.7 Commercial antibodies 
 
Anti-M13 antibody (HRP-labelled)  - GE Healthcare Bio-Sciences AB, 
       SE-751 84 Uppsala, Sweden. 
 
Mouse anti-HA (HRP-labelled) mAb  - Roche Diagnostics, 
       Grenzacherstrasse 124, 
Basel 4070, Switzerland. 
 
CRP-specific mAb (section 3.3.3)  - HyTest, 
Joukahaisenkatu 6, 
20520, Turku, Finland. 
 
CRP-specific mAb (section 3.5.3)  - Fitzgerald Industries International, 
30 Sudbury Road, Suite 1A North, 
Acton, MA, 01720, USA. 
 
Anti-histidine (HRP-labelled) mAb  - Sigma Aldrich,  
       3050 Spruce Street, 
St. Louis, MO 63103, 
USA. 
 
Anti-rabbit (HRP-labelled) pAb  - Sigma Aldrich 
 
Anti-mouse (HRP-labelled) pAb  - Sigma Aldrich 
 
Anti-FLAG tag M1 mAb   - Sigma Aldrich 
 
Anti-FLAG tag M2 mAb   - Sigma Aldrich 
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2.8 Generation and characterisation of rabbit anti-CRP polyclonal antibodies 
 
2.8.1 Immunisation of New Zealand White rabbits and antibody titre determination. 
 
CRP immunisations were administered by 1 mL sub-cutaneous injections with antigen-grade 
CRP (HyTest). On day 1, the rabbits were immunised with 200 μg of antigen grade CRP in 
PBS, mixed in a 1:1 ratio with Freund’s complete adjuvant (FCA). Freund’s complete 
adjuvant is an emulsified mineral oil antigen solution used as an immunopotentiator. The first 
boost (day 14) was then administered using 100 μg of CRP in PBS, mixed in a 1:1 ratio with 
Freund’s incomplete adjuvant (FICA). The final 3 boosts that followed (days 35, 49 and 70) 
all contained 50 μg of CRP and were administered in the same manner as the first boost. 
Finally, on day 75, the rabbits were sacrificed and both their spleens and bone marrow 
removed. 
 
2.8.2 Protein A purification of anti-CRP polyclonal antibody from rabbit serum. 
 
A 1 mL suspension of immobilised protein A (immobilised on Sepharose 4B, stored in 
sterile-filtered PBS containing 20% (v/v) ethanol) was equilibrated in a column with 30 mL 
of sterile-filtered PBS. Two vials of serum from the sacrificed rabbit were pooled and made 
up to a final volume of 10 mL with sterile-filtered 1 x PBS (pH 7.4). The 10 mL mixture of 
diluted pAb-rich serum was then passed through the column and the eluant collected and 
passed through the column a second time. A total of 30 mL of wash buffer (sterile-filtered 
PBS) was passed through the column and, subsequently, the retained protein was eluted with 
0.1 M glycine-HCl buffer (pH 2.5). Fractions of eluate were collected in micro-centrifuge 
tubes containing 150 μL of neutralisation buffer (2 M Tris-HCl, pH 8.5). This served to 
rapidly neutralise the highly acidic environment of the elution buffer, thereby, preventing 
denaturation of the eluted IgG fraction. The protein in each of the fractions was quantified 
using the NanoDrop™ ND-1000 using the pre-programmed ‘IgG’ option (mass extinction 
coefficient of 13.7 at 280 nm). The fractions containing high concentrations of IgG were 
pooled, desalted on a PD10TM size exclusion column against PBS and stored at -20°C until 
required for further use. All purification and desalting procedures were conducted at 4°C. 
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2.8.3 SDS-PAGE of anti-CRP pAb protein G purification. 
 
Proteins were separated using 10% (w/v) SDS-PAGE gels (20 µg/lane) to analyse purity and 
to determine the apparent molecular weight. The gel consisted of a resolving gel and a 
stacking gel. The resolving gel contained H20, 30% (w/v) acrylamide (Ultrapure Acrylagel, 
National Diagnostics), 2% (w/v) methylamine bisacrylamide (Bis-Acrylagel), 1.5 M Tris pH 
8.8, 10% (w/v) SDS, 10% (w/v) ammonium persulfate (APS) and TEMED. The stacking gel 
contained H20, 30% (w/v) acrylamide, 2% (w/v) methylamine bisacrylamide (Bis-acrylagel), 
1M Tris pH 6.8, 10% (w/v) SDS, 10% (w/v) ammonium persulfate and TEMED. These gels 
are left to polymerise between two clean glass plates. After the stacking gel was poured, a 
comb is inserted to make wells in preparation for loading of the protein samples. The samples 
were prepared by adding appropriate volumes of 4x gel loading buffer and deionised water. 
The gel loading buffer was prepared using Tris 0.5 M (pH 6.8), 20% (w/v) SDS, 15% (v/v) 
glycerol, bromophenol blue, 2-β-mercaptoethanol and deionised water. A 20 µg quantity of 
each protein sample was added into each well in a total volume of 20 µL. The gels were 
placed in an electrophoresis apparatus and submerged in electrophoresis buffer. The 
electrophoresis buffer was prepared using 50 mM Tris pH 8.3, 196 mM glycine and 0.1% 
(w/v) SDS. The apparatus is attached to a power supply and a voltage of 200 V is applied to 
the gel. The gels were allowed to run until the tracker dye had reached the bottom of the gel, 
taking approximately 30 - 45 minutes. The gels were taken out and stained using Coomassie 
stain (0.2% (w/v) Coomassie blue R-25, 45% (v/v) methanol, 45% water, 10% (v/v) acetic 
acid) for 3-4 h. Finally, the stained gels were destained overnight using Coomassie destain 
(10% (v/v) acetic acid, 25% (v/v) methanol, 65% (v/v) water). The destain solution was 
changed 2-3 times (until the background non-specific staining was removed).        
                                                           
2.8.4 Checkerboard ELISA of purified anti-CRP polyclonal antibody. 
  
A 96 well plate (Maxisorp™, Nunc) was coated with varying concentrations of CRP antigen 
in 1 x PBS (pH 7.4) and left O/N at 4°C. The following day, the antigen-coated plate was 
then blocked with a 3% (w/v) BSA -PBS solution (200 μL per well) for 1 h at 37°C. A vial of 
purified rabbit anti-CRP polyclonal antibody (pAb) (section 2.8.2) was removed from -20°C 
and thawed. Serial dilutions of the purified pAb were made in 1% (w/v) BSA in PBST, added 
(100 μL per well) to the corresponding coated/blocked well and incubated at 37°C for 1 h. 
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Following incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any 
unbound pAb. The CRP-pAb complex was detected using 100 μL per well of a 1/2000 
dilution of an anti-rabbit (HRP-labelled) secondary pAb produced in a goat (Sigma #A6154). 
After a 1 h incubation at 37°C with the secondary mAb, the plate was washed again with 
PBST (x3) and PBS (x3) to remove any unbound detection antibody. TMB substrate was then 
added (100 μL per well) and left to react for 20 min at 37°C. The reaction was quenched by 
the addition of 100 μL per well of 10% (v/v) HCl, after which the absorbance was determined 
at 450 nm on a Safire 2 plate reader (Tecan). 
 
2.8.5 Fluorescent labelling of purified rabbit anti-CRP pAb with commercial DyLight 647™ 
kit. 
 
Purified rabbit pAb (section 2.8.2) was diluted in sterile-filtered PBS to a concentration of 1 
mg/mL in a final volume of 100 μL. A 10 μL volume of borate buffer (0.67 M) was added to 
the diluted pAb. The lyophilised DyLight™ reagent was reconstituted with 20 μL of 
dimethylformamide (DMF) and then 5 μL added to the pAb in borate buffer. The mixture 
was inverted several times to ensure thorough mixing and then incubated for 45 min at room 
temperature (tube was wrapped in tin foil to protect from light). The caps of two Zeba™ 
columns (AGB) were loosened and the bottom plugs twisted off. Each column was placed 
into a 1.5 mL tube and centrifuged for 1 min at 1,750 x g to remove the storage solution. 
Following this centrifugation step, the columns were blotted against filter paper to remove 
any residual ethanol and then placed into clean 1.5 mL tubes. The caps were removed from 
the columns and 55 μL of the incubated reaction was directly applied to the centre of the 
compacted resin bed of each column. The labelled pAb was collected into the 1.5 mL tubes 
by centrifugation for 2 min at 1,750 x g and then stored at -20°C in 10 μL aliquots. 
 
2.8.6 Fluorescent sandwich ELISA of purified rabbit pAb labelled with DyLight 647™. 
 
Part 1 - Determination of the optimal rabbit anti-CRP pAb coating concentration: 
A black 96 well fluorescence plate (Greiner®) was coated with 6 different concentrations 
(10, 7.5, 5.0, 2.5, 1.0, 0.5 μg/mL) of purified anti-CRP pAb (section 2.8.2) incubated O/N at 
4°C (The primary difference between white and black plates is their reflective properties. 
White plates reflect light and will maximize light output signal, whereas black plates absorb 
light and reduce background). The following day, the coated plate was then blocked with a 
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3% (w/v) BSA-PBS solution (200 μL per well) for 1 h at 37°C. Next, CRP antigen was 
diluted in 1% (w/v) BSA-PBST to a final concentration of 1 μg/mL and 100 μL was added to 
each well of the coated/blocked well and incubated at 37°C for 1 h. The plate was then 
washed using PBST (x3) and PBS (x3) to remove any unbound CRP antigen. A vial of the 
DyLight 647 ™ - labelled rabbit anti-CRP pAb (section 2.8.5) was removed from -20°C and 
thawed. Serial doubling dilutions from 1/250 to 1/128000 of the fluorescently labelled pAb 
were made in 1% (w/v) BSA-PBST and then added to wells of a 96 well plate for a 1 h 
incubation at 37°C. Following incubation, the plates were washed using PBST (x3) and PBS 
(x3) to remove any unbound labelled pAb. The absorbance was then read on a Safire 2 plate 
reader (Tecan) using the conditions below: 
 
Measurement mode:     Fluorescence
Excitation wavelength:    652 nm 
Emission wavelength:     673 nm 
Excitation bandwidth:     9 nm 
Emission bandwidth:     9 nm 
Gain (Manual):     140  
Number of reads:     10  
FlashMode:      High sensitivity  
Integration time:     40 µs 
Lag time:      0 µs 
Plate definition file:     GRE96fb.pdf  
Z-Position (Calc. from Well B2):   4800 µm 
Shake duration (Orbital Medium):   5 s 
Target Temperature:     37°C 
Current Temperature:     27°C 
 
Part 2 – Titration of CRP antigen: 
A black 96 well plate (Greiner®) was coated with a set optimal concentration (determined in 
Part 1 of assay) of purified anti-CRP pAb and left O/N at 4°C. The following day, the coated 
plate was then blocked with a 3% (w/v) BSA-PBS solution (200 μL per well) for 1 h at 37°C. 
Next, serial doubling dilutions from 1000 ng/mL to 3.9 ng/mL of CRP antigen were made in 
1% (w/v) BSA-PBST and each concentration added to designated wells (100 μL per well) of 
the coated/blocked plate for a 1 h incubation at 37°C. The plate was then washed using PBST 
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(x3) and PBS (x3) to remove any unbound CRP antigen. A vial of DyLight 647™-labelled 
rabbit anti-CRP pAb (section 2.8.5) was removed from -20°C and thawed. The fluorescently 
labelled pAb was diluted in 1% (w/v) BSA-PBST to an optimised dilution of 1/500 and then 
added wells of a 96 well plate for a 1 h incubation at 37°C. Following incubation, the plates 
were washed using PBST (x3) and PBS (x3) to remove any unbound labelled pAb. The 
absorbance was then read on a Safire 2 plate reader (Tecan) using the same conditions 
described in part 1. 
 
 
2.8.7 Preconcentration study of rabbit anti-CRP polyclonal antibody onto a CM5 sensorchip. 
 
Purified rabbit anti-CRP polyclonal antibody (pAb) was diluted in sterile-filtered 10 mM 
sodium acetate buffers that had been adjusted with 10% (v/v) acetic acid to pH values 3.8, 
4.0, 4.2, 4.4, 4.6, 4.8, 5.0 and 5.2. The pAb was diluted at each respective pH to a final 
concentration of 25 μg/mL and sequentially passed over an un-activated carboxymethylated 
dextran sensor chip surface at a flow rate of 10 μL/min. The pH showing the greatest degree 
of pre-concentration, reflected by the highest response unit (RU) value and the sharpest slope, 
was chosen as the carrier buffer for immobilisation. The optimal conditions for EDC/NHS 
chemistry to take place, is at a pH of approximately 5.0. 
 
2.8.8 Immobilisation of rabbit anti-CRP polyclonal antibody onto CM5 sensorchip. 
 
The carboxymethylated dextran matrix on the sensor chip was activated by mixing equal 
volumes of 100 mM NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl-
aminopropyl) carbodiimide hydrochloride) and injecting the mixture over the sensor chip 
surface for 10 min at a flowrate of 5 μL/min. The purified rabbit anti-CRP pAb was diluted in 
10 mM sodium acetate, pH 4.0, to a concentration of 25 μg/mL. This solution was then 
injected over the activated chip surface for 20 min at a flowrate of 5 μL/min. A 1 M 
ethanolamine hydrochloride solution (pH 8.5) was injected for 8 min, resulting in both 
capping of any unreacted active groups and removal of loose non-covalently attached 
proteins. Finally, loosely bound material was further removed using two 30 s pulses of 5 mM 
NaOH. 
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2.9 Generation and characterisation of mouse anti-CRP scFv library 
 
2.9.1 Immunisation of BALB/c mice and antibody titre determination. 
 
All procedures involving animals were approved and licensed by the Department of Health 
and Children under license number B100/3816. Every precaution was taken to ensure the 
minimum distress to the animals. 
 
BALB/c mice aged 5-8 weeks were initially immunised with a final concentration of 50 
µg/mL CRP, mixed in a 1:1 ratio with Freund’s complete adjuvant. The mixture was 
vigorously shaken to ensure formation of a completely homogenous solution. A volume of 
200 µL was injected into the peritoneal cavity of the BALB/c mice for immunisation. 
Subsequent injections (200 µL) were performed with 25 µg/ml CRP mixed in a 1:1 ratio with 
Freund’s incomplete adjuvant. A tail bleed was taken from the mice 7 days after injection and 
the antibody titre against CRP determined. Once a high titre response to the CRP antigen was 
reached, the mice were given a final boost into the peritoneal cavity and then sacrificed 7 
days later. 
 
2.9.2 Extraction and isolation of total RNA from immunised mice. 
 
To ensure an uncontaminated environment (free from contaminant RNA) a Gelaire BSB 4 
laminar unit was sprayed with both IMS and RNase™ ZAP. The mice were sacrificed by 
cervical dislocation and their spleens removed using sterile surgical tools. All excess fat was 
trimmed from the spleen before being transferred into a 50 mL ‘RNase-free’ tube containing 
10 mL of TRI ™ reagent (MRC Ltd.). A homogenizer, previously autoclaved at 120°C for 15 
min and baked overnight (O/N) at 180°C, was used to homogenize the spleen. The 
homogenized spleen was incubated for 5 min at room temperature to allow for the total 
dissociation of nucleoprotein complexes while maintaining the integrity of the RNA. The 
homogenized spleen was then centrifuged at 2,465 x g (Eppendorf centrifuge 5810R) for 10 
min at 4°C to pellet any excess cell debris and the supernatant transferred into a 50 mL 
polypropylene Oakridge tube. Chloroform (2 mL) was then added to the tube containing the 
supernatant and then thoroughly mixed and incubated for 15 min at room temperature. 
Chloroform leads to the separation of the homogenized spleen into an upper aqueous phase 
(containing RNA) and a lower organic phase (containing DNA and protein). The resultant 
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mixture was then centrifuged at 17,500 x g (Eppendorf centrifuge 5810R) for 15 min at 4°C. 
The centrifugation produced 3 layers, consisting of a lower red phenol/chloroform phase, a 
protein interphase and a colourless liquid upper phase with the RNA. The upper aqueous 
phase was carefully transferred (ensuring no lower layer contamination) into an 85 mL 
polycarbonate Oakridge tube and subjected to RNA precipitation by addition of 5 mL of 
isopropanol. The RNA was allowed precipitate for 10 min at room temperature and then 
centrifuged at 17,500 x g (Eppendorf centrifuge 5810R) for 25 min at 4°C, resulting in a 
white RNA pellet. The isopropanol supernatant was carefully decanted and the pellet washed 
with 2 mL of 75% (v/v) ethanol by centrifugation at 17,500 x g for 10 min at 4°C. Finally, 
the pellet was allowed to air dry in the laminar hood and then resuspended in 250 µL of 
molecular grade water. 
 
2.9.3 Reverse transcription of total RNA to cDNA. 
 
Mixture 1 Component   10 µL Volume  Conc. in 10 µL reaction
Total RNA    1.85 µL   5 µg/rxn 
Oligo (dT) primer        1 µL            0.5 µg/rxn 
dNTP mix         1 µL              1 mM 
Molecular grade H2O   6.15 µL   N/A 
 
Mixture 2 Component   10 µL Volume  Conc. in 10 µL reaction 
10 X RT Buffer        2 µL   2 X 
MgCl2            4 µL   2.5 mM 
DTT          2 µL   20 mM 
RNase Out         1 µL   1 U/µL 
Superscript Ш enzyme       1 µL   200 U/µL 
 
A 20 X reaction for mixture 1 was set up on ice and then split up into 8 x 25 µL aliquots in 
sterile PCR tubes. The 8 PCR tubes were incubated at 65°C for 5 min and then placed on ice, 
while a 20 X reaction for mixture 2 was set up. Next, 25 µL of the incubated mixture 2 was 
added to all 8 of the 25 µL aliquots of mixture 1 and left to incubate at 50°C for 50 min, 
followed by 85°C for 5 min. Finally, 5 µL of RNase ™ H was added to each of the 8 x 50 µL 
reactions and incubated at 37°C for 20 min. 
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2.9.4 PCR primers for amplification of mouse scFv (pAK series) 
 
The primers listed below were obtained from Eurofins-MWG-Operon (318 Worple Road, 
Raynes Park, London, SW20 8QU) and are compatible with the primers set described by 
Krebber and co-workers (Krebber et al., 1997) for the pAK vector system. The sequences are 
given using the IUPAC nomenclature of mixed bases shown in underlined capital letters, R = 
A or G; Y = C or T; M = A or C; K = G or T; S = C or G; W = A or T; H = A or C or T; B = 
C or G or T; V = A or C or G; D = A or G or T. 
 
Variable light chain back primers 
LB1 5′gccatggcggactacaaaGAYATCCAGCTGACTCAGCC3′ 
LB2 5′gccatggcggactacaaaGAYATTGTTCTCWCCCAGTC3′ 
LB3 5′gccatggcggactacaaaGAYATTGTGMTMACTCAGTC3′ 
LB4 5′gccatggcggactacaaaGAYATTGTGYTRACACAGTC3′ 
LB5 5′gccatggcggactacaaaGAYATTGTRATGACMCAGTC3′ 
LB6 5′gccatggcggactacaaaGAYATTMAGATRAMCCAGTC3′ 
LB7 5′gccatggcggactacaaaGAYATTCAGATGAYDCAGTC3′ 
LB8 5′gccatggcggactacaaaGAYATYCAGATGACACAGAC3′ 
LB9 5′gccatggcggactacaaaGAYATTGTTCTCAWCCAGTC3′ 
LB10 5′gccatggcggactacaaaGAYATTGWGCTSACCCAATC3′ 
LB11 5′gccatggcggactacaaaGAYATTSTRATGACCCARTC3′ 
LB12 5′gccatggcggactacaaaGAYRTTKTGATGACCCARAC3′ 
LB13 5′gccatggcggactacaaaGAYATTGTGATGACBCAGKC3′ 
LB14 5′gccatggcggactacaaaGAYATTGTGATAACYCAGGA3′ 
LB15 5′gccatggcggactacaaaGAYATTGTGATGACCCAGWT3′ 
LB16 5′gccatggcggactacaaaGAYATTGTGATGACACAACC3′ 
LB17 5′gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3′ 
LBλ 5′gccatggcggactacaaaGATGCTGTTGTGACTCAGGAATC3′ 
 
Variable light chain forward primers  
LF1 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTGATTTCCAGCTTGG3′ 
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LF2 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG3′ 
LF4 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3′ 
LF5 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG3′ 
LFλ 5′ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG3′ 
 
Variable heavy chain back primers 
HB1 5′ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTTC3′ 
HB2 5′ggcggcggcggctccggtggtggtggatccGAGGTBCAGCTBCAGCAGTC3′ 
HB3 5′ggcggcggcggctccggtggtggtggatccCAGGTGCAGCTGAAGSASTC3′ 
HB4 5′ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3′ 
HB5 5′ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3′ 
HB6 5′ggcggcggcggctccggtggtggtggatccCAGGTYCARCTGCAGCAGTC3′ 
HB7 5′ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC3′ 
HB8 5′ggcggcggcggctccggtggtggtggatccGAGGTGAASSTGGTGGAATC3′ 
HB9 5′ggcggcggcggctccggtggtggtggatccGAVGTGAWGYTGGTGGAGTC3′ 
HB10 5′ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC3′ 
HB11 5′ggcggcggcggctccggtggtggtggatccGAKGTGCAMCTGGTGGAGTC3′ 
HB12 5′ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3′ 
HB13 5′ggcggcggcggctccggtggtggtggatccGAGGTGCARCTTGTTGAGTC3′ 
HB14 5′ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3′ 
HB15 5′ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3′ 
HB16 5′ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG3′ 
HB17 5′ggcggcggcggctccggtggtggtggatccCAGGTCCAACTVCAGCARCC3′ 
HB18 5′ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC3′ 
HB19 5′ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC3′ 
 
Variable heavy chain forward primers 
HF1 5′ggaattcggcccccgaggcCGAGGAAACGGTGACCGTGGT3′  
HF2 5′ggaattcggcccccgaggcCGAGGAGACTGTGAGAGTGGT3′ 
HF3 5′ggaattcggcccccgaggcCGCAGAGACAGTGACCAGAGT3′ 
HF4 5′ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT3′  
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2.9.5 Amplification of antibody variable domain genes using pAK series primers. 
 
The components for a 1 X reaction were as follows: 
 
Component    20 µL Volume  Conc. in 20 µL reaction
5 X Buffers (A,B,D,G)  4.0 µL    1 X 
VL/VH Forward Primer  0.4 µL    40 pM 
VH/VL Back Primer   0.4 µL    40 pM 
cDNA     0.4 µL               0.5 µg 
dNTP     0.4 µL               0.2 mM 
H2O               13.6 µL              N/A 
REDTaq® Polymerase             0.8 µL               1 U/µL 
 
 
PCR buffer compositions: buffer A (7.5 mM MgCl2, pH 8.5); buffer B (10 mM MgCl2, pH 
8.5); buffer D (17.5 mM MgCl2, pH 8.5); buffer G (12.5 mM MgCl2, pH 9.0). 
 
The PCR for the amplification of the mouse antibody variable domain genes was performed 
in the Biometra TGRADIENT PCR machine under the following conditions: 
 
Stage   Temperature (°C) Time (s) 
1 (1 cycle)  94   300 
2 (7 cycles)  94   60 
   68   30 
   72   60 
3 (24 cycles)  94   60 
   68   30 
   72   60 
4 (1 cycle)  72   600 
   4   pause 
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2.9.6 Purification of VH and VL variable gene fragments using the Promega clean up Kit. 
 
The VH and VL amplifications were resolved on a 1% (w/v) agarose gel until single bands for 
both the variable heavy and variable light chains were observed. Both bands were then 
excised separately using sterile scalpels and transferred into separate clean 1.5 mL micro-
centrifuge tubes. Next, 3 volumes of binding buffer was added to every 1 volume of gel slice 
and then incubated at 50°C until the gel had completely dissolved (approximately 10 min). 
The guanidine isothiocyanate component of the binding buffer allows for sufficient binding 
of the DNA to the silica membrane columns. One volume of isopropanol, equal to the 
original weight of the gel slice, was then added and mixed to allow for precipitation of the 
DNA. The mixture was then transferred to a clean collection tube and centrifuged at 20,817 x 
g (Eppendorf centrifuge 5810R) for 1 min to remove any residual buffer. The flow-through 
was discarded and the column was washed by centrifugation with 750 µL wash buffer and 
again with 250 µL wash buffer. The column was centrifuged at 20,817 x g (Eppendorf 
centrifuge 5810R) for 2 min to ensure all residual ethanol was removed and the DNA was 
eluted from the column using 30 µL molecular grade H2O. The purified DNA was quantified 
using the Nanodrop™ ND-1000. 
 
2.9.7 Splice by Overlap extension (SOE) PCR. 
 
The VH and VL purified fragments were joined using an SOE-PCR via a glycine-serine linker 
(G4S)4, producing a fragment of approximately 800 bp. The following primers were utilised: 
 
Single chain forward (scFor)  5′ggaattcggcccccgag3′ 
Single chain back (scback)  5′ttactcgcggccagccggccatggcggactaccccg3′ 
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Component    50 µL Volume  Conc. in 50 µL reaction 
5 X Buffer D    10 µL    1 X 
Sc Forward Primer     1 µL    50 pM 
Sc Back Primer     1 µL    50 pM 
VH chain      1 µL    25 ng/rxn 
VL chain      1 µL    25 ng/rxn 
dNTP       1 µL    0.2 mM 
H2O               33 µL    N/A 
REDTaq® Polymerase    2 µL    0.05 U/µL 
 
The SOE-PCR was performed in the Biometra TGRADIENT PCR machine under the following 
conditions: 
 
Stage   Temperature (°C)  Time (s) 
1 (30 cycle)   94    60 
    69    30* 
    72    60 
2 (1 cycle)   72    600 
    4    pause 
 
* A gradient was incorporated into the annealing step whereby a 0.5°C decrease was 
introduced in each successive cycle. 
 
2.9.8 SfiΙ restriction digest of purified SOE-PCR fragment and ligation into pAK 100 vector. 
 
The scFv fragment and pAK 100 vector (Krebber et al., 1997) for phage selection were cut 
using SfiΙ restriction enzyme. The SfiΙ enzyme allows for the unidirectional cloning of scFv 
fragment into the pAK 100 phage display vector. The enzyme recognises 8 bases which are 
interrupted by 5 non-recognised nucleotides (5′ggccnnnnnggcc3′), thus virtually eliminating 
internal digestion in antibody sequences. Both digestions (outlined below) were carried out 
for 5 h at 50°C. 
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SOE-PCR product SfiΙ digest    pAK 100 vector SfiΙ digest 
Component  50 µL Volume   Component  150 µL Volume 
SOE product  2.28 µL   pAK 100 vector 100 µL 
10 X Buffer 2       5 µL   10 X Buffer 2    15 µL 
10 X BSA       5 µL   10 X BSA    15 µL 
H20            31.72 µL   H20       8 µL 
SfiΙ        6 µL   SfiΙ     12 µL 
 
Both digests were resolved via electrophoresis on a 1% (w/v) agarose gel and then gel 
purified, as described in section 2.9.6. The restricted scFv gene was then ligated into the pAK 
100 vector in a 3:1 (insert:vector) ratio under the conditions below and left at 15°C O/N. 
 
Component    60 µL Volume  Conc. in 60 µL reaction 
5 X Ligase buffer        12 µL   1 X 
Digested pAK 100 vector         26.67 µL   1.2 µg/rxn 
Digested scFv gene                         8.74 µL   0.7 µg/rxn 
H2O                            0.59 µL   N/A 
T4 DNA Ligase        12 µL   400 U/µL 
 
The ligation was then subjected to an ethanol precipitation under the following conditions: 
 
Component    Volume 
Ligation mixture   120 µL 
3M NaAc, pH 5.2     12 µL 
Novagen pellet paint       2 µL 
100% (v/v) ethanol   264 µL 
 
The precipitation was left O/N at -20°C and then the DNA was harvested by centrifuging at 
20,817 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C. The ethanol supernatant was 
decanted and the pellet was washed by addition of 120 µL 70% (v/v) ethanol and centrifuging 
at 20,817 x g (Eppendorf centrifuge 5810R) for 10 min at 4°C. The pellet was allowed to air-
dry briefly and then gently dissolved in 5 µL of molecular grade H2O. 
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2.9.9 Electro-transformation of scFv-containing plasmid into XL-1 Blue E. coli cells. 
 
Transformation of the ligated product was performed by electroporation into a commercially 
available strain of XL-1 Blue E. coli cells (Stratagene). The apparatus used was a Gene 
Pulser Xcell ™ electroporation system with the parameters set to 25 µF, 1.25 kV and gene 
pulse controller at 200 Ω. After thawing on ice, 50 µL of the E. coli cells were added to the 5 
µL of ligation product, mixed by one gentle pipette action up and down and then left on ice 
for a 30 s incubation. The mixture was then transferred to a chilled 0.2 cm electroporation 
cuvette, ensuring all the mixture settled on the bottom and then placed securely in the 
‘Shockpod’. A pulse was then passed through the cuvette, which was then immediately 
flushed with 1 mL of pre-warmed SOC medium using a sterile tip. The time lapse between 
applying the pulse and transferring the cells to the growth media was kept to an absolute 
minimum for optimal recovery of E. coli transformants. A transfer delay of even 1 min has 
been reported to cause as much as a 3-fold drop in transformation efficiency. The 1 mL of 
rescued ligation was then transferred into a sterile 20 mL universal tube containing a further 2 
mL of pre-warmed SOC medium. The 3 mL of transformant suspension was then incubated 
for 1 h at 250 rpm at 37°C and then plated out on 2 x TY agar plates supplemented with 25 
µg/mL chloramphenicol and 1% (w/v) glucose. A negative control was also incorporated into 
the experiment by plating the XL-1 Blue cells containing no plasmid onto an identical 
chloramphenicol/glucose agar plates. All agar plates were incubated O/N at 37°C and then 
scraped into 2 x TY medium containing 20% (v/v) glycerol for long term storage at -80°C. 
 
2.9.10 Rescue and subsequent precipitation of scFv-displaying phage. 
 
A conical flask containing 200 mL sterile 2 x TY medium (2% (w/v) glucose and 25 µg/mL 
chloramphenicol) was inoculated with 200 µL of the transformed library glycerol stocks and 
incubated at 200 rpm and 37°C until mid-exponential phase of growth (OD~ 0.400 @ 600 
nm) was achieved. The culture was then pelleted by centrifugation at 3,200 x g at room 
temperature for 15 min and then resuspended in 200 mL of fresh 2 x TY media containing 25 
µg/mL chloramphenicol and 2 x 1011 pfu/mL helper phage. For subsequent F pilus 
conjugation to occur (an essential part of infection process) the culture was left static at 37°C 
for 30 min and then transferred into a 37°C shaking incubator (for 2 h at 250 rpm. Next, 
kanamycin was added to a final concentration of 50 µg/mL, before leaving the culture O/N at 
30°C and 250 rpm. The O/N culture was then centrifuged at 3,220 x g (Eppendorf centrifuge 
 
 
41
5810R) for 15 min at 4°C and the phage supernatant transferred into a sterile 250 mL Sorval 
™ centrifuge tube containing 8 g of PEG 8000 and 6 g of sodium chloride. The Sorval ™ 
was agitated at 250 rpm until both additives were dissolved and the phage then left precipitate 
for 1 h at 4°C. The phage was harvested by centrifugation at 6,440 x g for 25 min at 4°C and 
then resuspended in 2 mL of 2% (w/v) BSA-PBS buffer solution. The resuspended phage 
pellet was then added to a clean 1.5 mL micro-centrifuge tube and centrifuged at 20,817 x g 
for 5 min at 4°C to remove any bacterial debris. Lastly, the phage supernatant was transferred 
to a fresh micro-centrifuge tube and stored on ice at 4°C. 
 
2.9.11 Enrichment of a murine phage library via biopanning against immobilised antigens. 
 
An Immunotube (Maxisorp™, Nunc), previously coated O/N at 4°C with 500 µL of 50 
µg/mL CRP in PBS solution, was blocked for 2 h at room temperature with 3% (w/v) BSA in 
PBS. Following one wash with both PBST and PBS, 500 µL of rescued phage was then 
added to the immunotube and incubated on a roller mixer ‘SRT1’ for 2 h at room 
temperature. The immunotube was then washed with PBST (x 3) and PBS (x 3) to remove 
non-specific phage. Specific phage were then eluted by incubation with 500 µL of 100 mM 
glycine-HCl, pH 2.2, for 10 min, followed by immediate neutralisation with 30 µL of 2 M 
Tris-HCl, pH 8.0. Half of the eluted phage (265 µL) was added to mid-exponential phase XL-
1 Blue cells, allowed to infect for 30 min static at 37°C and then incubated at 37°C for 1 h at 
200 rpm. The culture was then harvested by centrifuging at 3,220 x g (Eppendorf centrifuge 
5810R) for 15 min at room temperature after which the pellet was resuspended in 600 µL 
fresh 2 x TY media. An input titre was performed by making serial dilutions (10-1-10-12) of 
the PEG-precipitated phage in exponential growth phase XL-1 Blue cells. Following a 15 min 
infection at 37°C, the 108 - 1012 serial dilutions were plated on 2 x TY agar plates containing 
25 µg/mL chloramphenicol and incubated O/N at 37°C. All of the subsequent rounds of 
panning were performed as described above, with the following amendments shown in Table 
3.2.11. Also, in the 4th round of panning an antigen challenge was incorporated into the 
protocol, which meant two separate phage outputs were produced. The antigen challenge 
involved incubating 5 µg of CRP on the washed immunotube for 10 min to remove any 
weakly binding phage-scFv fragments, which were infected as usual into mid-exponential 
phase XL-1 Blue cells. The remaining phage-scFv binding to the immunotube were then 
eluted as before, with glycine-HCl, and also infected into mid-exponential phase E. coli cells. 
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Table 2.9.11 Parameters varied in panning of murine anti-CRP scFv library 
 PAN 1 PAN 2 PAN 3 PAN 4 
Culture vol. (mL) 200 200 100 100 
CRP-coated 25 µg 25 µg 5 µg 1 µg 
Washes 
3 x PBST 
3 x PBS 
5 x PBST 
5 x PBS 
10 x PBST 
10 x PBS 
13 x PBST 
13 x PBS 
Antigen challenge No No No Yes 
 
 
2.9.12 Polyclonal phage ELISA and scFv check via ‘colony-pick’ PCR. 
 
A 96 well plate ELISA plate (Maxisorp™, Nunc) coated with 100 µL per well of 2 µg/mL 
CRP was incubated O/N at 4°C. The CRP solution was decanted and the plate was blocked 
with 3% (w/v) BSA in PBS for 1 h at 37°C. The phage outputs in XL-1 Blue cells from each 
round were then grown in 10 mL 2 x TY media. When mid-exponential phase of growth was 
achieved, the cells were rescued with helper phage and shaken O/N at 30°C following the 
addition of 50 µg/mL kanamycin. The culture was then centrifuged at 3,220 x g (Eppendorf 
centrifuge 5810R) for 10 min at room temperature and the phage supernatant diluted 10 fold 
in 1% (w/v) BSA in PBST. A 100 µL volume of each of the diluted phage supernatants were 
added in duplicate to the ELISA plate and incubated for 1 h at 37°C. Following the 
incubation of the phage, the plate was washed 3 times with both PBST and PBS. Next, 100 
µL of 1/5000 dilution of a HRP-conjugated anti-M13 antibody (GE Healthcare Life Sciences) 
in 1% (w/v) BSA-PBST was added to each well and incubated for 1 h at 37°C. The specific 
complex was then detected by the addition of 100 µL of TMB substrate and allowed to 
develop for 20 min at 37°C. Finally, the reaction was quenched using 100 µL of 1 M HCl and 
the absorbance values read at 450 nm on a Safire 2 plate reader (Tecan).  
 
Twenty single colonies were randomly picked from the 4th round of panning and 
incorporated into a ‘colony-pick’ PCR to ensure the vector was harbouring the scFv 
fragment. A sterile tip was used to pick a single colony into the following mixture, which was 
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then placed in a Biometra TGRADIENT PCR machine. The amplified scFv fragments were then 
analysed via gel electrophoresis on a 1% (w/v) agarose gel. 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
5 X Buffer D    10 µL    1 X 
Sc Forward Primer     1 µL    50 pM 
Sc Back Primer     1 µL    50 pM 
dNTP       1 µL    0.2 mM 
H2O                 35 µL    N/A 
REDTaq® Polymerase    2 µL    0.05 U/µL 
 
The SOE-PCR was performed in the Biometra TGRADIENT PCR machine under the following 
conditions: 
 
Stage  Temperature (°C) Time (s) 
1 (30 cycle)  94   60 
   69   30* 
   72   60 
2 (1 cycle)  72   600 
   4   pause 
 
* A gradient was incorporated into the annealing step whereby a 0.5°C decrease was 
introduced during each successive cycle i.e. annealing temperature of 54°C for final cycle. 
 
2.9.13 Subcloning of pan 4 output scFv fragments into pAK 400 vector for soluble 
expression. 
 
A culture of both the pan 4 output (XL1-Blue cells) and the pAK 400 vector (Krebber et al., 
1997) (XL1-Blue cells) were incubated O/N at 37°C and 250 rpm. Both cultures were then 
subjected to a plasmid purification using the Promega SV Miniprep ™ kit. The cells 
harbouring the plasmids were harvested by centrifugation at 3,220 x g (Eppendorf centrifuge 
5810R) for 15 min. The media supernatant was then decanted and the cell pellets resuspended 
in 250 µL cell resuspension solution. The resuspended pellets were then transferred to a 1.5 
mL sterile micro-centrifuge tube and 250 µL cell lysis solution was added, the tube inverted 4 
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times and incubated at room temperature for 5 min. A 10 µL aliquot of alkaline protease was 
then added to the lysed cells, mixed by inversion and then incubated for 5 min at room 
temperature. The addition of alkaline protease results in the inhibition of proteases released 
during the lysis step. The mixture was then neutralised using 350 µL of a solution containing 
guanidine hydrochloride, potassium acetate and glacial acetic acid and again mixed by 
inverting the tube several times. This neutralisation solution causes the genomic DNA and 
proteins present in the solution to precipitate. The lysed cells were then pelleted by 
centrifugation at 20,817 x g (Eppendorf centrifuge 5810R) for 10 min and the supernatant 
containing the plasmid DNA transferred to a spin column supplied with the kit. The spin 
column was placed in a clean collection tube and centrifuged at 20,817 x g (Eppendorf 
centrifuge 5810R) at room temperature for 1 min causing the plasmid DNA to bind to the 
spin column membrane. The membrane-bound DNA was then washed via a 1 min 
centrifugation with 750 µL of wash solution at 20,817 x g (Eppendorf centrifuge 5810R), 
followed by a 2 min spin with 250 µL of wash solution at 20,817 x g (Eppendorf centrifuge 
5810R). The washed spin column was then transferred to a new sterile 1.5 mL micro-
centrifuge tube and the plasmid DNA eluted with 100 µL of molecular grade H20. 
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The scFv fragments were then PCR-amplified from the pan 4 plasmid DNA using the 
following components and conditions: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
5 X Buffer D    10 µL    1 X 
Sc Forward Primer     1 µL    50 pM 
Sc Back Primer     1 µL    50 pM 
Plasmid DNA    20 µL    10 µg 
dNTP       1 µL    0.2 mM 
H2O                 15 µL    N/A 
REDTaq® Polymerase    2 µL    0.05 U/µL 
 
The PCR was performed in the Biometra TGRADIENT PCR machine under the following 
conditions: 
Stage  Temperature (°C) Time (s) 
1 (30 cycle)  94   60 
   69   30* 
   72   60 
2 (1 cycle)  72   600 
   4   pause 
 
* A gradient was incorporated into the annealing step whereby a 0.5°C decrease was 
introduced during each successive cycle. 
 
Next the pAK 400 vector and the amplified scFv fragments, respectively, were digested using 
the restriction enzyme SfiΙ for 5 h at 50oC using the components outlined below: 
 
Components   250 µL Volume Components  50 µL Volume 
pAK 400 Vector  196 µL  pan 4 plasmid prep  22.2 µL 
10 X buffer 2      25 µL  10 X buffer 2         5 µL 
100 X BSA    2.5 µL  10 X BSA        5 µL 
H2O               10.5 µL  H2O     12.8 µL 
SfiΙ restriction enzyme   16 µL  SfiΙ restriction enzyme      5 µL 
 
 
 
46
The restricted scFv inserts and pAK 400 vector were then purified using the same procedure, 
as outlined in section 2.9.6, and ligated in a 3:1 (insert:vector) ratio at 15°C O/N under the 
following conditions. 
 
Component    130 µL Volume  Conc. in 130 µL reaction 
5 X Ligase buffer     26 µL   1 X 
Digested pAK 400 vector            34.7 µL   1.2 µg/rxn 
Digested scFv gene                        57.7 µL   0.7 µg/rxn 
H2O                  5.1 µL   N/A 
T4 DNA ligase               6.5 µL   400 U/µL 
 
The ligation was then subject to an ethanol precipitation under the following conditions: 
 
Component    Volume 
Ligation mixture   130 µL 
3M NaAc, pH 5.2     15 µL 
Novagen pellet paint       2 µL 
100% (v/v) ethanol   325 µL 
 
Transformation of the ligated product into Top 10 F′ E. coli cells was performed, as described 
in section 2.9.9.  
 
2.9.14 Direct and inhibition ELISA of scFv fragments in pAK 400 expression vector. 
 
Individual colonies (384 in total) were picked and grown O/N at 200 rpm and 37°C in single 
wells containing 100 μL 2 x TY media with 25 μg/mL chloramphenicol (stock plates). The 4 
x 96 well stock plates were then subcultured into fresh 2 x TY media (180 μL) containing 1 x 
505 (Studier, 2005) (0.5% (v/v) glycerol, 0.05% (v/v) glucose final concentration), 1mM 
MgSO4 and 25 μg/mL chloramphenicol (subcultured plates). Glycerol was then added to the 
O/N stock plates to a final concentration of 15% (v/v) and then transferred to a -80°C freezer 
for long-term storage. Meanwhile, the subcultured plates were incubated at 37°C at 200 rpm 
until cells appeared turbid i.e. an optical density at 600 nm (OD600 nm) of ~0.6 was 
achieved. Expression was then induced by adding IPTG to a final concentration of 1mM and 
incubating at 30°C (180 rpm) O/N. Also, for each plate of clones, a 96 well plate 
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(Maxisorp™, Nunc) was coated with 1 μg/mL CRP in PBS solution (100 μL per well) and 
left O/N at 4°C. The following day, the antigen coated plate was then blocked with a 3% 
(w/v) BSA-PBS solution (200 μL per well) for 1 h at 37°C. Meanwhile, the O/N plates of 
expressed clones were removed from 30°C and subject to a freeze-thaw protocol for the 
production of scFv-enriched lysate. In this protocol the plates are placed at -80°C until frozen 
and then thawed at 37°C (this step was repeated a total of 3 times). The plates were then 
centrifuged at 3,220 x g (Eppendorf centrifuge 5810R) for 15 min to obtain the scFv-enriched 
lysate supernatant. Each lysate supernatant was then added (100 μL per well) to its 
corresponding coated/blocked well and incubated at 37°C for 1 h. (Alternatively, an 
inhibition ELISA was performed, whereby the lysate was pre-incubated with several 
concentrations of the free antigen and then added to the corresponding coated/blocked well). 
Following incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any 
unbound scFv. The CRP-scFv complex was detected with 100 μL per well of 1/2000 dilution 
of an anti-histidine (HRP-labelled) secondary mAb (Sigma). After a 1 h 37°C incubation with 
the secondary mAb, TMB was added (100 μL per well) and left react for 20 min at 37°C. The 
reaction was quenched by the addition of 100 μL per well of 10% (v/v) HCl, after which the 
absorbance was read at 450 nm on a Safire 2 plate reader (Tecan). 
 
2.9.15 Production of C11-2 scFv template for sub-cloning into pComb3X vector. 
 
An aliquot of a glycerol stock of the selected mouse anti-CRP scFv clones (C11-2 scFv 
contained in pAK 400 vector in Top 10 F′ cells ) was inoculated into 10 mL of SB medium 
(25 μg/mL chloramphenicol) and grown O/N at 37°C at 250 rpm. The O/N culture was then 
subjected to a plasmid purification using the Promega SV Miniprep ™ kit as described in 
section 2.9.13. Next, a SfiΙ restriction digest was performed on the plasmid preparation at 
50°C for 5 h using the following conditions: 
 
Components   200 µL Volume 
pAK 400 Vector    89 µL 
10 X buffer 2      20 µL 
10 X BSA     20 µL 
H2O                  64 µL 
SfiΙ restriction enzyme     7 µL 
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2.9.16 PCR  primers for sub-cloning of mouse scFv from pAK400 to pComb3X vector. 
 
Vκ 5′ Sense Primer 
MSCVK5 
5’ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3' 
 
VH 3′ Reverse Primer 
SubRev 
5’ CCT GGC CGG CCT GGC CAC TAG TGA GAG GAG ACT GTG AGA GTG GTG 
CCT TC 3’ 
 
2.9.17 Nested PCR for conversion of mouse scFv from pAK400 to pComb3X format. 
 
2.9.17 (a) Nested PCR (Part 1) - The components for a 1 X reaction were as follows: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
HIFI buffer (10x)      5 µL    1 X 
MSCVK5             1.67 µL    83 pM 
SubRev    0.5 µL    83 pM 
scFv template                 1 µL    27 ng/rxn 
dNTP        1 µL    0.2 mM 
MgSO4       2 µL    2 mM 
H2O             38.63 µL    N/A 
Platinum HIFI ™ Taq   0.2 µL    5 U/ µL 
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The SOE-PCR was performed in the PX2 thermal cycler (thermo electron corporation) under 
the following conditions: 
 
Stage   Temperature (°C)  Time (s) 
1 (1 cycle)  94    30 
2 (30 cycles)  94    30 
   60*    30 
   68    120 
3 (1 cycle)  68    600 
   4    pause 
 
*An annealing temperature gradient ranging from 50 - 60°C was incorporated into the PCR. 
 
2.9.17 (b) Nested PCR (Part 2) - The components for a 1 X reaction were as follows: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
HIFI buffer (10x)      5 µL    1 X 
MSCVK5             1.67 µL    83 pM 
SubRev    0.5 µL    83 pM 
New scFv template      1 µL    21.5 ng/rxn 
dNTP        1 µL    0.2 mM 
MgSO4       2 µL    2 mM 
H2O             38.63 µL    N/A 
Platinum HIFI ™ Taq   0.2 µL    5 U/ µL 
 
The PCR conditions employed for part 2 were the same as shown for part 1 except that only 
the most optimal annealing temperature (60°C) was used. 
 
2.9.18 SfiΙ restriction digest of nested PCR product and ligation into pComb3X vector. 
 
Both the purified nested PCR product (modified scFv gene) and purified pComb3X vector 
were digested using the restriction enzyme SfiΙ for 5 h at 50oC using the components outlined 
below: 
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Components   100 µL Volume Components  100 µL Volume 
Modified scFv insert (25 µg)   20.3 µL pComb3X vector (30 µg) 40.7 µL 
10 X buffer 2          10 µL 10 X buffer 2       10 µL 
10 X BSA        10 µL 10 X BSA      10 µL 
H2O                39.7 µL H2O     30.3 µL 
SfiΙ restriction enzyme       20 µL SfiΙ restriction enzyme      9 µL 
 
Following a 5 h incubation at 50°C, the digested pComb3XSS vector (see section 7.1.1 for 
vector map) was treated with Antarctic Phosphatase™ enzyme to prevent self-ligation. This 
enzyme catalyzes the removal of 5′ phosphate groups from DNA. The loss of the 5′ 
phosphoryl termini, therefore, prevents the ligase enzyme from working.  
 
Antarctic phosphatase treatment of digested pComb3XSS  vector 
 
Component     Volume 
pComb3X vector (5 µg)      50 µL 
Antarctic phosphatase buffer (10x)      5 µL 
Antarctic phosphatase enzyme                 2 µL 
 
The above reaction mixture was incubated for 1 h at 37°C and then the enzyme was heat 
inactivated at 65°C for 5 min. The restricted products were then purified using the same 
procedure, as outlined in section 2.9.6, and ligated in a 3:1 (insert:vector) ratio at 15°C O/N 
under the following conditions: 
 
Component      Volume 
Ligase buffer (10x)       20 µL 
Digested pComb3X vector (1.4 µg)                 80 µL 
Digested scFv gene (700 ng)     7.8 µL 
H2O                  82.2 µL 
T4 DNA ligase       10 µL 
Total Volume      200 µL 
 
The ligation was subjected to an ethanol precipitation, harvested and then transformed into 
electro-competent Top 10 F′ cells (general method described in section 2.9.9). Individual 
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transformed colonies were cultured and their lysates analysed via direct ELISA using the 
method described in section 2.9.14. 
 
2.9.19 Optimisation of scFv expression in Terrific Broth (TB) medium. 
 
An aliquot of a glycerol stock of the selected mouse anti-CRP scFv clone (C11-2 scFv 
contained in pAK 400 vector in Top 10 F′ cells ) was inoculated into 10 mL of SB medium 
(25 μg/mL chloramphenicol) and grown O/N at 37°C at 250 rpm. An aliquot of the O/N 
culture was then subcultured into 20 mL of TB media containing 1 x 505 (0.5% (v/v) 
glycerol, 0.05% (v/v) glucose final concentration), 1mM MgSO4 and 25 μg/mL 
chloramphenicol. The culture was incubated at 37°C at 200 rpm until cells appeared turbid 
i.e. an optical density at 600 nm (OD 600 nm) of ~0.6 was achieved. Expression was then 
induced by adding IPTG to a final concentration of 1mM and incubating at 30°C (180 rpm) 
O/N. The expressed culture was then harvested by centrifuging at 3,220 x g (Eppendorf 
centrifuge 5810R) for 20 min at 4°C after which the pellet was resuspended in 500 µL of 
either PBS (ELISA analysis) or HBS buffer (Biacore analysis). Next, the resuspended pellet 
was subjected to a freeze-thaw protocol to extract the scFv from the cells. The freeze-thaw 
protocol involved incubating the resuspended cells at -80°C for 15 min, followed by 
incubation at 37°C for 10 min. This process was repeated 3 times after which the lysed cells 
were centrifuged at 20,817 x g (Eppendorf centrifuge 5810R) for 15 min at 4°C to obtain the 
clear lysate supernatant. This scFv-rich lysate was transferred to a clean 1.5 mL micro-
centrifuge tube and stored for short-term at 4°C or long-term at -20°C. 
 
 
2.10 Generation and characterisation of a chicken anti-CRP scFv library 
 
2.10.1 Construction, screening and selection of avian anti-CRP scFv library. 
 
Antibody production and selection was performed as outlined by Leonard et al., (2007), 
following the methods described by Andris-Widhopf et al., (2000). RNA was extracted from 
the spleens and bone marrow of two chickens immunised with C-reactive protein and first-
strand cDNA synthesis performed using the Superscript III™ kit (see section 2.9.3).  The 
primer sets listed by Andris-Widhopf et al., (2000) were used for the amplification of the 
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antibody variable heavy and light chain genes from the synthesized cDNA template. SOE-
PCR (see section 2.9.7) was employed to join the amplified variable heavy and light chains 
via an 18 amino acid serine-glycine linker, which was subsequently cloned into the 
pComb3X vector (see section 7.1.1 for vector map) in a VL-VH scFv format. The cloned 
scFv library was then electroporated into E. coli XL-1 blue (see section 2.11.6) cells 
generating an antibody library of 3×107 clones. The scFv fragments were packaged on the 
surface of M13K07 phage and subjected to four rounds of panning against microtitre plate 
wells coated with CRP, whereby the level of stringency throughout the four rounds was 
gradually increased. Following enrichment of the library, the eluted phage were re-infected 
into E. coli TOP10F′ cells for soluble expression. Single colonies were selected, cultured and 
expressed for incorporation into a monoclonal ELISA to identify binding to CRP. Ninety-six 
CRP-specific clones were then evaluated via a high-throughput screening strategy using the 
Biacore A100 protein interaction array system. Crude bacterial extracts of these clones were 
ranked based on the percentage of the complex left (% left) after dissociation in buffer. 
Finally, kinetic rate constants (ka and kd) and affinity (KD) data were obtained on the final 
pool of best-performing clones.  
 
2.10.2 Cross reactivity analysis of avian scFv clones using capture ELISA method. 
 
A glycerol stock of the selected clone was inoculated into SB media with 100 μg/mL 
carbenicillin and grown O/N at 200 rpm at 37°C. The O/N culture was then subcultured into 
20 mL of fresh SB media containing 1 x 505 supplement (0.5% (v/v) glycerol, 0.05% (w/v) 
glucose final concentration), 1mM MgSO4 and 100 μg/mL carbenicillin. These cultures were 
incubated at 37°C and 200 rpm until the cells appeared turbid at ~0.600 (OD 600 nm) was 
achieved. Expression was then induced by adding IPTG to a final concentration of 1mM and 
transferring to 30°C while shaking (180 rpm) O/N. Also, for each plate of clones, a 96 well 
plate (Maxisorp™, Nunc) was coated with 5 μg/mL of purified rabbit anti-CRP pAb in PBS 
solution (100 μL per well) and incubated O/N at 4°C. The following day, the pAb-coated 
plate was then blocked with a 3% (w/v) BSA-PBS solution (200 μL per well) for 1 h at 37°C. 
A 2 μg/mL solution of both CRP and SAP in PBST was then added the coated/blocked plate 
(3 rows with CRP and 3 rows with SAP) and incubated for 1 h at 37°C. Following 
incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any unbound 
CRP and SAP. Meanwhile, the O/N cultures of expressed clones were removed from 
incubation at 30°C and centrifuged at 3,220 x g for 20 min to pellet cells. The cell pellet was 
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resuspended in 2 mL of PBST and subjected to the same freeze-thaw protocol as described in 
section 3.3.13. In this protocol, the plates were placed at -80°C until frozen and then thawed 
at 37oC, which was repeated a total of 3 times. The lysed cells were then centrifuged at 
20,817 x g for 5 min to obtain the scFv-containing lysate supernatant. Each lysate supernatant 
was diluted in PBST and then added in duplicate (100 μL per well) to both the rows with 
captured CRP and also the rows with captured SAP. A positive control was also incorporated 
into the ELISA. This consisted of a 1/2000 dilution of a commercially available CRP-specific 
mAb (HyTest). Following incubation at 37°C for 1 h, the plate was then washed using PBST 
(x3) and PBS (x3) to remove any unbound scFv and mAb. The scFv bound complexes were 
detected using a 1/2000 dilution of a mouse anti-HA (HRP-labelled) secondary mAb (Roche 
Applied Science) and the HyTest mouse anti-CRP mAb bound complex (positive control) 
was detected using a 1/2000 dilution of an anti-mouse (HRP-labelled) secondary pAb 
(Sigma). After a 1 h 37°C incubation with the secondary mAb’s, 100 μL per well of TMB 
was added and incubated for 20 min at 37°C. The reaction was quenched by the addition of 
100 μL per well of 10% (v/v) HCl, after which the absorbance was read at 450 nm on a Safire 
2 plate reader (Tecan). 
 
2.10.3 Large-scale protein expression and extraction from bacterial cultures. 
 
Approximately 5 mL of SB media, containing 100 μg/mL carbenicillin, was inoculated with 
100 μL of stock transformant and grown O/N at 37°C. A 5 mL volume of this culture was 
then inoculated into 500 mL TB media containing 100 μg/mL carbenicillin, 1 mM MgSO4, 
0.5% (v/v) glycerol and 0.05% (w/v) glucose. The subcultured clone was incubated at 37°C 
at 250 rpm until the cells appeared turbid at ~0.600 (OD 600 nm) was achieved. Expression 
was then induced by adding IPTG to a final concentration of 1mM and transferring to 30°C 
(250 rpm) O/N.  
The O/N expressed culture was then transferred to two 250 mL sorvals tubes and centrifuged 
at 15,000 x g in a GSM rotor for 20 min (‘brake on’) to pellet the bacterial cells. The media 
supernatant was discarded into a bucket of Virkon™ and the excess media removed by 
inversion of the sorval tube onto a paper towel. The cell pellet was thoroughly resuspended in 
30 mL of sonication buffer (1 x PBS, pH 7.4, 0.5 M NaCl and 20 mM imidazole) and 
aliquoted into 1 mL volumes in 2 mL micro-centrifuge tubes. Each aliquot was sonicated on 
ice for 45 s (3 s intervals) at an amplitude of 40, using a microtip Vibra CellTM sonicator and 
 
 
54
the cell debris removed by centrifuging at 20,817 x g for 10 min at 4°C. The lysate 
supernatant was then passed through a 0.2 μm filter to remove any residual cell debris.  
 
2.10.4 Purification of scFv fragments using immobilised metal affinity chromatography 
(IMAC). 
 
A 3 mL aliquot of Ni+-NTA agarose resin (QIAgen) was added to a 20 mL column and 
equilibrated with 20 mL of running buffer (1 x PBS, 0.5 M NaCl, 20 mM imidazole and 1% 
(v/v) Tween-20). The filtered lysate was then applied to the equilibrated column and the 
flow-through collected in a 50 mL tube. The column was then washed with 30 mL of running 
buffer to remove any loosely bound non-specific proteins, again collecting the flow-through 
in a 50 mL tube. The scFv fragment was eluted using of 100 mM NaAc, pH 4.4, and 
collected in 24 x 400 μL aliquots in 1.5 mL micro-centrifuge tubes containing 100 μL of 
filtered neutralisation buffer (50 μL 100 mM NaOH and 50 μL of 10 x PBS). The 12 mL of 
neutralised scFv was then thoroughly buffer exchanged against filtered PBS (1 x) using a 5 
kDa cut-off Vivaspin™ 6 column (AGB, VS0611). The buffer-exchanged scFv was then 
quantified using the Nanodrop™ ND-1000 and aliquoted into clean PCR tubes and stored at -
20°C.  
 
2.10.5 Preparation of monomeric CRP (mCRP). 
 
Modified monomeric CRP was produced according to the methods described by Kresl et al., 
(Kresl, Potempa and Anderson, 1998) (see section 2.10.5). In this procedure, 2 mg of 
pentameric CRP was chelated with 10 mM EDTA and incubated in 8.0 M urea for 2 h at 37 
°C. Urea was removed by passing the CRP through a PD-10 Sephadex G-25 column 
equilibrated in PBS (0.15 M NaCl, 2.5 mM potassium chloride, 10 mM disodium hydrogen 
phosphate and 18 mM sodium dihydrogen phosphate, pH 7.4). The modified CRP protein 
was quantified by determining absorbance at 280 nm using the Nanodrop™ ND-1000 
instrument and stored at 4 °C. 
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2.10.6 Amplification of Cλcys chain from isolated chicken cDNA. 
 
The components for a 1 X reaction were as follows: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
GoTaq Buffer (5x)      10 µL   1 X 
Cλcys For      0.5 µL   83 pM 
Cλcys Rev      0.5 µL   83 pM 
MgCl2                  2 µL    1.5 mM 
cDNA     0.5 µL    0.5 µg 
dNTP           1 µL    0.2 mM 
H2O             35.25 µL    N/A 
Go Taq ™ Polymerase           0.25 µL    5 U/ µL 
 
The PCR for the amplification of the constant lambda chain containing a terminal cysteine 
(Cλcys chain) was performed in the PX2 thermal cycler (thermo electron corporation) under 
the following conditions: 
 
Stage   Temperature (°C) Time (s) 
1 (1 cycle)  94          180 
2 (30 cycles)  94            15 
   56            30 
   72            60 
3 (1 cycle)  72          600 
   4          pause 
 
 
2.10.7 Replacement of the existing Cκ chain of the pMoPAC 16 vector with a Cλcys chain. 
 
A large-scale plasmid prep of the pMoPac 16 vector (Hayhurst et al., 2003) from ER2925 
cells was performed, using a commercially-available plasmid Midi kit (Qiagen). Next, the 
existing constant kappa (Cκ) chain was removed from the purified pMoPac 16 plasmid via 
digestion with both Not1 and Sal1 restriction enzymes. Additionally, the amplified Cλcys 
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chain was purified using the QIAquick ™ gel extraction kit and also subjected to digestion 
with the same restriction enzymes. 
 
pMoPac Not1-Sal1 digest    Cλcys chain Not1-Sal1 digest  
Component   Volume  Component   Volume 
pMoPac vector (10 µg)  15 µL   Cλcys chain (2 µg)    20 µL 
10 X buffer 3   10 µL   10 X Buffer 3       5 µL 
10 X BSA   10 µL   10 X BSA       5 µL 
H20               49 µL   H20                 10 µL 
Not Ι      6 µL   Not Ι        5 µL 
Sal Ι    10 µL   Sal Ι        5 µL 
Total volume            100 µL   Total volume     50 µL 
 
Following an incubation O/N at 37°C, the digested products were incubated at 65°C for 20 
min for deactivation of both the Not Ι and Sal Ι enzymes. Finally, the deactivated digests were 
both resolved via agarose gel electrophoresis, gel extracted and then ligated using the 
following conditions: 
 
Component        Volume 
Ligase buffer (10x)            2 µL 
Digested pMoPac vector (200 ng)      1.42 µL 
Digested Cλcys chain  (100 ng)     0.71 µL 
H2O        14.87 µL  
T4 DNA ligase            1 µL  
Total Volume           20 µL 
 
2.10.8 Analysis of Cλ-scFv (scAb) transformants clones via direct ELISA. 
 
Individual colonies (60 in total) were picked and inoculated into the inner 60 wells of sterile 
96 well plates containing 100 μL SB media with 100 μg/mL carbenicillin and grown O/N at 
200 rpm at 37°C (stock plates). The stock plates were then subcultured into fresh SB media 
(180 μL) containing 1 x 505 supplement (0.5% (v/v) glycerol, 0.05% (w/v) glucose final 
concentration), 1mM MgSO4 and 100 μg/mL carbenicillin (subcultured plates). Glycerol was 
then added to the stock plates to a final concentration of 15% (v/v), which were then 
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transferred to a -80°C freezer for long term storage. Meanwhile, the subcultured plates were 
incubated at 37°C and 200 rpm until cells appeared turbid (OD600 nm of ~0.6). Expression 
was then induced by adding IPTG to a final concentration of 1mM and transferring to 30°C 
(180 rpm) O/N. Also, for each plate of clones, a 96 well plate (Maxisorp™, Nunc) was 
coated with 1 μg/mL PSA-PBS solution (100 μL per well) and incubated O/N at 4°C. The 
following day, the antigen-coated plate was then blocked with 200 μL per well of PBS 
(containing 2.5% (w/v) milk and 2.5% (w/v) BSA) and incubated for 1 h at 37°C. 
Meanwhile, the O/N plates of expressed clones were removed from 30°C and subjected to a 
freeze thaw protocol for the production of scAb-containing lysate. The protocol consisted of 
the plates being placed at -80°C until frozen and then thawing at 37°C, which was performed 
a total of 3 times. The plates were then centrifuged at 3,220 x g for 15 min to obtain the 
scAb-containing lysate supernatant. Each lysate supernatant was then added (100 μL per 
well) to its corresponding coated/blocked well and incubated at 37°C for 1 h. Following 
incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any unbound 
scAb. Next, 100 μL of a 1/2000 dilution of Cλ-specific rabbit serum in PBST (containing 0.5 
% (w/v) milk and 0.5 % (w/v) BSA) was added to each well and incubated for 1 h at 37°C. 
The PSA-bound complex was then detected using a 100 μL per well of a 1/2000 dilution of a 
HRP-labelled anti-rabbit secondary mAb (Sigma). After a 1 h 37°C incubation with the 
secondary mAb, 100 µL per well of TMB was added and incubated for 20 min at 37°C. The 
reaction was quenched by the addition of 100 μL per well of 10% (v/v) HCl, after which the 
absorbance was read at 450 nm on a Safire 2 plate reader (Tecan). 
 
2.10.9 Nested PCR for cloning of H2 scFv gene into the pMoPac 16 vector. 
 
The H2 scFv gene template for the PCR was prepared by purifying the pComb3X plasmid 
containing the H2 scFv gene and digesting it with Sfi1 enzyme. The resultant H2 scFv gene 
digest was then purified via gel extraction using a QIAquick ™ gel extraction kit. 
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2.10.9 (a) Nested PCR (Part 1) - The components for a 1 X reaction were as follows: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
HIFI buffer (10x)      5 µL    1 X 
CSCpAK-For             1.58 µL    83 pM 
CSCpAK-Rev             1.25 µL    83 pM 
H2 scFv (Sfi1digested)     1 µL    6 ng/rxn 
dNTP        1 µL    0.2 mM 
MgSO4       2 µL    2 mM 
H2O             37.97 µL    N/A 
Platinum HIFI ™ Taq   0.2 µL    5 U/ µL 
 
The SOE-PCR was performed in the PX2 thermal cycler (Thermo electron corporation) under 
the following conditions: 
 
Stage   Temperature (°C)  Time (s) 
1 (1 cycle)  94    120 
2 (30 cycles)  94    30 
   56    30 
   72    120 
3 (1 cycle)  72    600 
   4    pause 
 
2.10.9 (b) Nested PCR (Part 2) - The components for a 1 X reaction were as follows: 
 
Component    50 µL Volume  Conc. in 50 µL reaction 
HIFI buffer (10x)      5 µL    1 X 
CSCpAK-For             1.58 µL    83 pM 
CSCpAK-Rev             1.25 µL    83 pM 
PCR product from part 1  0.2 µL    2 ng/rxn 
dNTP        1 µL    0.2 mM 
MgSO4       2 µL    2 mM 
H2O             38.77 µL    N/A 
Platinum HIFI ™ Taq   0.2 µL    5 U/ µL 
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The PCR conditions employed for part 2 of the ‘nested-type’ PCR were identical to those 
shown for part 1. 
 
2.10.10 SfiΙ restriction digest of nested PCR product and ligation into pMoPac 16 vector. 
 
Both the purified nested PCR product and purified pMoPac vector were digested using the 
restriction enzyme SfiΙ for 5 h at 50oC using the components outlined below: 
 
Components   50 µL Volume  Components  100 µL Volume 
H2-pAk scFv gene  (5 µg)   16.7 µL E3 pMoPac vector (10 µg)    50 µL 
10 X buffer 2            5 µL 10 X buffer 2       10 µL 
10 X BSA          5 µL 10 X BSA      10 µL 
H2O                19.3 µL H2O        23 µL 
SfiΙ restriction enzyme         4 µL SfiΙ restriction enzyme      7 µL 
 
The restricted products were then gel purified and ligated in a 3:1 (insert:vector) ratio at 15°C 
O/N under the following conditions: 
 
Component      Volume 
Ligase buffer (10x)         2 µL 
Digested E3 pMoPac vector (200 µg)               2.8 µL 
Digested H2-pAK scFv gene (100 ng)            1.56 µL 
H2O                12.64 µL 
T4 DNA ligase         1 µL 
Total Volume        20 µL 
 
The ligation was subjected to an ethanol precipitation, harvested and then transformed into 
electro-competent Top 10 F′ cells (method described in section 2.9.9). 
 
2.10.11 Transfer of purified D9 scAb to nitrocellulose membrane and western blot analysis. 
 
Six sheets of Whatmann filter paper and one sheet of 3 mm nitocellulose (per gel) were cut to 
the same dimensions of the SDS gel. Each of the layers of filter paper, the nitrocellulose 
membrane and the SDS gel were soaked in transfer buffer for 15 – 30 min. A three layer 
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sandwich consisting of 3 sheets of filter paper, followed by the SDS Gel, nitrocellulose 
membrane and filter paper was assembled. All air bubbles were removed by carefully rolling 
each of the layers with a disposable 10 ml serological pipette. Proteins were transferred from 
the acrylamide gel to the nitrocellulose using a Trans-Blot® Semi-Dry Transfer cell (BioRad) 
@ 15 V for 15 min. The nitrocellulose membrane was then carefully transferred into a large 
weighing boat containing 20 mL of 5 % (w/v) milk-PBS solution and blocked for 2 h at room 
temperature or at 4°C overnight with agitation. Any excess blocking solution was removed 
from the membrane via two washes with PBS. Next, the blocked membrane was incubated 
with 20 mL of 1 % (w/v) milk-PBST solution containing 2 µg/mL of CRP for 1 h at room 
temperature with gentle agitation. The CRP solution was then discarded and the membrane 
washed in 0.05 % (v/v) PBST (x3) and PBS (x3). Next, a 1/2000 dilution of Cλ-specific 
rabbit serum was prepared in 20 mL of 1 % (w/v) milk-PBST and again left incubate with the 
membrane at room temperature for 1 h with agitation. A 1/2000 dilution of a HRP-labelled 
anti-rabbit secondary mAb (Sigma) was then used for detection of the bound Cλ-specific 
serum antibodies. Following a 1 h incubation, the membrane was washed as before, followed 
by a brief wash with distilled water. Development of the specific complex was achieved via 
the addition of liquid TMB substrate and stopped by multiple washes with distilled water. 
 
 
 
2.11 Generation and characterisation of a chicken anti-MPO scFv library 
  
2.11.1 Immunisation and serum titre of MPO-immunised chickens 
 
Two white Leghorn chickens aged 5-8 weeks were initially immunised with a final 
concentration of 75 µg/mL MPO, mixed in a 1:1 ratio with Freund’s complete adjuvant. The 
mixture was vigorously shaken to ensure formation of a completely homogenous solution. A 
total volume of 1000 µL of this solution was injected over four separate subcutaneous sites of 
each chicken for immunisation. Subsequent injections were performed with 50 µg/ml MPO 
mixed in a 1:1 ratio with Freund’s incomplete adjuvant. A bleed was taken from the chickens 
10 days after each injection and the antibody titre against MPO determined. Once a high titre 
response was reached, the chickens were given a final boost and then sacrificed 6 days later. 
Two further immunogens, namely heart fatty acid binding protein (H-FABP) and C-reactive 
protein (CRP), were administered in an identical manner to the same two chickens. The 
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phylogenetic nature of the avian host allowed for the administration of this cocktail of 
mammalian proteins, simultaneously. 
 
2.11.2 Extraction and isolation of total RNA from MPO-immunised chickens. 
 
To ensure an uncontaminated environment (free from contaminant RNA) the inner surface of 
a Gelaire BSB 4 laminar unit was sprayed with both IMS and RNase ZAP. The spleen and 
bone marrow were removed from the chickens and all excess fat was trimmed from the 
spleen before being transferred into a 50 mL ‘RNase-free’ tube containing 30 mL of TRI ™ 
reagent. A homogenizer, previously autoclaved at 120°C for 15 min and baked O/N at 180°C 
was used to homogenize the spleen/bone marrow. The mixture was incubated for 5 min at 
room temperature to allow for the total dissociation of nucleoprotein complexes while 
maintaining the integrity of the RNA. The homogenized spleen/bone marrow was then 
centrifuged at 2,465 x g for 10 min at 4°C to pellet any excess cell debris and the supernatant 
transferred into a 50 mL polypropylene oakridge tube. Chloroform (6 mL) was then added to 
the tube containing the supernatant, thoroughly mixed through and then incubated for 15 min 
at room temperature. The resultant mixture was then centrifuged at 17,500 x g (Eppendorf 
centrifuge 5810R) for 15 min at 4°C. The centrifugation step produced 3 layers, a lower red 
phenol/chloroform phase, a protein interphase and a colourless liquid upper phase containing 
the RNA. The upper aqueous phase was carefully transferred (ensuring no lower layer 
contamination) into a 85 mL polycarbonate Oakridge tube and precipitated by addition of 15 
mL of isopropanol. The RNA from both chickens was left to precipitate for 10 min at room 
temperature and then centrifuged at 17,500 x g for 25 min at 4°C, resulting in white RNA 
pellets. The isopropanol supernatant was carefully decanted and the pellets washed with 30 
mL of 75% (v/v) ethanol by centrifugation at 17,500 x g for 10 min at 4°C. Finally, the 
pellets were allowed air dry in the laminar hood and then each resuspended in 500 µL of 
molecular grade water. The RNA preparations from both of the chickens were then quantified 
using the Nanodrop™ ND-1000 and pooled in an equimolar ratio. 
 
2.11.3 Reverse transcription of total RNA to cDNA. 
 
Protocol was performed as described in section 2.9.3. 
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 2.11.4 PCR primers for amplification of chicken scFv (pComb series) 
 
Vλ Primers 
CSCVK (sense) 
5´ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG TC 3´ 
CKJo-B (reverse) 
5´ GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 3´ 
 
VH Primers 
CSCVHo-F (sense), Short Linker 
5´ GGT CAG TCC TCT AGA TCT TCC GCC GTG ACG TTG GAC GAG 3´ 
CSCVHo-FL (sense), Long Linker 
5´ GGT CAG TCC TCT AGA TCT TCC GGC GGT GGT GGC AGC TCC GGT GGT GGC 
GGT TCC GCC GTG ACG TTG GAC GAG 3´ 
CSCG-B (reverse) 
5´ CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT GAC TTC GGT CC 3´ 
 
Overlap Extension Primers 
 
CSC-F (sense) 
5´ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 3´ 
CSC-B (reverse) 
5´ GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG GCC ACT AGT GGA 
GG 3´ 
 
2.11.5 Construction of chicken anti-MPO scFv library 
 
Antibody production and selection was performed as described by Andris-Widhopf et al., 
(2000). 
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2.11.6 Electro-transformation of scFv containing plasmid into XL-1 Blue E. coli cells. 
 
Transformation of the ligated product was performed via electroporation into a commercially 
available strain of XL-1 Blue. The apparatus used was a Gene Pulser Xcell ™ electroporation 
system with the parameters set to 25 µF, 1.25 kV and the gene pulse controller at 200 Ω. The 
ligation mixture was split into 3 x 10 µL aliquots. After thawing on ice, 100 µL of the E. coli 
cells was added to each of the 3 x 10 µL aliquots of ligation product, mixed by one gentle 
pipette up and down and then left on ice for a 30 s incubation. The mixture was then 
transferred to a chilled 0.2 cm electroporation cuvette, ensuring all the mixture settles on the 
bottom and then placed securely in the ‘ShockPod’. A pulse was then passed through the 
cuvette, which was then immediately flushed with 1 mL of pre-warmed SOC medium using a 
sterile tip. A further 2 x 1 mL volumes of SOC media were used to flush the cuvettes. The 
time lapse between applying the pulse and transferring the cells to the growth media must be 
kept to an absolute minimum for optimal recovery of E. coli transformants. A transfer delay 
of even 1 min has been reported to cause as much as a 3-fold drop in transformation 
efficiency. The 3 mL of rescued ligation for the library was then incubated for 1 h at 250 rpm 
at 37°C. Following incubation, the 3 mL culture was plated out on 2 x TY agar plates 
supplemented with 100 µg/mL carbenicillin and 2% (w/v) glucose. A negative control was 
also incorporated into the experiment by plating the XL-1 Blue cells containing no plasmid 
onto an identical carbenicillin/glucose agar plate. All agar plates were left grow O/N at 37°C 
and then scraped into 2 x TY medium containing 20% (v/v) glycerol for long term storage at 
-80°C. 
 
2.11.7 Rescue of chicken anti-MPO scFv-displaying phage. 
 
A 2 mL aliquot of the scraped library was inoculated into 400 mL of SB medium (30 µg/mL 
carbenicillin and 10 µg/mL tetracycline) for the chicken scFv library. Due to the high level of 
turbidity, the culture was left grow for approximately 1 h shaking at 37°C, after which more 
carbenicillin was added to a final concentration of 30 µg/mL. The library was then rescued by 
the addition of 900 µL of commercial M13K07 helper phage (Isis, Cat No. N0315S), left 
static at 37°C for 20 min and then transferred to a 37°C shaking incubator for 2 h at 250 rpm. 
Next, kanamycin was added, to a final concentration of 70 µg/mL, before leaving the culture 
O/N at 37°C while shaking at 250 rpm.  
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2.11.8 Enrichment of library via biopanning against immobilised antigens. 
 
Several wells of a 96-well ELISA plate (Maxisorp™, Nunc) coated O/N at 4°C with a set 
concentration MPO in PBS solution (See Table 3.4.8) were then blocked by filling with 3% 
(w/v) BSA-PBS and leaving at room temperature for 2 h. Meanwhile, the rescued phage-
induced library was centrifuged at 15,000 x g in a GSM rotor for 20 min (‘brake on’ option 
selected) to pellet the bacterial cells. The phage supernatant was decanted into 250 mL sterile 
sorval tubes, to which 4 g of PEG and 3 g of NaCl was added for every 100 mL of phage. To 
ensure all the PEG and NaCl was dissolved, the sorval tubes were placed in a 37°C shaking 
incubator for 10 min at 200 rpm. 
For precipitation of the phage, the sorval tubes were placed in ice and left in a cold room for 
45 min. The PEG-precipitated phage was then harvested by centrifugation at 15,000 x g in a 
GSM rotor for 20 min (‘brake off’) and the media supernatant carefully decanted into a 
bucket of Virkon™ (Lennox, C222/0154/05). After removal of excess supernatant by 
inversion of the sorval tubes, the phage pellets were thoroughly resuspended in 2 mL of 1% 
(w/v) BSA-PBS and aliquoted into 2 mL micro-centrifuge tubes. The micro-centrifuge tubes 
were then centrifuged at 20,817 x g for 5 min at 4°C to pellet excess bacterial cells and the 
phage supernatants transferred into clean 1.5 mL micro-centrifuge tubes on ice (phage input). 
Meanwhile, the coated/blocked wells of the ELISA plate were washed 1 x PBST and 1 x PBS 
to remove excess BSA. Next, a specified aliquot (See Table 2.11.8) of the phage-BSA 
mixture was then added to the coated/blocked wells of the ELISA plate and left incubate at 
37°C for 2 h. The wells were then decanted and washed several times with PBST and PBS 
(See Table 2.11.8) to remove weak-binding phage. To elute the bound phage an aliquot of 10 
mg/mL trypsin in 1 x PBS (pH 7.4) was added to the washed wells, incubated static at 37°C 
for 20 min and finally agitated using an SRT1 roller mixer at room temperature for 10 min. 
The trypsin solution was vigorously pipetted up and down several times in the each of the 
wells to ensure all bound phage were eluted and then infected into 2 mL of XL1-Blue cells 
(OD600 nm of ~0.5) for 15 min at room temperature. Next, 6 mL of pre-warmed SB media 
(containing 12 µL of 5 mg/mL tetracycline and 1.6 µL of carbenicillin) was added to a sterile 
50 mL tube. The 2 mL of eluted phage was then added to the 6 mL of pre-warmed SB media 
and 4 µL was removed from this culture into 396 µL of SB medium for estimation of the 
output titre. The 8 mL phage infected culture was incubated at 37°C (250 rpm) for 1 h, after 
which 2.4 µL of carbenicillin was added to the culture and incubated at 37°C for a further 1 
h. All 8 mL of the infected culture was then added to a 250 mL conical containing 92 mL of 
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pre-warmed SB medium (containing 184 µL of tetracycline and 46 µL of carbenicillin). For 
rescue of the library, 350 µL of commercial M13K07 helper phage was then added to the 100 
mL culture. The helper phage was allowed infect the stationary culture at room temperature 
for 10 min and then incubated at 37°C (250 rpm) for 2 h. Finally, 140 µL of 50 mg/mL 
kanamycin was added to the culture which was left incubate at 37°C (250 rpm) O/N. 
 
Output titre: The 1/100 dilution output titre (4 µL in 396 µL SB media) was then used to 
prepare output titre plates. Two 2 x TY agar plates (containing 100 µg/mL carbenicillin) were 
plated with 100 µL of the 1 in 100 dilution of the culture). Two further 2 x TY agar plates 
(containing 100 µg/mL carbenicillin) were plated with 10 µL of the 1/100 dilution of the 
culture). Plates were labelled pan output titre plates and incubated stationary at 37°C O/N.  
Input titre: Dilutions of the input phage supernatant were prepared (10-1 → 10-8) using SB 
media. A 2 µL aliquot of each of the 10-7, 10-8, 10-9 phage dilutions were then infected into 3 
separate sterile micro-centrifuge tubes containing 98 µL of XL1-Blue cells  (OD600 nm of 1) 
for 15 min at room temperature. A 50 µL volume of each dilution were then plated onto 2 x 
TY agar plates (containing 100 µg/mL carbenicillin) in duplicate. Plates were labelled pan 
input titre plates and incubated while stationary at 37°C O/N. 
 
Table 2.11.8 Variable parameters of panning of chicken anti-MPO scFv library 
 PAN 1 PAN 2 PAN 3 PAN 4 
Culture vol. 400 mL 100 mL 100 mL 100 mL 
CRP-coated 10 µg 5 µg 1 µg 1 µg 
No. of wells 4 2 2 1 
Input phage vol. 200 µL 100 µL 100 µL 50 µL 
Washes 5 x PBST 
5 x PBS 
10 x PBST 
5 x PBS 
10 x PBST 
5 x PBS 
10 x PBST 
10 x PBS 
 
 
 
66
2.11.9 Polyclonal phage ELISA. 
 
Designated wells of a 96 well ELISA plate (Maxisorp™, Nunc) were coated with either H-
FABP, CRP or MPO each at a concentration of 2 µg/mL in PBS and incubated O/N at 4°C. 
Each of the protein solutions were then decanted and the plate blocked with 3% (w/v) BSA in 
PBS for 1 h at 37°C. Some of the 3% (w/v) BSA solution was also added to several empty 
wells of the plate as a negative control to identify any background binding. The phage pools 
to be tested were diluted 1:1 with PBST containing 1% (w/v) BSA and a 100 µL aliquot of 
each added to designated wells of the coated/blocked ELISA plate. Following a 2 h 
incubation with the phage at 37°C, the plate was subjected to 3 washes with both PBST and 
PBS. Next 100 µL of 1/2000 dilution of an AP-conjugated anti-M13 antibody (GE 
Healthcare Life Sciences) in PBST containing 1% (w/v) BSA was added to each well and 
incubated for 1 h at 37°C. The specific complex was then detected by the addition of 100 µL 
of PNPP substrate and allowed to develop for 20 min at 37°C. Finally, the absorbance values 
were read at 405 nm on a Safire 2 plate reader (Tecan).  
 
2.11.10 Infection of enriched phage pool into E. Coli Top 10 F′ (non-suppressor strain) for 
soluble expression. 
 
A 20 µL aliquot of the PEG-precipitated ouput phage from pan 4 was added to 2 mL of Top 
10 F′ cells (OD600 nm of ~0.5) and incubated for 15 min at room temperature to promote 
infection. Next, 6 mL of pre-warmed SB media (containing 12 µL of 5 mg/mL tetracycline 
and 1.6 µL of carbenicillin) was dispensed into a sterile 50 mL tube. The 2 mL of infected 
Top 10 F′ cells were then added to the 6 mL of pre-warmed SB media and 30 µL was 
removed from this culture into 270 µL of SB medium for titering to obtain single colonies for 
analysis. The remaining 8 mL phage infected culture was left incubate at 37°C (250 rpm) for 
1 h, spun at 3,220 x g for 15 min and then resuspended in 500 µL of SB medium. The 
resuspended cells and titres were then plated on 2 x TY agar plates (containing 100 µg/mL 
carbenicillin) and incubated at 37°C O/N. 
 
2.11.11 Direct and inhibition ELISA of soluble expressed scFv fragments. 
 
Individual colonies (120 in total) were picked and inoculated into the inner 60 wells of a 
sterile 96 well plates containing 100 μL SB media with 100 μg/mL carbenicillin and grown 
 
 
67
O/N at 200 rpm at 37°C (stock plates). The 2 x 96 well stock plates were then subcultured 
into fresh SB media (180 μL) containing 1 x 505 supplement (0.5% (v/v) glycerol, 0.05% 
(w/v) glucose final concentration), 1mM MgSO4 and 100 μg/mL carbenicillin (subcultured 
plates). Glycerol was then added to the stock plates to a final concentration of 15% (v/v), 
which were then transferred to a -80°C freezer for long term storage. Meanwhile, the 
subcultured plates were incubated at 37°C and 200 rpm until cells appeared turbid (OD600 
nm of ~0.6). Expression was then induced by adding IPTG to a final concentration of 1mM 
and transferring to 30°C (180 rpm) O/N. Also, for each plate of clones, a 96 well plate 
(Maxisorp™, Nunc) was coated with 2 μg/mL MPO-PBS solution (100 μL per well) and 
incubated O/N at 4°C. The following day, the antigen-coated plate was blocked with a 3% 
(w/v) BSA-PBS solution (200 μL per well) for 1 h at 37°C. Meanwhile, the O/N plates of 
expressed clones were removed from 30°C and subjected to a freeze thaw protocol for the 
production of scFv-containing lysate. The protocol consisted of the plates being placed at -
80°C until frozen and then thawing at 37°C, which was performed a total of 3 times. The 
plates were then centrifuged at 3,220 x g for 15 min to obtain the scFv-containing lysate 
supernatant. Each lysate supernatant was then added (100 μL per well) to its corresponding 
coated/blocked well and incubated at 37°C for 1 h. (Alternatively, an inhibition ELISA was 
performed, whereby the lysate was pre-incubated with several concentrations of the free 
antigen and then added to the corresponding coated/blocked well). Following incubation, the 
plates were washed using PBST (x3) and PBS (x3) to remove any unbound scFv. The scFv-
bound MPO complex was detected using 100 μL per well of a 1/2000 dilution of an alkaline 
phosphatase (AP)-labelled anti-HA secondary mAb (Sigma, Cat. No. A5477). After a 1 h 
37°C incubation with the secondary mAb, 100 µL per well of PNPP was added and incubated 
for 20 min at 37°C. The absorbance was then read at 405 nm on a Safire 2 plate reader 
(Tecan). 
 
2.11.12 Immobilisation and reference cell surface capping for anti-MPO scFv analysis. 
 
For capture-based analysis of the anti-MPO scFv clones, a monoclonal HA epitope tag 
(Affinity BioReagents, Cat. No. MA1-21314) was required for immobilisation onto FC2 of 
the CM5 chip surface. Initial preconcentration analysis was performed for identification of 
the optimal pH for immobilisation of the HA tag, as described in section 2.8.7. 
Immobilisation of the HA epitope tag to the CM dextran surface was performed at pH 4.0, 
following the protocol described in section 2.8.8. The only modification to the protocol was 
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the use of freshly prepared ethylenediamine (pH 8.5), as opposed to ethanolamine, as a 
capping agent. The reference flow cell to be used for the analysis (FC1) was also activated 
with EDC and NHS chemistry and then capped with ethylenediamine to reduce any potential 
non-specific binding of the MPO to the CM dextran surface. 
 
2.11.13 Off-rate analysis of anti-MPO scFv clones. 
 
Crude scFv-containing bacterial lysates (containing 12 mg/mL BSA and 12 mg/ml CM-
dextran to reduce any potential non-specific binding to CM-dextran surface) were 
subsequently injected (10 μL at a flow rate of 10 μL/min) over FC1 and FC2 using reference 
subtraction of FC2-FC1. Next, MPO at a concentration of 3 nM was passed over the 
captured-scFv at a flow rate of 30 μl/min. The association and dissociation times used were 3 
and 10 min, respectively. Regeneration of the chip surface consisted of a 2 x 30 s injections 
of 20 mM NaOH. 
 
2.11.14 Titration ELISA of purified avian anti-MPO B10B scFv. 
 
A 96 well plate (Maxisorp™, Nunc) was coated with 1 μg/mL MPO-PBS solution (100 μL 
per well) and incubated O/N at 4°C. The following day, the antigen-coated plate was then 
blocked with 200 μL per well of PBS (containing 2.5% (w/v) milk and 2.5% (w/v) BSA) and 
incubated for 1 h at 37°C. Any excess blocking solution was removed via a single wash with 
PBST followed by PBS. A 1/1000 dilution of the purified scFv stock was made in PBST 
(containing 0.5% (w/v) milk and 0.5% (w/v) BSA). Next, serial halving dilutions of this were 
prepared in the same buffer as far as 1/500,000,000. A 100 μL aliquot of each of the dilutions 
were added in duplicate to the coated/blocked wells and incubated for 1 h at 37°C. Following 
incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any unbound 
scFv. The scFv-bound MPO complex was detected using a 100 μL per well of a 1/2000 
dilution of an AP-labelled anti-HA secondary mAb (Sigma, Cat. No. A5477). After a 1 h 
37°C incubation with the secondary mAb, 100 µL per well of PNPP was added and incubated 
for 20 min at 37°C. The absorbance was then read at 405 nm on a Safire 2 plate reader 
(Tecan). 
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2.11.15 Novel assay for direct detection of captured MPO. 
 
A 96 well plate (Maxisorp™, Nunc) was coated with 5 μg/mL of IMAC purified anti-MPO 
scFv in PBS (100 μL per well) and incubated O/N at 4°C. The following day, the scFv-coated 
plate was then blocked with 200 μL per well of PBS (containing 2.5% (w/v) milk and 2.5% 
(w/v) BSA) and incubated for 1 h at 37°C. Any excess blocking solution was removed with a 
wash with PBST followed by PBS. Serial halving dilutions of MPO were prepared in PBST 
(containing 0.5% (w/v) milk and 0.5% (w/v) BSA) ranging from 50000 to 97.5 ng/mL. A 100 
μL aliquot of each of the dilutions were added in quadruplicate to the coated/blocked wells 
and incubated for 1 h at 37°C. Following incubation, the plates were washed using PBST (x3) 
and PBS (x3) to remove any unbound MPO. The scFv-bound MPO complex was detected by 
the addition of either TMB or OPD in duplicate to the wells and incubated for 20 min at 
37°C. For quenching, 100 μL per well of 10% (v/v) HCl was added, after which the 
absorbance was read at 450 nm on a Safire 2 plate reader (Tecan). 
 
2.11.16 Preliminary hybrid lateral flow/western blot assay for detection of MPO. 
 
IMAC-purified avian MPO-specific scFv was diluted in PBS to a final concentration of 500 
µg/mL. Next, HiFlow Plus HF07504 nitrocellulose membrane (Millipore) was sprayed with 
the diluted scFv at a flow-rate of 600 nL/s using the Linomat 5 system (CAMAG) across the 
width of the strip. Following a 15 min incubation at 37°C, the sprayed membrane was cut 
into 4 identical strips each containing embedded scFv. All 4 strips were then transferred into 
a large weighing boat containing 20 mL of 5 % (w/v) milk-PBS solution and blocked for 2 hs 
at room temperature or at 4°C overnight with agitation. Any excess blocking solution was 
removed from the membrane via two washes with PBS. Next, each of the strips were placed 
in 4 separate small weighing boats and incubated with 5 mL of 1 % (w/v) milk-PBST 
solution each spiked with varying concentrations of MPO. Following a 1 h incubation at 
37°C, each of the MPO-spiked solutions were discarded and the membranes washed in PBST 
(x 2) and PBS (x 2). Development of each of the membrane strips was achieved via the 
addition of liquid TMB substrate and stopped by multiple washes with distilled water. 
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2.12 Immunoassays using novel platforms. 
 
2.12.1 Lateral flow assay using purified avian B10B anti-MPO scFv. 
 
A strip of HiFlow Plus HF07504 nitrocellulose membrane (Millipore) was cut to specific 
dimensions of 4 cm x 1 cm. An avian anti-MPO scFv purified via IMAC was diluted in 1% 
(w/v) trehalose – 50 mM sodium phosphate buffer, pH 7.5, (spotting buffer) to a final 
concentration of 500 µg/mL. The diluted scFv was then sprayed at a flow-rate of 400 nL/s 
using the Linomat 5 system (CAMAG) across the width of the strip (3 cm up the strip – test 
line). Also anti-rabbit IgG (HRP labelled) (Sigma) was diluted in the spotting solution to a 
concentration of 5 µg/mL and sprayed across the width of the strip (3.5cm up the strip – 
control line). The membrane is then left in a 37°C incubator for 20 min to ensure sufficient 
drying of both the scFv (test) and rabbit IgG (control) to the membrane surface. The sprayed 
nitrocellulose strip was set up to stand vertically with the bottom of the strip touching a strip 
of parafilm. A 200 µL aliquot of MPO-depleted human serum (HyTest Ltd., Cat. No. 
8MPFS), spiked with a set concentration of MPO, was then applied to the parafilm. The 
MPO-spiked serum travels up the length of the strip via capillary action, assisted by wicking 
with Whatman paper at the end of the strip. A wash buffer solution consisting of 50 mM 
sodium phosphate pH 7.5 (0.05% (v/v) Tween 20) was then applied (200 µL volume) to the 
bottom of the strip. The Tween-20 (mild detergent) assists in the breakage of any 
hydrophobic bonds which may occur between the serum and the membrane, allowing 
movement of the serum and its components up the strip towards both the test and control 
lines. The MPO in the serum sample binds to the avian anti-MPO scFv saturated test line, 
with all other non-specific proteins etc. washed away. The bound MPO is then detected by 
the addition of TMB Liquid substrate (Sigma) to the bottom of the strip, which travels up via 
capillary action and reacts with the scFv captured-MPO forming a blue colour at the test line.  
 
2.12.2 Fluorescent competition assay using the Åmic Open Lateral Flow (OLF) platform. 
 
The capture antibodies were diluted in spotting solution (1% (w/v) trehalose, 50 mM NaPO4 
buffer, pH 7.5) to a final concentration of 0.4 mg/mL and deposited onto dextran 
functionalized slides in two rows across the channel. Each mixture was spotted under humid 
conditions (relative humidity 70%) with a sciFLEXARRAYER ™ S3 (Scienion, Germany). 
A PLC 60 nozzle was used to spot the diluted capture antibodies. Each spot consisted of one 
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droplet (~25 nL). CRP (Scipac, UK) was spiked into CRP-depleted serum (Scipack, UK) at 
several concentrations (30, 10, 3.3, 1.1, 0.55 and 0 µg/mL). Alexa ™ 647 labelled CRP was 
then added to each of the spiked samples to a final concentration of 100 ng/mL. A 15 μL 
volume of each of the CRP sample solutions was applied to the sample zone on the chip. 
Following migration of the entire sample droplet into the pillar array, a 15 μL volume of 
unspiked CRP-depleted serum was added to the rear of the sample zone as a washing step. 
The signal intensities were recorded in a prototype fluorescence scanner. All assays were 
performed in triplicate and total assay time was approximately 10 min. 
 
2.12.3 Fluorescent sandwich-based assay on novel supercritical angular fluorescence (SAF) 
enhanced parabolic chip platform. 
 
Purified rabbit anti-CRP pAb (section 2.8.2) was diluted in a 1% (w/v) trehalose-sodium 
phosphate solution (0.1M) at pH 7.5 to a final concentration of 200 µg/mL. The pAb solution 
was then accurately deposited onto each paraboloid platform using a non-contact 
sciFLEXARRAYER™ (Scienion AG, Germany) piezo dispensing system. Following a 1 h 
incubation in 70% humidity at room temperature, the spotted chips were blocked in a 5% 
(w/v) milk-PBS solution O/N at 4°C. Excess blocking solution from the incubation was 
removed by another washing step with PBS. Next, varying concentrations of CRP antigen 
diluted in either 1% (w/v) milk-PBST or CRP-depleted serum were pipetted onto each of the 
washed chip surfaces (330 per chip). The chips were incubated at room temperature for 1 h, 
constantly agitating the CRP-spiked sample on the chip surface using a pipette. Another wash 
step was performed comprising PBST (x3) and PBS (x3) to remove excess unbound CRP 
antigen. A 1/400 dilution of fluorescently labelled anti-CRP pAb (section 2.8.6) in 1% (w/v) 
milk-PBST was then pipetted onto the chip surface and left to incubate for a further 2 h. An 
identical wash step was then performed, followed by a wash with deionised water, to remove 
any excess salt. Finally, the washed chips were dried using compressed nitrogen and then 
read using a custom-built biochip reader. 
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2.12.4 Analysis of the re-engineered CRP-specific H2 avian scFv using the surface plasmon 
resonance (SPR)-based Spectral platform. 
 
Prior to each experiment the poly(methyl methacrylate) or PMMA substrate of the Spectral 
device was cleaned with ultra-pure water and dried with a nitrogen stream. A cleaning step 
with argon plasma (Harrick Plasma) for 5 min was also performed to assure that no organic 
contaminants were present at the surface. The first baseline signal was extrapolated by 
passing degassed ultra-pure water through the flow channel and recording the resultant signal 
both with depolarized light and also no light (high frequency noise). This procedure was then 
repeated using degassed 1 x PBS buffer. The SPR signal was recorded for both solutions until 
the baseline levels stabilised. Next, the purified CRP-specific D9 scAb (section 3.3.6 to 3.3.8) 
was diluted in degassed PBS to a final concentration of 15 µg/mL. Immobilisation onto the 
gold surface was achieved by passing a 190 µL aliquot of the diluted scAb through the test 
channel at a flow rate of 40 µL/min (the flow of all solutions was kept constant at this 
flowrate). All solution injections were performed using a REGLO Digital peristaltic pump 
(ISMATEC, Glattbrugg, Switzerland). A dedicated temperature controller was used to 
maintain a set temperature of 20°C throughout the experiments. The new baseline level was 
identified again by passing degassed 1 x PBS through the scAb-immobilised test channel. 
Blocking of the test channel was achieved by passing through a 400 µL volume of a 
commercial blocking agent (Candor, Ref. 110-125). The latest baseline level was then 
calculated with 1 x PBS as before. CRP-depleted serum (Hytest, ref. 8CFS) was then spiked 
with a specified set of concentrations of CRP, each of which was passed across the 
blocked/scAb immobilised test channel. Finally 1 x PBS was again used to determine the 
change in baseline level which correlated directly to the binding response. 
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3.1 Generation and characterisation 
of rabbit anti-CRP polyclonal 
antibodies 
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3.1.1 Rabbit immune system 
 
The rabbit immune system has been found to generate antibody diversity and optimise 
affinity by different mechanisms than those used by mice and other rodents. One attractive 
feature of the immune system of rabbits is the use of both gene conversion and somatic 
hypermutation to diversify rearranged heavy and light chain genes. Although, antibody 
diversity generated by VHDJH rearrangements in rabbits is much more restricted than in 
mice or humans, compensation is sought in the far superior diversity obtained from VKJK 
rearrangements in rabbits. For example, both mice and humans possess only one kappa light 
chain isotype, whereas rabbits have two (K1 and K2), including several highly diverse allelic 
variants of K1 (Popkov et al., 2003). Further diversity to the immune repertoire may be 
contributed from the kappa light chain regions due to the unusual germline VK-encoded 
variability in the length of complementarity determining region 3 (LCDR3). Moreover, B 
lymphopoiesis has led to B cell recombination excision circles (BRECS), being found in bone 
marrow as early as twelve days into the gestation period of rabbits, indicating the occurrence 
of Ig gene rearrangement even at this early stage. Much interest has also been generated from 
the role that both gut-associated lymphoid tissues (GALT) and the intestinal flora play in 
development of the preimmune rabbit antibody repertoire (Mage et al., 2006). IgM B cells 
have been shown to undergo further Ig repertoire diversification in both the appendix and 
other GALT tissues. This observation has been further supported by a study, showing poor 
responses to immunisations against several antigens in germ-free rabbits (Tlaskalova-
Hogenova and Stepankova, 1980). This project involved the generation of both polyclonal 
and recombinant antibodies from female New Zealand white rabbits. 
 
3.1.2 CRP as a target analyte 
 
CRP is composed of five identical non-covalently linked polypeptide subunits (molecular 
weight of 23 kDa), each containing 206 amino acid residues (Thompson et al., 1999) (See 
Figure 4.2). These monomeric subunits are arranged in a planar ring with pentameric 
symmetry. Each subunit has a concave face in which the ligand-binding site, containing two 
calcium atoms, is located. The conservation of the structure of CRP and of its calcium-
dependent specific binding of ligands containing phosphocholine (PC) (Volanakis and 
Kaplan, 1971) and related substances, together with the failure thus far to detect any 
polymorphism or deficiency of CRP in man, argue strongly that CRP has an important 
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physiological role (Thompson et al., 1999). This proteins slow evolution is also evident in its 
close homology to other species, where the 206 amino acid structure of CRP in mice and 
rabbits, shows a 70 – 80% sequence homology with human CRP (Urich, 1994). 
The ability of CRP to dissociate into individual subunits (discussed in section 1.7) is another 
characteristic attribute of this analyte. These CRP isoforms, referred to as modified or 
monomeric CRP (mCRP), express several neo-epitopes and display properties distinct from 
those of native CRP (Potempa et al., 1987; Zouki et al., 2001; Khreiss et al., 2004b,). 
Therefore, the common use of EDTA-containing tubes for hospital blood sampling may 
prove problematic, due to the potential chelation of CRP in the sample. Another potential 
obstacle associated with antibody-based CRP detection is cross-reactivity to homologous 
proteins. CRP is a member of the pentraxin family of cyclic oligomeric Ca++-binding 
proteins, of which the homologous protein, Serum amyloid P (SAP), is also a member (Steel 
and Whitehead, 1994; Gewurz et al., 1995). Structurally, SAP is a molecular homologue of 
CRP with approximately 70% amino acid sequence homology (Pepys and Baltz, 1983).  
 
 
CRP SAP   
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2 Cartoon models of CRP (ZD Net Healthcare, Accessed 18th January, 2009) and 
its homologous Serum Amyloid P (SAP) protein. Helices are highlighted in red, sheets in 
yellow and coils in green. 
 
This protein may prove to be a major contaminant analyte in the identification of CRP levels, 
considering the high concentration of SAP found in normal human serum (30–40 μg/mL) 
(Lund and Olafsen, 1999). Consequently, cross-reactivity analysis against SAP remains an 
essential step in the screening of antibodies against CRP. 
All of these features of CRP have led to its recognition as a valuable target molecule and 
resulted in its common use as a model analyte (Koskinen et al., 2004; Peoples, Phillips et al., 
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2007). CRP has also been selected as a relevant analyte in the Integrated Project founded by 
the European Community, entitled “Healthcare by biosensor measurements and networking 
(Care-Man),” for developing innovative analytical devices for fast molecular diagnostics 
(Bini et al., 2008). 
 
3.1.3 New Zealand white rabbits (XZB5 and XZCG) serum titres. 
 
A serum titre was performed on both rabbits (XZB5 and XZCG) following an extensive 
immunisation regime (section 2.8.1) with antigen-grade CRP. Serum from the immunised 
rabbits was diluted (1/100 to 1/1,000,000 dilution) in PBS containing 1% (w/v) milk marvel 
and tested against CRP in a direct ELISA format. Both rabbits produced serum titres in 
excess of 1/100,000 against the CRP antigen, making both rabbits good candidates for 
extraction of CRP-specific polyclonal antibody. In addition, to the serum taken from the 
rabbits for production of polyclonal antibody, both the spleens and bone marrow were 
harvested for future construction of a recombinant antibody library. 
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3.1.4 Protein A purification of rabbit anti-CRP polyclonal antibody. 
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Figure 3.1.4 SDS-PAGE gel of fractions from Protein A purification of rabbit anti-CRP pAb. 
The fractions were loaded as flow-through 1 (Lane 2), wash 1 (Lane 3), ‘flow-through’ 2 
(Lane 4), wash 2 (Lane 5) and finally the eluted purified pAb (Lane 6). A protein marker 
ladder (Sigma) was also loaded alongside the samples in lane 1 for estimation of the apparent 
molecular weights of the each of the protein samples. 
 
Fractions from each stage of the protein A purification of the polyclonal antibody (pAb) 
(section 2.8.2) were kept for further analysis. SDS-PAGE was utilised to assess the efficiency 
of the purification protocol and subsequently identify the purity of the final eluted fraction of 
pAb. The fractions were resolved on a freshly prepared 10% (w/v) SDS-PAGE gel (Figure 
3.1.4), stained and destained, as described in section 2.8.3. The two bands in lane 6 represent 
the heavy chain (~55 kDa) and the light chain (~25 kDa) of the polyclonal antibody, which 
showed a high level of purity.  
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3.1.5 Checkerboard ELISA to determine titre of purified rabbit anti-CRP polyclonal 
antibody. 
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Figure 3.1.5 (a) Checkerboard ELISA using purified rabbit anti-CRP polyclonal antibody 
(pAb). CRP coating concentrations of 10, 7.5, 5.0, 2.5, 1.0, 0.5 μg/mL were all investigated 
in the ELISA. The purified rabbit pAb was then serially diluted (1/250, 1/500, 1/1000, 
1/2000, 1/4000, 1/8000, 1/16000, 1/32000, 1/64000, 1/128,000) and the CRP-bound pAb 
complex detected using a HRP-labelled anti-rabbit pAb 
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Figure 3.1.5 (b) Assay format used for checkerboard ELISA. 
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A simple checkerboard ELISA was performed (See format in Figure 3.1.5 b) on the purified 
rabbit anti-CRP polyclonal antibody (pAb), whereby both the concentrations of the coated 
CRP antigen and the anti-CRP pAb were varied (section 2.8.4). A good correlation between 
the polyclonal antibody and CRP may be observed in Figure 3.1.5 (a). Although good assay 
functionality was observed using this approach, the assay was limited by the many reagents 
(commercial secondary antibodies) required. To circumvent this, it was decided to directly 
label the purified pAb using a commercially available fluorescence-labelling kit (section 
2.8.5). The fluorescently labelled pAb may then be incorporated into a more functional and 
direct assay. 
 
3.1.6 Fluorescent sandwich ELISA using purified rabbit pAb labelled with DyLight 647. 
 
The purified rabbit anti-CRP pAb was labelled using a commercially available mAb labelling 
kit (Pierce). The DyLight™ reagent contains an N-hydroxysuccinimide (NHS) ester, which is 
the most commonly used reactive group for labeling proteins. The NHS ester on the 
fluorescent label cross-links to primary amines forming a stable, covalent amide bond and 
releasing the NHS group. The optimisation of this fluorescent sandwich ELISA was 
undertaken in a two part assay (see section 2.8.6) using the same assay format (See Figure 
3.1.6 a). The first part involved the determination of the optimal coating concentration of the 
purified rabbit anti-CRP pAb, whereby several coating concentrations were compared. The 
remainder of the assay involved the CRP antigen concentration being kept constant at 1 
µg/mL and then varying the concentration of the labelled detection pAb.  
 
 
 
 
 
 
 
 
 
Figure 3.1.6 (a) Assay format used for both fluorescent sandwich ELISAs. 
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Figure 3.1.6 (b) Fluorescent sandwich ELISA using purified unlabelled rabbit anti-CRP pAb 
as capture antibody and fluorescently-labelled rabbit anti-CRP pAb as detection antibody. 
Several coating concentrations of purified CRP-specific pAb were used (10, 7.5, 5, 2.5, 1 and 
0.5 µg/mL - legend). A set concentration of 1 µg/mL CRP was utilised in the assay. Finally, 
the pAb-captured CRP was detected with varying concentrations of fluorescently-labelled 
pAb (1/250, 1/500, 1/1000, 1/2000, 1/4000, 1/8000, 1/16000, 1/32000, 1/64000, 1/128000). 
The parameters used for measurement of the fluorescent signal, including the excitation and 
emission wavelengths are described in section 2.8.6. 
 
Both the optimal pAb coating concentration and its corresponding fluorescently-labelled pAb 
concentration was then calculated from the plotted graph, shown in Figure 3.1.6 (b). The 5 
µg/mL coating concentration of the purified pAb was chosen as the opimal concentration as 
the responses using the two higher concentrations of 7.5 and 10 µg/mL were almost identical. 
This suggested that sufficient saturation of the plate surface may be achieved using the 5 
µg/mL coating concentration and, therefore, a higher concentration would be wasteful. This 
optimal coating concentration was then applied to part two of the assay optimisation (see 
section 2.8.6), which investigated the effect of varying the inner CRP concentration used in 
the assay.  
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Figure 3.1.6 (c) shows the plotted averaged data from part two of the fluorescent sandwich 
ELISA optimization, performed in triplicate. An optimised coating concentration of 5 µg/mL 
of purified CRP-specific pAb was used. The inner concentration of CRP was then varied 
from 1000, 500, 250, 125, 62.5, 31.25, 15.63, 7.8 to 3.9 ng/mL. The fluorescently-labelled 
detection pAb was also used at a set concentration (a 1/500 dilution). The mean response was 
plotted and the vertical error bars represent the SD over the 3 data points taken for each 
concentration (n = 3). Section 2.8.6 describes the parameters used for measurement of the 
fluorescent signal, including the excitation and emission wavelengths. 
 
A good overall trend was observed for part 2 of the fluorescently labelled sandwich assay, 
however, performance of the assay involved several time-consuming steps. For instance, four 
separate incubation steps (coating, blocking, analyte, detection Ab) were required and the 
overall stability of fluorescent labels can cause significant assay variability. Therefore, it was 
decided to perform a more robust characterisation of the purified CRP-specific pAb using an 
automated SPR-based system. 
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3.1.7 ‘Real-time’ characterisation of rabbit anti-CRP polyclonal antibody using Biacore. 
 
Although ELISA is a robust immunoanalytical tool, it is very limited in its capacity for 
providing comprehensive information needed for antibody characterisation. Conversely, 
Biacore offers real-time, label-free analysis of binding interactions. A simple direct binding 
format was utilised for characterisation of the purified rabbit anti-CRP polyclonal antibody 
(pAb) on the Biacore 3000 system. Firstly, preconcentration analysis (section 2.8.7) was 
performed on the purified rabbit anti-CRP pAb for identification of the optimal pH to employ 
for immobilisation onto the chip surface. The pAb was immobilised onto the surface of a 
CM5 sensorchip (GE Healthcare Life Sciences) using simple EDC-NHS coupling chemistry 
(see section 2.8.8). Next several concentrations of CRP antigen diluted in HBS buffer were 
passed across the chip surface. Each automated run incorporated a range of CRP 
concentrations, each concentration having 4 replicates. This run was performed 8 times in 
series, therefore yielding 32 data points for each concentration investigated. However, only 
replicates 2, 3 and 4 for each concentration were included in the data analysis, as replicate 1 
consistently produced values for all 8 runs outside the data range. Figure 3.1.7 (a) shows a 
plot of the mean response values (RU) over each day of analysis.  
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Figure 3.1.7 (a) shows a plot of the average CRP-binding response measured in response 
units (RU) on the Biacore 3000 system. A direct capture format was employed in the analysis 
involving a CM5 chip coated with purified rabbit anti-CRP pAb.  Eight concentrations of 
CRP spiked into HBS buffer (500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9 ng/mL) were passed 
across the pAb-immobilised chip surface. Also, a zero concentration made up of unspiked 
HBS buffer was ran across the chip for subtraction analysis. The plotted results show the 
mean response ± SD (vertical error bars), over each of the 3 days on which the assay was 
performed. 
 
An excellent correlation between the CRP concentration and the binding response (RU) was 
observed. The standard error bars also further emphasized the high level of reproducibility 
within the assay. For a more comprehensive examination of the data, a 4-parameter equation 
calibration curve of the mean RU values was plotted against the standard CRP concentrations 
(ng/mL) on a logarithmic x-axis (Figure 3.17 b), using dedicated Biaevaluation software. 
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Figure 3.1.7 (b) shows a 4-parameter calibration curve generated from 9 identical direct 
capture assays on the Biacore 3000 system, involving purified rabbit anti-CRP pAb. The 
calibration curve was generated using dedicated Biaevaluation software. 
 
The mean values for the standard CRP concentrations were then entered as ‘input values’ into 
the fitted equation and the resulting mean, back-calculated ‘output values’ found for each of 
the 9 data points of the assay. These output values represent how close the RU value is to its 
theoretical counterpart. The differences between the actual or ‘input’ concentrations and the 
‘output’ concentrations extrapolated from the curve were used to calculate the % accuracy 
(Table 3.1.7), which determines a value for the precision of analytical measurement at 
different standard concentration points relative to the fitted 4-parameter plot. This value was 
calculated using the following equation: 
 
100100*1
.
+⎟⎟⎠
⎞⎜⎜⎝
⎛ ⎟⎠
⎞⎜⎝
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Table 3.1.7 Response Units (RU) from direct binding assay of CRP antigen to CM5 chip 
immobilised with purified anti-CRP polyclonal antibody. 
S.D. – Standard Deviations 
CRP conc. (ng/mL) S.D. values Biaevaluation 
Output value 
% Accuracy value 
0 4.73 Low - 
3.9 5.52 4.2 108.6 
7.8 3.28 7.9 100.8 
15.6 4.25 15.8 100.9 
31.3 7.17 31.8 101.7 
62.5 18.83 61.5 98.3 
125 16.19 124.8 99.8 
250 19.46 252.2 100.9 
500 20.99 497.8 99.6 
 
Following observation of the accuracy values for each of the assay data points, it was clear 
that the assay has a high level of reproducibility. Generally, any accuracy value between 80 
and 120 is acceptable (Wong et al., 1997), therefore, the accuracy values for concentrations 
of 7.8 – 500 ng/mL show a high level of accuracy. The poorest accuracy value obtained from 
the statistical analysis was observed for the 3.9 ng/mL concentration (108.59), however, this 
accuracy value was still within the acceptable range. Furthermore, detection of CRP at this 
low range is not needed due to its relatively high basal concentration in the blood. 
Both the limit of detection (LOD) and limit of quantitation (LOQ) values were also 
extrapolated from the 4-parameter calibration curve. An input value for the LOD and LOQ 
were calculated as follows: 
 
? LOD – Zero value + 5 (Standard deviations) 
? LOQ – Zero value + 10 (Standard deviations) 
 
The 4-parameter equation was then used to extrapolate the LOD and LOQ values in ng/ml, 
which were 7.6 ng/mL and 18 ng/mL, respectively. 
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3.1.8 Discussion of results 
 
The relatively rapid generation of polyclonal antibodies has led their frequent use in the field 
of diagnostics. It has been suggested that pAbs can be generated much more rapidly, at less 
expense and even with less technical skill than is required to produce mAbs (Lipman et al., 
2005). Once a sufficiently high serum titre response to the desired immunogen is achieved, a 
simple purification step (section 2.8.2) can yield large quantities of this useful reagent. 
Consequently, this bypasses the use of expensive molecular reagents and also the time-
consuming process involved with construction of a recombinant antibody library. Polyclonal 
antibodies are a mixture of immunoglobulin molecules secreted against a specific antigen, 
each recognising a different epitope. The heterogenous nature of polyclonal antibody can 
hinder their specificity. This was indeed the case for the polyclonal antibody produced in this 
research, which showed cross-reactivity to SAP, a close homologue of CRP. The mixed 
population of polyclonal preparations, however, makes them ideal candidates as sensitive 
capture antibodies. Moreover, when combined with the specificity of a monoclonal antibody 
in a sandwich assay format, a potentially highly sensitive and specific test may be developed. 
The pAb generated in this research was successfully incorporated into both a fluorescent 
sandwich ELISA and also a direct capture assay on the Biacore 3000 system. Although the 
high sensitivity of the pAb is apparent on analysis of the fluorescent ELISA, a more accurate 
indication of the true sensitivity of the pAb was observed from the Biacore assay. The lowest 
concentration used in the assay was 3.9 ng/mL, however, the RU values observed for the zero 
concentration (control) were consistently lower than that for the 3.9 ng/mL concentration, 
suggesting a potential sensitivity even below the range of analyte concentrations investigated. 
One potential drawback associated with the use of pAb’s, however, is the fact that they are 
limited in supply to the volume of serum taken from the sacrificed immune host. Conversely, 
the supply of recombinant antibodies can simply be replenished by culturing the specific 
clone harbouring the scFv-encoding DNA and purifying it from the expressed bacterial lysate 
(Ohara et al., 2006). The use of recombinant phage display technology also allows for the 
production of monoclonal antibodies. The homogenous nature of monoclonal antibodies has 
led to their superiority in terms of specificity over polyclonal antibodies. Furthermore, one of 
the most defining characteristics of phage display is the direct link that exists between the 
phenotype and genotype of each of the clones in the recombinant library (Azzazy and 
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Highsmith, 2002; Paschke, 2006). This key feature facilitates the ability to refine almost any 
feature of the antibody such as their size, valency, affinity and even effector functions.  
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3.2 Generation and characterisation 
of mouse anti-CRP scFv library 
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3.2.1 Murine immune system 
 
One of the first reports of the use of the murine immune system for monoclonal antibody 
production was accredited to Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 
(Köhler and Milstein, 1975), who shared the Nobel Prize in Physiology or Medicine in 1984 
for the ‘ground-breaking’ discovery of ‘hybridoma technology’ (discussed in section 1.8). 
These immortalised cell lines can produce an unlimited supply of a homogeneous, well-
characterised antibody for use in a variety of applications, including in particular diagnosis 
and immunotherapy of pathological disorders. Subsequently, mice have become very popular 
for immunisation because of the ease of generation of murine monoclonal antibodies using 
hybridoma technology. However, this has extended into their application in the ever-growing 
field of recombinant antibody technology. 
Use of the murine immune system for the construction of recombinant antibody libraries is 
well documented and has led to the production of high affinity recombinant antibodies to a 
vast array of specific antigens (Krebber et al., 1997; Barbas et al., 2001). Due to its small 
size, scFv fragments (See Figure 1.1) have been known to be more genetically stable than 
their larger Fab fragment counterpart (Hoogenboom et al., 1998). Also, an extensive range of 
both PCR primers (particularly for Balb/c strain) and also methods for construction of mouse 
libraries have also been widely reported (Krebber et al., 1997; Barbas et al., 2001). 
Furthermore, the availability of a wide range of secondary reagents for the detection of 
mouse antibodies, have led to the murine immune system becoming a popular choice for 
antibody library construction. 
 
3.2.2 Mouse serum titre. 
 
Prior to sacrifice of the immunised mice, serum titres were performed to determine if a 
sufficient antibody response against the CRP antigen was generated. Serum from the 
immunised mouse was diluted (1/100 to 1/1,000,000 dilution) in PBS containing 1 % (w/v) 
milk marvel and tested against CRP in a direct ELISA format. A titre in excess of 1/100,000 
against CRP was observed from the ELISA, indicating a high level of antibody generation, 
which indicates the presence of sufficient specific mRNA for creation of a recombinant 
antibody library against the specific antigen. 
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3.2.3 Mouse variable heavy and light chain optimisation in various buffer compositions. 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.2.3 The optimisation of the variable heavy (VH) and variable light (VL) chain 
amplifications using the cDNA from a CRP-immunised Balb/c mouse. Lanes 1 and 10 
contain a 1 kb Plus DNA molecular weight ladder (Invitrogen). The optimisation of the VH 
chains are represented in lanes 2-5 and the VL chains in lanes 6-9. The various buffer 
compositions were as follows: buffer A (7.5 mM MgCl2, pH 8.5), buffer B (10 mM MgCl2, 
pH 8.5), buffer D (17.5 mM MgCl2, pH 8.5) and buffer G (12.5 mM MgCl2, pH 9.5).  
 
The VH and VL amplifications were resolved on a 1% (w/v) agarose gel and single bands at 
386-440 bp (VH chain) and 375-402 bp (VL chain) were observed (See Figure 3.2.3). The 
results indicated that the most optimal buffer composition for the VH and VL chain 
amplifications were buffer G and buffer B, respectively. A large-scale PCR amplification was 
then performed, using the conditions described in section 3.1.5, for each of the variable 
chains in their respective buffers. Following purification of the VH and VL chains (see 
section 2.9.6), a SOE-PCR (section 2.9.7) was employed to fuse the two chains via a serine-
glycine linker (G4S)4 resulting in the formation of the scFv fragment.  
 
400 bp 
1,650 bp 
Buffer   A      B      D      G      A      B      D      G 
1       2       3       4        5       6      7       8       9      10      
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3.2.4 Mouse SOE-PCR of variable heavy and light chain. 
 
 
1,650 bp 
650 bp 
850 bp 
  1            2           3           4          5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4 SOE-PCR using different DMSO concentrations to optimise the product yield. 
A 1 kb Plus DNA molecular weight marker was added to lane 1. Several DMSO 
concentrations were investigated i.e. 3, 5, 8 and 12% (v/v) as represented by lanes 2, 3, 4 and 
5, respectively. 
 
Both the purified VH and VL chain amplifications were incorporated in equimolar ratios into 
a SOE-PCR, producing a product size of ~800 bp. Some initial non-specific product was 
amplified. However, this was counteracted via the inclusion of DMSO into the PCR mixture. 
The resultant SOE products resolved on a 1% (w/v) agarose gel may be observed in Figure 
3.2.4. The PCR mixture with a final DMSO concentration of 5% (v/v) proved to be the most 
optimal and was therefore used for the large-scale SOE-PCR of the scFv gene. Although a 
higher specific product yield was obtained using 3% (v/v) DMSO (lane 2), a reduced level of 
contaminant non-specific product was amplified using 5% (v/v) DMSO (lane 3).  
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3.2.5 Library construction and subsequent enrichment via biopanning. 
 
The large-scale SOE product was concentrated via ethanol precipitation and quantified using 
the Nanodrop ND-1000 ™. Following quantification, the SOE product was then ligated into 
the pAK 100 vector (Krebber et al., 1997) using the restriction enzyme SfiΙ (see section 
2.9.8). The successfully ligated product was then transformed into electrocompetent XL1-
Blue cells by electroporation, using the protocol described in section 2.9.9. Several methods 
exist for the introduction of DNA into a bacterial host. One commonly used method is the 
chemical transformation or ‘heat shock’ technique, which may be employed when high 
efficiencies are not essential. In the case of diverse library building, however, a highly 
efficient method such as electroporation should be used. Electroporation is known to produce 
transformation efficiencies of 100 – 1000 times greater than those shown by chemically 
treated cells (Brown, 2000). The transformed mouse anti-CRP scFv library produced had a 
size of 2.94 x 106 cfu/mL. This library size may be considered relatively low, especially if the 
library was constructed from a non-immune/naïve B cell repertoire. However, in the case of 
immune libraries such as the one constructed in this work, the B cell repertoire used has the 
advantage of exposure to the required antigen. Consequently, there is a natural bias towards 
to required antigen and it has been reported that a library size of 5 x 107 should be sufficient 
for an immune library (Barbas et al., 2001). Considering this library is approximately only 10 
fold smaller than this figure, it was decided to proceed with the transformed library. The 
library was subject to phage display biopanning against immobilised CRP antigen, as 
described in sections 2.9.10 and 2.9.11.  
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Table 3.2.5 The phage input and output titres over the 4 rounds of biopanning of the mouse 
anti-CRP scFv library. 
Biopanning round Colony forming units/mL 
Input 1 
Output 1 
4.35 x 1012
2.65 x 109
Input 2 
Output 2 
1.00 x 1013
8.65 x 109
Input 3 
Output 3 
9.2 x 1012
6.0 x 107
Input 4 
Challenge output remaining bound* 
Challenge output dissociated* 
1.0 x 1013
2.7 x 107
5.4 x 105
* See section 2.9.11 for explanation 
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3.2.6 Mouse Polyclonal phage ELISA. 
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Figure 3.2.6 Polyclonal phage ELISA involving the phage pools of the unpanned library and 
the phage outputs from each of the successive rounds of panning. Each of the scFv-displaying 
phage pools were tested against the immunised CRP antigen, prostate specific antigen (PSA) 
and bovine serum albumin (BSA). M13K07 helper phage was also tested to identify any 
background non-specific binding.  
 
The precipitated input phage from each round of panning were then incorporated into a 
polyclonal phage ELISA (section 2.9.12) to test for enrichment against the CRP antigen. PSA 
was included in the ELISA as parallel screening against PSA was being conducted in the lab 
during the same period, therefore, any potential cross-reactivity due to phage contamination 
may be identified. BSA was also tested as a negative control to observe the degree of non-
specific ‘background’ binding. The ELISA also tested an antigen-challenged phage pool. The 
antigen challenge involved incubating 5 µg of CRP on the washed immunotube for 10 min to 
remove any weakly binding phage-scFv fragments, which were infected as usual into mid-
exponential phase XL-1 Blue cells.  The scFv-displaying phage were detected using a HRP-
conjugated mouse anti-M13 antibody (GE Healthcare Life Sciences) and the resultant 
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absorbance read at a wavelength of 450 nm following a 20 min incubation with TMB 
substrate. The sharp increase in absorbance from the second round onwards (Figure 3.2.6), 
suggested the presence of CRP-specific scFv-harbouring phage within the panned library. 
Additionally, minimal or no binding was observed against both PSA and BSA. 
 
3.2.7 Identification of scFv gene insert in panned murine scFv library. 
 
A ‘colony-pick’ PCR (section 2.9.12) was then performed on 20 randomly selected individual 
colonies from the pan 4 output of the murine scFv library. The initial incubation of the colony 
at 94°C for 10 min results in the bacterial cell bursting, releasing the scFv-harboring plasmid 
DNA. The serine-glycine overlap extension primers then anneal to their respective sequences 
and amplify the scFv gene from the plasmid. The amplified scFv fragments were then 
analysed via gel electrophoresis on a 1% (w/v) agarose gel. Figure 3.2.7 shows the resultant 
scFv gene product (~ 800 bp) for 10 individual colonies from the pan 4 output of the murine 
scFv library. 
 
     1       2        3        4        5       6       7       8        9       10      11    
1,650 bp 
850 bp 
650 bp 
 
 
 
 
 
 
 
 
Figure 3.2.7 ‘Colony-pick’ PCR showing amplification of scFv gene inserts from 10 
randomly selected clones from the murine library subjected to 4 rounds of bio-enrichment 
against CRP. A 1 kb Plus DNA molecular weight marker was added to lane 1. Lanes 1-10 
represent the 10 successfully amplified scFv gene inserts. 
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3.2.8 Soluble expression and direct ELISA of mouse anti-CRP scFv clones. 
 
Screening of the pan 4 output may be performed via monoclonal phage ELISA, however, due 
to the multivalent display on the phage, avidity affects may allow selection of antibodies with 
lower affinity (Kwasnikowski et al., 2005). Therefore, the pan 4 output was subcloned into 
the expression vector pAK 400 (see section 2.9.13) and transformed into Top 10 F′ E. coli 
cells for analysis via monoclonal soluble ELISA. A large number of single colonies (384) 
were then grown, solubly expressed and incorporated into a direct ELISA to identify scFv 
candidates for more ‘in-depth’ analysis (see section 2.9.14). 
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Figure 3.2.8 Direct ELISA using scFv-enriched lysate of 96 murine anti-CRP scFv clones.  
The bars highlighted in blue represent all the positive CRP-specific clones and the negative 
clones (response below the background level) are illustrated in red. 
 
The scFv-enriched lysate was tested against both the target protein (CRP) and also BSA 
(negative control). Figure 3.2.8 represents absorbance values minus the background binding 
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values to BSA. Approximately, 250 clones specific for CRP were identified from the direct 
ELISA and taken forward for inhibition analysis (see section 2.9.14) to demonstrate their 
ability to bind CRP in solution. 
  
3.2.9 Soluble inhibition ELISA of mouse anti-CRP scFv clones. 
 
Initially, a crude inhibition ELISA format was performed on each of the expressed lysates of 
the 250 positive clones, identified from the the direct ELISA (previous section). This crude 
inhibition ELISA only utilised the higher free CRP concentrations (500 and 250 ng/mL), to 
identify clones showing any degree of depletion of CRP from solution (competitive clones). 
All of the competitive clones were then incorporated into a more comprehensive inhibition 
assay, investigating a large range of inhibiting CRP concentrations (Figure 3.2.9 a). These 
assays were used to extrapolate the degree of competitivity of each of the clones tested.  
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Figure 3.2.9 (a) An inhibition ELISA using the scFv-enriched lysate expressed from the 
murine anti-CRP scFv clone C11(2). 
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Figures 3.2.9 (a) illustrates typical inhibition ELISA data on crude lysate obtained from 5 mL 
cultures of the one of the best performing clones from inhibition analysis. The scFv-enriched 
lysate from clone C11(2) was pre-incubated with varying concentrations of CRP antigen 
(500, 250, 125, 62.5, 31.25, 15.625, 7.8, 3.9 ng/mL), which was then applied to a plate coated 
with CRP antigen (See Figure 3.2.9 b for assay format used). The scFv’s ability to bind the 
free CRP in the pre-incubation is then determined by comparison of the absorbance response 
to the A0. The A0 consists of an aliquot of the same lysate without any prior incubation with 
free CRP. The scFv-captured CRP complex was detected using an anti-HIS (HRP-labelled) 
monoclonal antibody (mAb). It was observed that depletion of the free antigen is evident 
down to the low ng/mL range, as the absorbance level for the 3.9 ng/mL incubation is still 
clearly below that of the A0 control. Ten clones showing the most consistent and highest 
level of competition were taken forward for sequence analysis (section 3.2.10).  
 
Anti-HIS pAb 
(with HRP label) 
Mouse anti-
CRP scFv 
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Blocking 
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Figure 3.2.9 (b) Assay format used for inhibition ELISA. 
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3.2.10 Sequencing of 10 mouse anti-CRP scFv clones.  
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Figure 3.2.10 Amino acid sequence alignment of functional variable domains of 10 murine 
anti-CRP scFv fragments. The three CDR regions for both the variable light (CDR-L) and 
variable heavy (CDR-H) regions are highlighted in blue. These blue regions determine the 
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specificity of the scFv for its target antigen. A glycine-serine linker (red) fuses the variable 
heavy and light regions together. This linker has sufficient flexibility to allow the two 
domains to assemble into a functional antigen-binding pocket. To aid in the purification and 
characterisation of the scFv fragments, both a poly-histidine tag (orange) and a FLAG tag 
(green) are incorporated into the structure.  
 
The characterization process for each of the scFv clones in the pAK 400 vector (Krebber et 
al., 1997) was severely hampered by the poor expression of the murine clones. The level of 
expression was so poor that a true IC50 value could not be established because of the 
inability to titre the lysates against plates coated with CRP antigen. Consequently, an IC50 
value was estimated for inhibition analysis of each of the clones. Despite the fact that this 
approach still clearly identifies antigen depletion, the exact level or range of antigen depletion 
may not be reliable.  
 
3.2.11 Biacore analysis of mouse anti-CRP scFv C11-2 in pAK400 format. 
 
Several antibody-antigen assay formats may be employed on the Biacore system to obtain 
kinetic rate constants and binding affinities. For instance, a direct binding format may be 
used, involving the immobilization of purified CRP antigen on the sensor chip surface. Next, 
several concentrations of known concentration of purified scFv fragment may be passed 
across the CRP-immobilised surface. This approach may not be an accurate representation of 
the antibody-antigen interaction, however, as it is possible that the immobilization of the CRP 
to the surface may result in a non-native conformation. Furthermore, this approach requires 
purification of scFv from bacterial lysate and also the exact concentration of the purified scFv 
must be known. This direct binding format may be also be performed in reverse, whereby the 
purified scFv is immobilized onto the chip surface, followed by several concentrations of 
CRP antigen being passed across. In this case, there is no control over the scFv orientation on 
the sensor surface. Therefore, a large proportion of the scFv molecules will be non-
functional, due to their binding epitopes being inaccessible. Consequently, it was decided to 
implement a capture-based assay format. Two potential capture tags may be used for 
detection of scFv fragments generated using the pAK system. Both a His and a FLAG tag are 
located in the C-terminal and N-terminals, respectively. During analysis of the scFv by both 
direct and inhibition ELISA (section 2.9.14), an anti-HIS (HRP-labelled) mAb was used for 
detection of the complex. Use of the His tag in such formats is acceptable, however, its non-
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specific nature, restricts its application in more highly sensitive platforms such as Biacore. A 
study by Knappik and colleagues (Knappik and Pluckthun, 1994) found the commercially 
available anti-FLAG M1 antibody to be specific for the incorporated shortened FLAG tag 
sequence (Figure 3.2.10) of the pAK system. 
Pre-concentration analysis followed by immobilization of the anti-FLAG M1 antibody were 
performed on a CM5 sensor chip (GE Healthcare), as described in sections 2.8.7 and 2.8.8, 
respectively. The mouse scFv clone C11-2 was cultured and expressed using an optimized 
expression medium (section 2.9.19) and the resultant lysate passed across the immobilized 
chip surface. No binding of the scFv to the anti-FLAG mAb immobilized surface was evident 
(Figure 3.2.11 a). An ‘in-house’ scFv with a fully-functional FLAG tag was also tested on the 
chip surface as a control and again no response was produced (results not shown). 
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Figure 3.2.11 (a) Sensogram of C11-2 lysate (pAK 400 format) following passage across a 
CM5 chip immobilized with an anti-FLAG M1 mAb. The baseline level (anti-Flag mAb 
only) is represented by the red dotted line. The change from HBS buffer to scFv-rich lysate 
and vice-versa caused two drastic refractive index spikes, labelled as A and D, respectively. 
During passage of the lysate across the chip surface (B), an overall change in refractive index 
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(C) was observed. The final response (E) following completion of injection of the lysate was 
identical to the initial baseline level, indicating no binding. 
 
As a further control, the same lysate was passed across another CM5 chip immobilized 
directly with CRP (Figure 3.2.11 b). Using an identical injection to that used with the anti-
FLAG chip, a large binding response of approximately 380 RU’s was observed. This 
eliminates the possibility of poor scFv expression being the cause of the lack of binding to the 
anti-FLAG chip. Moreover, this result would suggest that either the anti-FLAG mAb shows 
poor functionality or the N-terminal FLAG tag of the scFv is inaccessible.  
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Figure 3.2.11 (b) Sensogram of C11-2 lysate (pAK 400 format) being passed across a CM5 
chip immobilised with mCRP. The red dotted line represents the baseline level i.e. the CRP 
immobilised chip surface. The change from HBS buffer to lysate and vice-versa caused two 
drastic refractive index spikes, labelled as A and D, respectively. Additionally, during 
passage of the lysate across the CRP-immobilised chip surface (B), an overall change in 
refractive index (C) was observed. Finally, a change in the RU level (E) is shown following 
completion of the lysate injection. 
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3.2.12 Primer design and subcloning of C11-2 scFv via ‘nested’ PCR. 
 
Both the non-specificity issues associated with his-tag capture and the flag tag inaccessibility 
of the pAK400 vector, have significantly reduced the capacity to produce reliable kinetic data 
on the C11-2 scFv clone in this format. To counteract this problem, it was decided to 
subclone the mouse anti-CRP C11-2 scFv into an alternative vector, namely the pComb3X 
vector (Barbas et al., 2001). One of the main reasons behind the employment of this vector is 
its use of a highly specific hemagglutinin (HA) decapeptide tag. Use of the pComb3X system 
incorporates this affinity tag at the N-terminal of the scFv fragment, allowing for both more 
efficient screening and characterisation processes. In addition, it is possible that incorporation 
of the scFv into the pComb3X vector may lead to an improvement in its expression to further 
enhance the characterization process.  
 
The SfiΙ restriction sites were found to differ between the pAK and pComb systems as shown 
below: 
SfiΙ restriction site 
pAK400 vector pComb3X vector 
GGCCTCGGGGGCC GGCCAGGCCGGCC 
 
Therefore, to successfully subclone the C11-2 scFv into the pComb3X vector, this new SfiΙ 
restriction site must be integrated into the scFv sequence. Firstly, the pComb series of murine 
primers (section 2.9.16) were analysed to identify the variable kappa (VK) sense primer 
showing the closest homology to that of the 5′ end of the scFv light chain sequence. The 
sequence of the relevant VK forward primer (MSCVK5) is shown below: 
 
 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3′ 
 
Next, a variable heavy (VH) anti-sense primer was designed, which consisted of a generic 
sequence (shown below) common to the 5’ end of all the VH reverse primers of the pComb 
series.  
 
5′ CCT GGC CGG CCT GGC CAC TAG TGA 3′ 
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This was coupled with a sequence of bases common to the scFv variable heavy chain at the 3′ 
end of a generic pAK sequence (shown below). 
 
5′ GAG GAG ACT GTG AGA GTG GTG CCT TC3′ 
 
The full sequence of the designed primer (SubRev) was as follows: 
 
5′ CCT GGC CGG CCT GGC CAC TAG TGA GAG GAG ACT GTG AGA GTG GTG 
CCT TC 3′ 
 
The C11-2 clone was cultured and subjected to a plasmid extraction (section 2.9.13) to purify 
the pAK400 vector harbouring the scFv. Next, an SfiΙ restriction digest was performed on the 
plasmid preparation to isolate the scFv insert (section 2.9.13) and then resolved via 
electrophoresis on a 1% (w/v) agarose gel. Following sufficient resolution, the scFv insert 
(~800 bp) was purified using a QIAquick ™ gel extraction kit. This restricted scFv gene 
product was used as the template DNA for part 1 of a ‘nested’ type PCR reaction (section 
2.9.17). This so-called ‘nested’ PCR was performed in two parts: 
 
Part 1 – C11-2 scFv in pAK format used as the template for PCR. 
Part 2 – PCR product from part 1 used as the template for PCR. 
 
The use of a two part ‘nested’ PCR was required to enrich against the old pAK400 format of 
the scFv, thus reducing the potential for any contamination of this old pAK format in the final 
amplified product from part 2. To further ensure that the final product from part 2 was the 
scFv in the new pComb format, the minimum level of product from part 1 (~21 ng) was used 
as the template DNA. 
An annealing temperature gradient was also incorporated into part 1 (section 2.9.17 a) of the 
‘nested’ PCR. This was employed to identify the most optimal conditions for avoidance of 
contamination from any non-specific amplified products. The five different annealing 
temperatures investigated were 50.9, 52.9, 55.5, 58.4 and 59.8°C (Figure 3.2.12). 
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1,650 bp 
 
850 bp  
 
 
 
Figure 3.2.12 Optimisation of part 1 of the ‘nested’ PCR using various annealing 
temperatures. Lanes 3-7 represent the PCR products of the annealing temperatures of 50.9, 
52.9, 55.5, 58.4 and 59.8°C, respectively. Lane 1 contains a 1 kb Plus DNA molecular weight 
ladder (Invitrogen). A small quantity of the scFv template used in the PCR was also resolved 
on the gel in lane 2. Finally, lane 8 shows a negative control, consisting of all the PCR 
components except the template DNA.  
 
The PCR reaction using an annealing temperature of 59.8°C proved to be the most optimal, 
as the non-specific bands were least prevalent under these conditions. This reaction was 
scaled-up and resolved via electrophoresis on a 1% (w/v) agarose gel and gel-purified again 
using the QIAquick ™ gel extraction kit. Part 2 (section 2.9.17 b) of the PCR then used this 
purified product as template for amplification of the final modified scFv gene. The amplified 
product was again resolved and gel-purified as before. 
 
3.2.13 Identification of successfully subcloned scFv fragments via direct and inhibition 
ELISA. 
 
The purified C11-2 scFv in the pComb format (product from part 2) was cloned into the 
pComb3X vector using SfiΙ restriction enzyme as outlined in section 2.9.18. Prior to the 
ligation of the modified scFv gene, the digested pComb3X vector was treated with Antarctic 
Phosphatase™ enzyme to prevent self-ligation of the vector (see section 2.9.18). The ligated 
product was then electroporated into Top 10 F′ cells for soluble expression (general method 
described in section 2.9.9). 
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 Twenty single colonies from the transformation titre plates were then cultured, solubly 
expressed and incorporated into a direct ELISA (as per the general protocol described in 
section 2.9.14) to identify successfully subcloned scFv fragments. The expressed lysates of 
each of the clones were tested in duplicate against wells coated with 10 µg/mL of CRP in 
PBS. Detection of the bound scFv using a HRP-labelled anti-HA mAb (Roche Applied 
Science) identified three potential scFv candidates (Figure 3.2.13 a). 
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Figure 3.2.13 (a) Direct ELISA using scFv-enriched lysate from 20 candidate scFv clones. 
The bars highlighted in green represent potential scFv candidates in new pComb format and 
clones considered to be negative are illustrated in blue.  
 
Some lysate from the C7 clone was titred and than then taken forward for use in a quick 
inhibition ELISA (Figure 3.2.13 b) to identify the scFv’s ability to bind CRP from solution. 
Depletion of the CRP antigen was clearly evident from the inhibition analysis and, 
furthermore, the overall expression of the scFv in the pComb3X vector showed a minor 
improvement from that observed in the pAK400 vector. 
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Figure 3.2.13 (b) An inhibition ELISA using the scFv-enriched lysate expressed from the 
murine anti-CRP scFv C11(2) subcloned into the pComb3X vector. The binding response of 
the scFv-rich lysate with no inhibition of free CRP (Ao) is shown in green. The bars in blue 
represent the same lysate incubated with varying concentrations of CRP antigen. 
 
3.2.14 Sequence analysis of mouse anti-CRP scFv C11-2 subclone. 
 
Both the sequences of the initial murine CRP-specific C11-2 scFv (pAK version) and its 
subsequent reformatted pComb version were compared to identify successful reformatting of 
the fragment into its new format. On analysis of the translated sequences of both clones 
(Figure 3.2.14), it was evident that the reformatted version was identical to its original 
format, except the flag tag was removed and also the highly-specific HA tag was 
incorporated alongside the already existing his tag. 
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C11-2 scFv (pAK format) 
 
A D Y K D I V Met T Q S P A T L S V T P G D R V S L S C R A S Q S I S D Y L H 
W Y Q Q K S H E S P R L L I K Y A S Q S I S G I P S R F S G S G S G S D F T L S 
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C11-2 scFv (pComb format) 
 
A A E L D I V Met T Q S P A T L S V T P G D R V S L S C R A S Q S I S D Y L H W 
Y Q Q K S H E S P R L L I K Y A S Q S I S G I P S R F S G S G S G S D F T L S I N 
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S G F T F T D Y V I S W V K Q R T G Q G L E W I G E I Y P V S D S T Y Y N E N F 
K G K A T L T A D K S S N T A Y Met Q L S S L T S E D S A V Y F C A R S A R L L 
R S S Y D Y W G E G T T L T V P L T S G Q A G Q H H H H H H G A Y P Y D V P 
D Y A S 
 
Figure 3.2.14 Sequences of the mouse anti-CRP C11-2 scFv clone in its original pAK format 
and its engineered pComb format. The three CDR regions for both the variable light (CDR-L) 
and variable heavy (CDR-H) regions are highlighted in blue and red, respectively. A glycine-
serine linker (green) fuses the variable heavy and light regions together (green font). In the 
pAK format, a FLAG tag is shown in brown. A hexa-histidine tag (orange) is incorporated 
into both formats. Finally, a novel HA epitope tag (purple) is integrated into the scFv by the 
pComb system. 
 
In all known species with an adaptive immune system, CDR-H3 is more diverse than any of 
the other five CDR regions (CDR-H1, CDR-H2, CDR-L1, CDR-L2, CDR-L3) that together 
form the outside border of the antigen-binding site (Kirkham and Schroeder, 1994; Padlan, 
1994; Al-Lazikani et al., 1997; Litman et al., 1999). However, although the CDR-H3 region 
is generally associated with a high level of variability, the actual amino acid utilization is 
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typically non-random, whereby neutral hydrophilic amino acid residues such as tyrosine, 
glycine and serine have been shown to dominate (Ivanov et al., 2002). On closer inspection 
of the amino acid sequence of the murine C11-2 scFv, such dominance of amino acids like 
tyrosine and serine is particularly evident. Tyrosine dominance in particular has been 
identified as a common feature associated with the murine CDR-H3 repertoire (Zemlin et al., 
2003). The use of tyrosine may confer structural diversity as it allows for many forms of 
inter- and intramolecular bonding (hyrdrogen bonding through its hydroxyl group, 
hydrophobic and electrostatic interactions via its aromatic ring. 
 
3.2.15 Cross-reactivity analysis of mouse anti-CRP scFv C11-2 subclone via ELISA. 
 
Another essential task in antibody characterisation is the analysis of cross-reactivity to 
homologous analytes. As discussed previously, SAP has been shown to have a high sequence 
homology to that of CRP. Any cross-reactivity of the scFv fragment to SAP, will lead to false 
positive results in patient blood testing. Therefore, the exclusion of cross-reactivity to such 
contaminant analytes is a key requirement in the field of diagnostics. 
Expressed lysate from the C7 clone was incorporated into a direct ELISA (general protocol in 
section 2.9.14) against CRP, its homologous counterpart SAP and also BSA (background 
binding reponse). Both purified avian anti-CRP H2 scFv (see section 3.3.5) and rabbit anti-
CRP pAb (see section 3.1.4) were also employed in the ELISA as negative and positive 
controls, respectively. HRP-labelled anti-HA mAb (Roche Applied Science) was used as a 
secondary antibody for detection of both the subcloned C11-2 scFv and the avian H2 scFv via 
the HA tag. The purified rabbit polyclonal antibody (positive control) was detected using a 
HRP-labelled anti-rabbit secondary antibody. Figure 3.2.15 (a) clearly illustrates the lack of 
any reactivity, of both the murine C11-2 scFv subclone and the avian H2 scFv, with SAP. 
Furthermore, the response to SAP was shown to be almost identical to that of the background 
binding levels (BSA), which again highlights the lack of any cross-reactivity to this 
homolgous analyte. 
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Figure 3.2.15 (a) Cross reactivity analysis of mouse C11-2 scFv subclone, avian H2 scFv 
and rabbit pAb via direct ELISA. The bars in blue, red and green represent the binding 
response in absorbance units to CRP, SAP and BSA (negative control), respectively. 
 
Further verification of this result was conducted via analysis on the Biacore 3000 system. A 
capture-based approach was used involving an anti-HA mAb directly immobilised onto the 
CM5 chip (as per the general protocol described in section 2.8.8). Lysate from the expressed 
C11-2 scFv subclone was then passed across the immobilized chip-surface, resulting in 
subsequent capture of the scFv. Finally, CRP and SAP were both diluted in HBS buffer to a 
concentration of 1 μg/mL, passed across the scFv captured surface and their binding reponses 
(RU value) monitored. Figure 3.2.15 (b) clearly identifies no binding of both the scFv 
subclone and the avian H2 scFv to the SAP analyte. CRP was also passed across the scFv-
captured surface as a positive control to ensure functionality of the scFv used in the analysis. 
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Figure 3.2.15 (b) Cross reactivity analysis of C11-2 scFv subclone lysate using an anti-HA 
capture method on the Biacore 3000. The sensogram represents the capture level of the C11-2 
scFv subclone (A) on the anti-HA immobilized CM5 chip surface. Also, the subsequent 
binding reponses of the captured scFv to both SAP (B) and CRP (C) are shown. 
 
3.2.16 Kinetic analysis of C11-2 scFv subclone using the Biacore 3000 system. 
 
The native pentameric form of CRP proves to be somewhat troublesome when a capture-
based kinetic analysis format is employed. One of the simplest and yet most efficient models 
for obtaining high precision and reliable kinetic data is the 1:1 Langmuir equation. As the 
name suggests, a 1:1 ratio of ligand (scFv) to analyte (CRP) is required for implementation of 
this model. The use of native CRP in this format would result in a much more complex 
interaction of CRP with the captured scFv. Such is the complexity of the interaction that a 
simple 1:1 equation proves insufficient. Consequently, the monomeric sub-unit of CRP 
referred to as monomeric or modified CRP (mCRP) was employed in the ‘real-time’ analysis. 
The modified form of CRP was prepared using the method described by Kresl and colleagues 
(Kresl et al., 1998) (see section 2.10.5). Furthermore, mCRP has been shown to directly 
facilitate endothelial cell adhesion molecule expression, leukocyte adhesion, and MCP-1 and 
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IL-8 production, indicating that mCRP rather than native CRP may contribute to the 
development of vascular inflammation (Khreiss et al., 2004a). Therefore, antibodies with 
specificity for detection of both native CRP and its monomeric counterpart may prove to be 
key requirements in more accurate risk stratification. 
 
Some preliminary Biacore analysis was first performed to ensure that the C11-2 scFv 
subclone does in fact bind the mCRP sub-unit. It is possible that the scFv fragment reacts 
with CRP at the linker regions responsible for combining the monomeric units into its native 
pentameric structure. Fresh C11-2 subclone lysate was prepared using an optimized 
expression protocol (section 2.9.19) and passed across the anti-HA immobilized chip. Both 
CRP and its monomeric sub-unit mCRP were then passed across the capture scFv at a 
concentration of 1 μg/mL in HBS buffer. It is evident from Figure 3.2.16 (a) that the C11-2 
scFv subclone binds both the native pentameric form and its monomeric sub-units. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.2.16 (a) Analysis of reactivity of the C11-2 scFv subclone with mCRP using an 
anti-HA capture method on the Biacore 3000. The sensogram illustrates the level of C11-2 
scFv subclone captured (A) by the anti-HA mAb immobilized surface, followed by the 
binding responses of either CRP or mCRP (B). As discussed earlier, the change from HBS 
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buffer to scFv-rich lysate and vice-versa caused two drastic refractive index spikes, labelled 
as A and C, respectively. 
 
The employment of a capture-based format for kinetic analysis allows for the use of crude 
scFv-containing bacterial lysates (section 2.9.19). Capture of the scFv was performed using a 
3 min injection of the crude lysate across the anti-HA chip surface at a flow rate of 10 
μL/min, followed by a stabilization period of 3 min.  Next, mCRP was spiked into HBS at 
concentrations of 200, 100, 50, 25, 12.5, 6.3, 3.1 nM and passed across the captured scFv at a 
flow rate of 30 μL/min. This high flow rate was employed to remove any potential 
interference from mass transfer effects. The 12.5 nM concentration was run in duplicate and a 
zero concentration included, enabling double referencing. Association and dissociation 
phases were monitored for 3 and 10 min, respectively. Sensograms for each of the mCRP 
concentrations were fit globally to a 1:1 interaction model using Biacore 3000 dedicated 
software. A good fit (Figure 3.2.16 b) was observed for the kinetic run using the Langmuir 
equation. This 1:1 interaction model was subsequently used to extrapolate the relevant kinetic 
constants and binding affinities of the scFv for mCRP (Table 3.2.16). The overall accuracy of 
the kinetic analysis was further justified by a considerably low Chi2 output value of 0.123. 
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Figure 3.2.16 (b) Kinetic analysis fit of the mouse C11-2 scFv subclone using the Biacore 
3000 system. Shown is the local fit of a 1:1 interaction model (with drifting baseline) to the 
response data obtained from the Biacore 3000 with multiple analyte concentrations. The 
black lines represent the local fit to the response data shown as coloured lines. 
 
 
Table 3.2.16 Kinetic constants and binding affinity calculated for the C11-2 scFv subclone 
Kinetic parameter ka (M−1 s−1) kd (s−1) KD (M) 
Value 2.97 × 105 6.24 × 10-3 2.1 × 10-8
 
 
3.2.17 Discussion of results 
 
Following analysis of the sequences of the ten murine anti-CRP scFv clones (Figure 3.2.10), 
it is clear that a single scFv sequence pattern dominates the pool of clones. The top nine scFv 
sequences all contain this dominant sequence pattern, with only minor base pair differences 
occurring in the framework regions. However, the H2-3 scFv sequence (3.2.10) deviates 
substantially from this dominant sequence pattern, showing extensive modifications to the 
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CDR regions in both the heavy and light chains. This phenomenon of a final dominant 
antibody sequence was previously reported. One such study by Kashyap and colleagues 
(Kashyap et al., 2008) encountered this result, referring to it as the “jackpot solution”. Both 
the natural progression of affinity maturation and selected synthetic antibody libraries (Rajpal 
et al., 2005; Lerner, 2006) can yield this repeating dominant antibody sequence to a specific 
antigen. Consequently, the presence of these so-called “jackpot libraries” validates the 
panning procedure and its level of stringency. 
Although, the murine immune repertoire provides us with a relatively simple and readily 
available system for the generation of recombinant antibodies, its use is accompanied by 
several disadvantages. Due to mice being such a close relative of humans, the generation of 
antibodies against conserved epitopes of the antigen of interest is less likely to occur 
compared to when more phylogenetically distant species are used e.g chickens (section 
3.3.1). Furthermore, the CDR-H3 region has been shown to be a major contributing factor 
toward the affinity of antibodies (Tonegawa, 1983; Chothia et al., 1989; Wilson and 
Stanfield, 1994; Schroeder et al., 1998; Deng and Notkins, 2000; Eisenhardt et al., 2007) and 
diversity within this region may be restricted by shorter lengths of this region within the 
murine repertoire compared to those of chickens. In addition, to capture a good representation 
of the murine immune repertoire, an excessively large number of primer combinations must 
be employed. The incorporation of all the appropriate heavy and light chain variable regions 
into the library, would involve the amplification of a total of 166 separate primer 
combinations. Due to this method being both time-consuming and impractical, a master mix 
was prepared for both the forward and reverse primers for both the variable heavy and light 
primers. While this modified approach leads to a much simpler and rapid construction of the 
scFv library, there is the potential for the loss of some diversity from the immune repertoire. 
For instance, certain primer combinations may amplify efficiently, whereas, other 
combinations may need extensive optimisation. This occurrence may lead to bias towards 
abundant genes over more conserved genes, which may be integral to the development of a 
highly specific scFv library. Following construction of the mouse library and its subsequent 
enrichment against the antigen of interest (in this case CRP), several obstacles were 
encountered during both screening and characterisation of the scFv candidates from the 
library. For example, initial high-throughput screening of the scFv clones using crude lysate 
proved problematic due to the very poor levels of scFv expression, even following sub-
cloning of the enriched scFv fragments into the supplied vector (pAK 400) for optimised 
expression. This poor expression level is another negative feature associated with the 
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employment of the murine genetic system (Mavrangelos et al., 2001). The lack of any highly-
specific affinity tags within the pAK system also limits the screening capacity of the clones. 
Both a histidine and FLAG tag were incorporated into the vectors, however, both tags proved 
to be either non-specific or inaccessible during characterisation via either ELISA or Biacore. 
Subsequently, the best-performing murine scFv (C11-2) was subcloned into the pComb3X 
vector. An appealing characteristic of the pComb vector is the incorporation of the 
hemagglutinin (HA) decapeptide tag at the 3′ end of the HIS tag for capture of the 
recombinant antibodies produced, allowing for a more efficient screening and 
characterisation process. It also incorporates a 6x histidine (HIS) tag enabling universal 
protein purification. The HA-tag proved to be extremely useful for both detection of the scFv 
via ELISA and also capture of scFv during Biacore analysis. Subsequently, use of this highly-
specific affinity tag facilitated the determination of reliable kinetic data on the C11-2 scFv 
fragment. 
Although, some good potential scFv candidates with specificity towards CRP were produced 
from this murine library, several problems such as those mentioned were encountered 
throughout construction, screening and characterisation of the murine library. Consequently, 
it was decided to investigate alternative hosts and vector systems (see section 3.3) for the 
generation of scFv fragments specific for CRP. 
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3.3 Generation and characterisation 
of a chicken anti-CRP scFv library 
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3.3.1 Avian immune system 
 
The avian immune system was the subject of considerable focus over the years and is now 
regarded as an extremely simple and efficient model for the generation of highly specific 
recombinant antibody fragments. The large phylogenetic distance from humans is one of the 
primary advantages of the avian genus. Therefore, the avian immune system can often 
produce a more vigorous antibody response to highly conserved mammalian antigens, 
whereas in the case of closely related species such as rabbits or mice (Song et al., 1985; 
Michael et al., 1998; Andris-Widhopf et al., 2000,), a much more limited immune response 
may be observed due to immunological tolerance. This characteristic of the avian immune 
system can also provide a greater opportunity to generate antibodies to certain epitopes that 
may be dominant in mammalian immune responses (Andris-Widhopf et al., 2000). 
Furthermore, birds generate their immunoglobulin repertoire from single VH and VL germ 
line sequences (McCormack et al., 1993), making antibody library construction relatively 
simple. This phenomenon can also lead to a reduction in the loss of rare transcripts because 
of variability in priming efficiency (previously discussed in section 3.2.17). Due to the 
existence of only a single set of germlines, the molecular mechanisms by which chickens 
achieve their immunoglobulin diversity are sought via gene conversion, as well as the 
common mammalian hypermutation pathway (McCormack et al., 1993). Further diversity 
may also be provided in the greater length of the CDR3 residues compared to those exhibited 
by mice, which was confirmed in findings from this research. Another factor contributing to 
both a more ethical and resourceful library construction, is the ability of the chicken to yield 
specific monoclonal antibodies to several antigens from the same immunised chicken (Hof et 
al., 2008). In this particular project, the same male white leghorn chicken was immunised 
with CRP and the cardiac markers Fatty-Acid Binding protein (FABP) and Myeloperoxidase 
(MPO), simultaneously. The higher core body temperature of chickens (41°C) has also led to 
suggestions that avian-derived scFv fragments are more stable at both elevated temperatures 
and even wider pH ranges compared to other species (Chiou, 2002; Narat, 2003). Finally, the 
use of recombinant antibodies generated from the avian immune system, prevents any 
potential assay interference from both heterophile and human anti-mouse antibody (HAMA) 
contaminants. 
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3.3.2 Construction, screening and selection of avian anti-CRP scFv library 
 
All data associated with the immunisation strategy, library construction, selection and 
screening of the avian anti-CRP scFv library was previously published by (Hearty et al., 
2006; Leonard et al., 2007). A summary of the methodology employed for construction, 
selection and screening of the library may be found in section 2.10.1.  
Following an intensive screening and selection strategy, four scFv clones were chosen (F6, 
F8, G5 and H2) from the library, based on their affinities for the CRP antigen. This section 
will focus on characterisation of these four avian anti-CRP scFv antibodies. 
 
3.3.3 Cross-reactivity analysis of avian anti-CRP scFv antibodies 
 
A vital component of immunoassay development involves determination of the specificity of 
the scFv fragments for the antigen of interest i.e. for CRP. Therefore, it is essential to test for 
the most likely cross-reactants in clinical samples that may lead to invalid test results. The 
protein showing the highest level of homology to CRP is SAP (discussed in section 3.1.2). Its 
homologous structure makes it an essential analyte to be incorporated into the 
characterisation of the specificity of anti-CRP scFv fragments. 
It was decided to perform an antibody capture-based method for the determination of CRP 
cross-reactivity by ELISA (section 2.10.2). The capture method exploited the pAb’s ability to 
bind both CRP and SAP. The format involved a 96 well plate (Maxisorp™, Nunc), coated 
with the purified rabbit anti-CRP pAb, capturing either the CRP or SAP proteins. Crude 
lysate containing expressed scFv was then passed over the captured proteins. The binding 
complex was then detected using an HRP-labelled anti-HA mAb.  
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Figure 3.3.3 (a) Cross reactivity analysis of 4 avian scFv’s and commercial mAb using direct 
ELISA. The bars in blue and yellow represent the binding response expressed as absorbance 
to CRP and SAP, respectively. 
 
The plotted data from the cross-reactivity analysis can be seen in Figure 3.3.3 (a). It was 
clearly evident that all four of the avian anti-CRP scFv’s showed no cross-reactivity to the 
homologous SAP protein. This was also the case for the HyTest anti-CRP mAb used as a 
positive control in the ELISA.  
Further cross-reactivity analysis was performed using a Biacore SPR-based biosensor. A 
capture-based approach was again used involving an anti-HA mAb directly immobilised onto 
the CM5 chip surface (as per the general protocol described in section 2.8.8). Filtered lysate 
from the four avian clones was then passed across the anti-HA mAb, resulting in subsequent 
capture of the expressed scFv contained in the lysate. The final step involved passing either 
CRP or SAP (both at a concentration of 2 μg/mL) or HBS buffer across the captured scFv.  
 
 
122
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
po
ns
e
s 
(R
U
)
Figure 3.3.3 (b) Cross reactivity analysis of scFv-enriched H2 clone lysate using an anti-HA 
capture method on the Biacore 3000. 
 
Figure 3.3.3 (b) shows one of the resultant sensorgrams of the avian clones (H2) tested. 
Again, as seen in the ELISA cross reactivity analysis, no binding of the SAP protein was 
observed (Red line). Significant binding responses to CRP (grey line) were produced (as high 
as 500 response units (RU)). Conversely, no significant binding to the SAP protein was 
evident, producing RU values equal to that of the background level of the HBS buffer (blue 
line) negative control. All 4 avian anti-CRP scFvs produced identical results to these, 
therefore, it was concluded that the 4 avian anti-CRP scFvs do not bind the SAP protein. 
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3.3.4 Kinetic analysis of avian anti-CRP scFv clones using the Biacore A100 system 
 
As discussed in section 3.2.16, multivalent analytes such as CRP add complexity to protein–
protein interactions, which cannot be fitted using a simple 1:1 Langmuir equation. Therefore, 
high precision kinetic analysis was again performed with purified modified monomeric CRP 
(mCRP). A capture-based assay format was employed for kinetic analysis of the scFvs 
(Figure 3.3.4 a). This format design enabled both high-throughput and high precision kinetic 
analysis to be performed on the CRP-specific scFvs. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.4 (a) Capture assay format used on the Biacore A100 instrument. Biotinylated 
anti-HA antibody was immobilised on spots 1, 2, 4 and 5 of a series S SA chip. The scFv 
antibody fragments were subsequently captured on spots 1 and 5 of each flowcell resulting in 
8 scFv antibodies being analysed per cycle. Spots 2 and 4 were used as reference surfaces. 
Antigen was passed over each spot simultaneously for 2 min and the dissociation of antigen 
in buffer monitored for 10 min. 
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Figure 3.3.4 (b) Typical kinetic analysis fit of avian anti-CRP scFv clone (F8) using the 
Biacore A100 system. The global fit of a 1:1 interaction model to the response data obtained 
from the Biacore A100 for clone F8 with multiple analyte concentrations is shown. 
Monomeric CRP was injected across the captured scFv at 30 μL/min for 2 min at 50, 25, 12.5 
(duplicate), 6.25, 3.12 and 1.56 nM concentrations. The black lines represent the global fit to 
the response data shown as coloured lines. 
 
Sensograms for each of the mCRP concentrations used in the kinetic analysis were fit 
globally to a 1:1 interaction model using Biacore 3000 dedicated software (Figure 3.3.4 b). 
The 1:1 Langmuir interaction model was subsequently used to extrapolate the relevant kinetic 
constants and binding affinities of the scFv for mCRP (Table 3.3.4). 
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Table 3.3.4 Summary of kinetic constants and binding affinities calculated for the four scFv 
antibody fragments that bound monomeric CRP 
Clone ka (M−1 s−1) kd (s−1) KD (M) 
F6   8.90[1] a×104 2.26[2] b ×10-3 2.54×10-8
F8 1.39[1]×105 1.41[1]×10-3 1.01×10-8
G5 1.75[1]×105 6.15[4]×10-4 3.52×10-9
H2 5.76[3] ×105 2.03[2] ×10-4 3.53×10-10
 
a The number in brackets represents the standard error in the last significant digit of ka value 
from each experiment. 
b The number in brackets represents the standard error in the last significant digit of kd value 
from each experiment. 
 
3.3.5 Large-scale IMAC purification of anti-CRP scFv’s 
 
The use of crude lysate extract for preliminary characterisation of scFv fragments is 
acceptable; however, a high level of purity is required for the incorporation of these scFv 
fragments into sensitive novel assay platforms. Consequently, the four avian anti-CRP scFv 
clones (F6, F8, G5 and H2) were expressed in large-scale (section 2.10.3) and purified using 
IMAC purification (section 2.10.4). Figure 3.3.5 shows both the crude lysate and purified 
scFv fragment from all four expressed cultures of the avian anti-CRP scFv clones. The IMAC 
purification produced a highly pure sample of scFv fragment for all four of the avian clones, 
with no significant non-specific protein contamination.  
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Figure 3.3.5 Crude scFv-enriched lysate (L) and purified scFv (S) for all 4 avian anti-CRP 
scFv antibodies. Each of the 4 analysed fragments are F6 (lane 2 and 3), F8 (lane 4 and 5), 
G5 (lane 6 and 7) and H2 (lane 8 and 9) resolved on an SDS gel. A protein marker ladder 
(Sigma) was loaded in lanes 1 and 10 for estimation of the apparent molecular weights of the 
components of each of the protein samples. 
 
3.3.6 Engineering of avian CRP-specific H2 scFv for direct conjugation on the 
SPRSpectral® platform 
 
A final goal of this research was the incorporation of these fully-characterised antibodies into 
a novel point-of-care (POC) biosensor platform. The scFv showing the highest affinity for 
CRP (H2 clone) was chosen for application in an SPR-based biosensor (see section 3.5.5). A 
classically used substrate for SPR-based analysis is a thin layer of gold on a high refractive 
index glass support (Homola et al., 1999). Prior to its incorporation into this biosensor 
platform, it was decided to modify the H2 scFv fragment to allow for its direct conjugation 
onto the gold surface. To ensure that the engineered scFv fragment adopts a functional 
conformation on the gold surface, the terminal region of the scFv fragment was subjected to 
the genetic engineering process. One method in which direct conjugation of the antibody 
fragment to a gold surface may be achieved is via the incorporation of a terminal cysteine 
residue on the scFv fragment. A terminal cysteine residue would result in a free thiol group 
with reactive properties for the gold surface. The constant lambda (Cλ) chains of chicken 
antibodies have been shown to possess a C-terminal cysteine residue used for linking the 
adjoining chain. Attaching a chicken Cλ chain onto the scFv fragment, will provide both the 
desired terminal cysteine residue for direct conjugation and also have a beneficial impact on 
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the stability of the recombinant antibody. This format of an scFv fused to a constant chain 
(kappa or lambda) is referred to as a scAb fragment (Figure 4.3.5 a) (McGregor et al., 1994) 
and it was previously shown that this structure has superior expression, stability and serum 
half-life compared to scFv fragments (Maynard et al., 2002). 
 
scAb (~40 kDa) 
CL
scFv (~28 kDa) 
Chicken Cλ 
chain (~12 kDa) 
 
 
 
 
 
 
 
Figure 3.3.6 (a) Illustration of a scAb fragment, composed of an scFv fused to a constant 
chain (kappa or lambda). 
 
The methodology used to convert the H2 scFv into this scAb format (containing reactive 
terminal cysteine) may be found in sections 2.10.6 to 2.10.10. Firstly, primers were designed 
and incorporated into a PCR for amplification of the Cλ chain from cDNA isolated from an 
immunised chicken (see section 2.10.6). The amplified chicken Cλ chain contains a naturally-
occurring terminal cysteine residue and, therefore, the amplified chain will be referred to as 
Cλcys. Figure 3.3.6 (b) shows the amplified Cλcys product resolved via agarose gel 
electrophoresis.  
 
Primer sequences used for amplification of the Cλcys chain: 
 
Cλcys For 
5′ ATA AGA ATG CGG CCG CTC AGC CCA AGG T 3′ 
 
Cλcys Rev 
3′ CCG GCA ATG GCC GAC GTC GAC GCA CTC G 3′ 
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Figure 3.3.6 (b) PCR amplification of the Cλcys chain from chicken cDNA using ‘in-house’ 
designed primers (Lane 2). A 1 kb Plus DNA molecular weight marker was added to lane 1. 
Also, a negative control containing no template DNA is shown in lane 3. 
 
Not1 and Sal1 restriction sites were incorporated into the primers to allow for direct cloning 
of the Cλcys chain into the pMoPac 16 vector (Hayhurst et al., 2003) (see Figure 3.3.6 c). 
This vector already contains a constant kappa (Cκ) chain flanked by the Not1 and Sal1 
restriction sites. Therefore, the existing Cκ chain was replaced with the amplified Cλcys 
chain using the methods described in section 2.10.7 and then transformed into 
electrocompetent Top 10 F′ cells for soluble expression. 
The existing scFv gene harboured by the vector coded for an scFv fragment specific for 
prostate specific antigen (PSA). For confirmation of the successful incorporation of the 
Cλcys chain into the pMoPac 16 vector, sixty of the transformant clones were cultured and 
their expressed lysates tested in a direct ELISA format against PSA (see section 2.10.8). 
Figure 3.3.6 (d) illustrates the responses of the expressed lysates of the sixty individual PSA 
specific scAb clones (Cλcys chain).  
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Figure 3.3.6 (c) Schematic diagram of the expression cassettes employed by the pMoPac 
series of vectors (Hayhurst et al., 2003), a modification of the pAK series (see section 
3.2.17). Abbreviations: F, FLAG tag; H, His6 tag; M, myc tag; Ck, human kappa light chain 
constant domain and Skp, seventeen kilo Dalton protein (periplasmic chaperone). 
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Figure 3.3.6 (d) Direct ELISA using scAb-enriched lysate from 60 PSA-specific scAb 
clones. The bar highlighted in green represented the E3 clone which displayed the highest 
level of expression. 
 
On analysis of the ELISA results, E3 was found to be the clone showing the highest level of 
expression of scAb against PSA. The E3 clone was cultured and its plasmid harbouring the 
PSA-specific scAb purified using the Promega SV Miniprep ™ kit.  
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The next step involved replacing the existing anti-PSA scFv gene with the avian anti-CRP H2 
scFv gene, cloning into the pMoPAc 16 vector (E3 clone) via flanking Sfi1 restriction sites. 
As discussed in section 3.2.12, the Sfi1 restriction sites of the pAK (parent vector of pMoPac 
vectors) and the pComb vector are different. Consequently, a further set of primers were used 
for modifying the flanking Sfi1 restriction sites of the H2 scFv gene from the pComb format 
to the pMoPac format. 
 
Primer sequences used for cloning H2 scFv gene into the pMoPac 16 vector (E3 clone): 
 
CSCpAK-For 
5' GAG GAG GAG GAG GAG GAG GTG GCC CAG CCG GCC CTG ACT CAG 3' 
 
CSCpAK-Rev 
5' GAG GAG GAG GAG GAG GAG GAG CTG GCC CCC GAG GCC ACT AGT GGA 
GG 3' 
 
The specifically designed primers are a modified version of the SOE primers employed by 
the pComb system. Instead of the usual Sfi1 site utilised by the pComb system, a pAK-
derived Sfi1 site was incorporated into the primers, to allow for direct cloning of the H2 scFv 
gene into the pMoPac 16 vector (E3 clone). In theory, the original H2 scFv format should not 
ligate into the pMoPac 16 vector due to the incompatibility of their respective Sfi1 sites. 
However, to avoid any potential background interference from the old pComb format of the 
H2 scFv gene, a 2 step ‘nested-type’ PCR was performed (see section 2.10.9). This will allow 
for enrichment of the new pMoPac format of the H2 scFv over the existing pComb format, as 
discussed in section 3.2.12. Several quantities of template H2 scFv were investigated (6, 12 
and 18 ng) to identify the lowest quantity of template, which may be used for sufficient 
amplification of the required pAK format. Figure 3.3.6 (e) shows the amplified H2 scFv gene 
in its new pAK format, resolved via agarose gel electrophoresis. 
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Figure 3.3.6 (e) PCR amplification of the H2 scFv gene using ‘in-house’ designed primers 
for incorporation of pAK format Sfi1 sites. A 1 kb Plus DNA molecular weight marker was 
added to lane 1. Lanes 3 – 5 represent amplifications of the H2 scFv gene using various 
quantities of H2 scFv template (6, 12 and 18 ng, respectively). Lane 2 shows a 25 ng quantity 
of the PCR template used for the PCR. A negative control containing no template DNA is 
shown in lane 6. 
 
The PCR using 6 ng of template was scaled-up and resolved via electrophoresis on a 1% 
agarose gel and gel purified again using the QIAquick ™ gel extraction kit. Part 2 (section 
2.10.9 b) of the ‘nested-type’ PCR then used this purified product as template for 
amplification of the final modified H2 scFv gene. Following purification, the final PCR 
product was cloned into the pMoPac vector (E3 clone) using SfiΙ restriction enzyme, as 
outlined in section 2.10.10. The ligated product was then electroporated into Top 10 F′ cells 
for soluble expression. Individual colonies from the transformation plates (60 in total) were 
then cultured, solubly expressed and incorporated into a direct ELISA. The format of the 
ELISA performed is identical to that described in section 2.10.8, except the antigen being 
tested against was CRP instead of PSA. The expressed lysates of each of the clones were 
tested in duplicate against wells coated with 5 µg/mL of CRP in PBS. Figure 3.3.6 (f) shows 
the absorbance levels for all 60 of the expressed CRP-specific scAb lysates. 
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Figure 3.3.6 (f) Direct ELISA using scAb-enriched lysate from 60 CRP-specific scAb 
clones. The bars highlighted in blue represent potential positive candidates and clones 
considered to be negative are illustrated in red. Both bars highlighted in green were found to 
possess the highest level of expression of CRP-specific scAb. 
 
On analysis of the ELISA results, D9 and G3 (highlighted in green) were identified as the 
clones showing the highest level of expression of the CRP-specific scAb. Due to the almost 
identical performance of both of the clones, only one of the clones was taken forward for 
large-scale expression and purification. 
 
3.3.7 Large-scale expression and purification of the CRP-specific scAb fragment 
 
For further characterization of the CRP-specific scAb clone and also its incorporation into a 
sensitive bioplatform, a purified sample of scAb fragment was essential. Therefore, a 1 litre 
culture of the D9 clone was subjected to large-scale expression and purification as outlined in 
sections 2.10.3 and 2.10.4. It was envisaged that the free thiol group from the terminal 
cysteine residue of the scAb fragment may lead to the formation of non-specific disulphide 
bonds. For this reason, a 15 mM concentration of β-mercaptoethanol was added to both the 
sonication and wash buffers of the IMAC purification. The β-mercaptoethanol will result in 
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the reduction of any non-specific disulphide bond formation throughout the purification 
process. Each of the sample preparations of the IMAC purification were resolved via SDS-
PAGE (see section 2.8.3), which may be observed in Figure 3.3.7. 
 
1      2       3      4        5        6      7   
 100 kDa 
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Figure 3.3.7 SDS-PAGE gel of each fractions of the IMAC purification of the CRP-specific 
D9 scAb fragment. The fractions were loaded as crude lysate (Lane 2), ‘flow-through’ 1 
(Lane 3), ‘flow-through’ 2 (Lane 4), wash (Lane 5) and lanes 6-7 represent 4 µg and 2 µg 
quantity of the purified D9 scAb, respectively. A protein marker ladder (Fermentas) was also 
loaded in lane 1 for estimation of the apparent molecular weights of the each of the protein 
samples. 
 
Analysis of the purified D9 scAb via SDS-PAGE identified several protein bands, indicating 
a lack of purity of the preparation. The approximate size of a scAb fragment is 40 kDa 
(Mabry et al., 2005). However, instead of a single band at this point, three distinct protein 
bands were observed. In addition, two more unidentifiable bands were found at the ~30 kDa 
point. Finally, a band was also visible at the 80 kDa point, although this band was thought to 
represent a dimerized format of the scAb fragment. To elucidate the presence of these 
numerous bands in the purified scAb preparation, it was decided to perform a western blot on 
some of the purified scAb. The western blot will be used to ascertain which of the several 
bands show reactivity for CRP. Consequently, any bands showing no reactivity with CRP 
may be regarded as non-specific contaminant proteins. 
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3.3.8 Western blot analysis of the CRP-specific D9 scAb purified via IMAC 
 
A 12.5% SDS-PAGE gel was prepared following the protocol in section 2.8.3. A protein 
ladder (Fermentas) and a 2 µg aliquot of the purified D9 scAb were run in duplicate on the 
gel. The fully resolved gel was then split down the middle, resulting in two identical gels (A 
and B – see Figure 3.3.8 a). Gel A was subjected to the usual staining/destaining protocol, 
whereas gel B was transferred to nitrocellulose membrane and a western blot (see section 
2.10.11). The western blot involved incubation of the scAb-containing membrane with a CRP 
solution. Detection of the scAb-CRP complex was achieved via incubation with diluted Cλ-
specific rabbit serum, followed by a commercial HRP-labelled anti-rabbit mAb. Both the 
SDS gel and its corresponding western blot are shown in Figure 3.3.8 (a). 
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Figure 3.3.8 (a) Left - SDS-PAGE gel containing protein marker ladder (Fermentas) in lane 
1 and purified D9 scAb in lane 2. Right - A developed nitrocellulose membrane of an 
identical gel showing protein marker ladder (Lane 1) and CRP-reacting bands of purified D9 
scAb (Lane 2). 
 
Following development of the nitrocellulose membrane with liquid TMB substrate, all three 
of the bands at the ~ 40 kDa mark and the two bands at the ~ 30 kDa mark were found to 
bind to CRP. It was thought that the two bands at the ~ 30 kDa mark may represent a 
contaminant scFv in the final purified scAb fraction. Although this seemed highly 
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improbable, it was decided to investigate this theory via western blot analysis. As before, a 
12.5% SDS gel was prepared and loaded with both a protein marker ladder and a 2 µg sample 
of the purified D9 scAb in duplicate. A 2 µg sample of the purified H2 scFv (section 3.3.5), 
the scFv from which the scAb fragment was derived, was also loaded onto the gel as a 
positive control. Following sufficient resolution of the proteins, the gel was split into two and 
subjected to either a staining/destaining protocol or western blot. The western blot protocol 
described in section 2.10.11 was followed up to the blocking step and its subsequent wash. 
Next, the nitrocellulose membrane was incubated with a 1/2000 dilution of a mouse anti-HA 
(HRP-labelled) secondary mAb in 1 % Milk-PBST. Figure 3.3.8 (b) shows the resultant 
nitrocellulose membrane developed with TMB substrate. 
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Figure 3.3.8 (b) Left - SDS-PAGE gel containing purified D9 scAb (Lane 1), protein marker 
ladder (Lane 2) and purified H2 scFv (Lane 3). Right – the corresponding nitrocellulose 
membrane probed with the HRP-labelled HA-specific mAb. 
 
On first analysis of the gel, the sizes of the two bands under investigation in lane 1 (~ 30 kDa 
mark) were found be inconsistent with that of the H2 scFv positive control in lane 3. 
Furthermore, neither of the two bands showed any reactivity with the HA epitope tag as 
opposed to the H2 scFv. It may be concluded that each of the protein bands represent scAb 
fragment, as each of the bands were shown to react with CRP antigen and also Cλ-specific 
serum. No definitive conclusion, however, may be drawn with regards to the inconsistent 
migration patterns of the scAb fragment in the SDS gel. It may be conceivable that the free 
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thiol group of the terminal cysteine residue of the scAb fragment may be causing some 
interference in its migration through the SDS gel.  
 
3.3.9 Discussion of results 
 
An alternative system was employed for construction of the chicken scFv library, namely the 
pComb system (Barbas et al., 2001). The use of chickens for the production of antibody 
libraries has already many advantages over other hosts such as mice (section 3.1), as 
discussed previously. However, the use of the pComb system in conjunction with this, led to 
several additional benefits. Construction of the scFv library using the pComb chicken scFv 
primers required minimal optimisation of all PCR reactions. Several phagemid systems, 
including pHEN (Hoogenboom et al., 1991) and pCANTAB (Amersham Pharmacia 
Biotech), use the entire pIII as the fusion partner. In these systems, the phagemid-driven 
expression of the pIII fusion must first be shut down to allow superinfection by the helper 
phage, after which expression is induced to allow production of the fusion for phage display. 
Use of the pComb3X system, however, does not require this step due to the inclusion of a 
truncated pIII protein, comprised of the carboxy-terminal residues of the pIII. This truncated 
pIII can serve as the required fusion partner for the displayed protein by mediating 
incorporation of the fusion into the phage coat without producing immunity to helper phage 
infection. Also, soluble expression was achieved immediately after bio-panning, by simply 
infecting the phagemid into a non-suppressor strain (Top 10 F′), made possible by the 
presence of an amber codon between the 3′ SfiΙ restriction site and the 5′ end of gene III. 
Propagation of phage in suppressor strains such as XL1-Blue allows production of gene III 
fusion proteins for phage display. However, if a male nonsuppressor strain such as Top 10 F′ 
is infected with the phagemid phage, the stop codon will be read and soluble protein will be 
produced. Thus, the pComb3X facilitates the expression, detection, and purification of 
soluble protein following phage selection. This removes the time-consuming process of sub-
cloning the enriched pool of scFv genes into a suitable expression vector for their subsequent 
screening and characterisation. Moreover, sub-cloning of the scFv genes into another vector 
may jeopardise the libraries diversity due to the potential loss of some of the more conserved 
and potentially superior scFv genes.  
Considerably large yields of expressed scFv were obtained for each of the four fully-
characterised scFv clones, with F8 being particularly good. A 500 mL bacterial culture of the 
clone produced approximately 15.5 mg of pure scFv using a simple IMAC protocol (section 
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2.10.4). Each of the recombinant fragments were also shown to recognise different epitopes 
of the CRP molecule. Both the pentameric (pCRP) and monomeric (mCRP) forms of CRP 
were detectable by pairing the G5 and F6 scFv fragments in a sandwich assay. Conversely, 
only the pentameric form was detected when H2 and F6 were combined in a sandwich assay 
format. Therefore, these four scFv fragments are capable of detecting both forms of this 
molecule, each of which play key roles in the development of life-threathening 
cardiovascular events. All four of the clones proved to be ideal candidates for model assay 
development due to their stable expression and high level of purity. However, to further 
enhance their applicability for a novel biosensor platform, it was decided to subject the 
highest affinity H2 clone to a novel engineering process. This novel engineering provided a 
re-formatted CRP-specific fragment (scAb), which may be directly conjugated to gold 
biosensor surfaces via the terminal thiol group. Therefore, the final characterisation of the re-
engineered CRP-specific fragment involved incorporation into a commercial SPR-based 
device (See section 3.5.5). The novel format of the final engineered fragment allows for both 
direct conjugation to the gold surface and also ensures positioning of the fragment in a fully-
functional confirmation. The combination of such novel strategies appreciably rationalises 
the task of generating and mining diverse panels of candidate antibodies for use in novel 
diagnostic biosensor formats and expedites the route from antibody production to functional 
biosensor assay development. 
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3.4 Generation and characterisation 
of a chicken anti-MPO scFv library 
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3.4.1 Multimarker detection 
 
In the field of cardiac diagnostics, it has been shown that in certain instances, the cumulative 
information derived from a multimarker panel can be superior to traditional cTnI laboratory 
testing (Straface et al., 2008). Considerable interest still remains in generating multimarker 
scores that use a composite of several biomarkers (measured in parallel) for the purpose of 
predicting disease risk and patient outcomes (de Lemos et al., 2001; Newby et al., 2001; Ng 
et al., 2001; Sabatine et al., 2002; Baldus et al., 2003; James et al., 2003; Bodí et al., 2005; 
Heeschen et al., 2005; Kip et al., 2005). Therefore, the general consensus is that the future of 
cardiac diagnostics will involve a multimarker approach. 
As previously mentioned in section 1.6, CRP has been consistently flagged as having great 
potential, particularly in the field of cardiac risk assessment. However, as a marker of disease 
activity and vascular inflammation, CRP detection has been affiliated with long-term risk 
stratification. Therefore, the implementation of a more comprehensive risk assessment 
strategy should also include a cardiac marker capable of identifying short-term risk cardiac 
patients. As was mentioned in section 1.7, MPO, being a marker of plaque instability and 
neutrophil activation may be prove to be a key marker for short term stratification. 
Furthermore, it has been suggested that both markers may even be complementary in the 
assessment of patient cardiac risk (Loria et al., 2008). Consequently, this work also involved 
the generation of recombinant antibodies against MPO. This section will discuss the 
construction, screening and characterisation of an immune avian library against MPO. 
 
3.4.2 Myeloperoxidase (MPO) as a target analyte 
 
Native MPO (150 kDa) is a dimer consisting of two 15-kDa light chains and two variable-
weight glycosylated heavy chains bound to a prosthetic heme group (Figure 3.4.2). Three 
isoforms of MPO have been identified (MPO A, MPO B, and MPO C), differing in the size 
of their heavy chains. Each contains a calcium binding site with 7 ligands, forming a 
pentagonal pyramid conformation. One of these ligands is the carbonyl group of Asp 96. 
Calcium-binding is important for the structure of the active site due to the close proximity of 
Asp 96 to the catalytic His 95 side chain. 
In general, MPO is assumed to form a complex with anionic proteins such as albumin in 
serum, because it is a highly cationic protein with an isoelectric point higher than 10 
(Tiruppathi et al., 2004; Salavej et al., 2006). Consequently, non-specific binding may prove 
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to be a significant obstacle in terms of antibody characterization against MPO, particularly in 
highly sensitive platforms such as Biacore. 
Finally, the peroxidase nature of MPO may be exploited to allow for a more direct detection 
method. This may be achieved by employing a capture-based format, whereby the developed 
antibodies will be coated or immobilised onto the assay platform and the MPO-spiked sample 
passed across. Subsequently, the captured MPO can be used the detection enzyme of the 
assay and its concentration calculated via the addition of peroxidase-reactive substrates such 
as TMB or OPD. This ability to bypass secondary immunological detection agents may prove 
crucial in the development of a more rapid assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2 Ribbon representation of the MPO dimer structure (left) (Anonymous  Last 
Accessed January, 2009). Chain A = dark green; chain C = light green; chain B = dark cyan; 
chain D = light cyan. An enlarged view of the incorporated inter-chain disulphide of MPO 
(CysC-153-CysD-153) is also shown (right). 
 
3.4.3 Serum titre of MPO-immunised chickens 
 
Following an extensive immunisation strategy (section 2.11.1), the responses of both 
chickens to the MPO immunogen were analysed via serum titre. Serum from the immunised 
chickens was diluted (1/100 to 1/1,000,000 dilution) in PBST (containing 0.5 % (w/v) milk 
marvel and 0.5% (w/v) BSA) and tested against MPO in a direct ELISA format. The 
antibody-MPO complex was detected using an AP-labelled anti-chicken antibody. 
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Figure 3.4.3 Titration curve illustrating the MPO-specific response of serum taken from the 
final bleeds (red and blue) for chickens A and B, respectively. A negative control, serum 
from a pre-bleed (green and pink) was also tested for both of the chickens.  
 
Both chickens were found to produce serum titres in excess of 1/100,000 against the MPO 
antigen (Figure 3.4.3). These responses were deemed sufficiently high for the construction of 
a recombinant antibody library. As a control, serum taken from the chickens prior to any 
immunisations was also tested in the ELISA, to identify any non-specific binding of the 
serum matrix to MPO. However, a consistently low level of background binding was 
observed for all dilutions of the control serum.  
 
3.4.4 RNA extraction and cDNA synthesis 
 
High quality RNA was extracted from the spleen and bonemarrow of both chickens, as 
described in section 2.11.2, and then pooled in an equimolar ratio. The RNA pool was then 
transcribed to cDNA using a commercial RT-PCR kit (section 2.11.3). This cDNA was then 
used as the template for construction of the avian recombinant scFv library. 
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3.4.5 Library construction and subsequent enrichment via biopanning 
 
Both construction and enrichment of the library was performed using the methodology as 
described by Andreas Widhopf and colleagues (Andris-Widhopf et al., 2000). Briefly, both 
the variable light and heavy chains were individually amplified using the primers sets 
described in section 2.11.4. Construction of the subsequent scFv gene proceeded by fusing 
equimolar concentrations of the variable heavy and variable light chain using the pComb 
overlap primers (CSC-F and CSC-B). The fusion product may be produced using either a 
short serine-glycine linker (GGSSRSS) or a long linker (GGSSRSSSSGGGGSGGGG) 
depending on the overlap primers used. The long linker was utilised to favour formation of 
monomeric scFv fragments over diabody formation. Following quantification of the SOE-
PCR reaction, the resultant scFv gene was cloned into the pComb3X vector using SfiΙ 
restriction enzyme. The successfully ligated product was then electroporated into commercial 
XL-1 Blue cells, resulting in a transformed library size of 7.5 x 107 colony forming units 
(cfu)/mL. The transformed avian library was then ‘rescued’ using M13K07 helper phage 
(section 2.11.7) and then enriched via four rounds of phage display biopanning against 
immobilised MPO antigen, as described in section 2.11.8. All of the variable panning 
parameters used throughout the panning process may be found in Table 2.11.8. 
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3.4.6 Polyclonal phage ELISA 
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Figure 3.4.6 Polyclonal phage ELISA involving both the pre-panned and pan 4 phage pools 
from panning of the chicken scFv library. Both the pre-panned and pan 4 phage pools were 
tested in a direct ELISA format against their respective cognate antigens (CRP, FABP or 
MPO) and also against BSA (negative control). 
 
Both the pre-panned and pan 4 phage pools were then incorporated into a polyclonal phage 
ELISA (Figure 3.4.6), as described in section 2.11.9. Due to the peroxidase nature of MPO, 
an AP-labelled secondary antibody was employed as opposed to the HRP-labelled secondary 
antibody used for detection of the CRP and FABP-specific phage. Therefore, following 
addition of the relevant substrates (PNPP for AP conjugate and TMB for HRP conjugate), the 
resultant absorbance values were read at either 405 nm or 450 nm, respectively. On analysis 
of the polyclonal phage ELISA, it is clearly evident that the final phage pool shows a 
significant level of enrichment towards MPO, which was also observed for the phage pools 
enriched against FABP and CRP. In each case, no non-specific binding of the phage against 
the BSA control protein was observed. This result clearly demonstrates the successful 
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employment of pooled immune chicken libraries for the generation of specific recombinant 
antibodies against multiple biomarker panels. 
 
3.4.7 Soluble expression and direct ELISA of chicken anti-MPO scFv clones. 
 
Based on analysis of the polyclonal phage ELISA, the phage output from round 4 was chosen 
for infection into Top 10 F′ for soluble expression using protocol 2.11.10. The Top 10 F′ 
bacterial strain is a non-suppressor strain that recognises the amber stop codon as a stop 
codon for production of soluble protein. The solubly-expressed enriched libraries were then 
analysed using expressed lysates of 120 single colonies in a direct soluble monoclonal ELISA 
(Figure 3.4.7) format, as described in section 2.11.11.  
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Figure 3.4.7 Direct soluble ELISA involving scFv-enriched lysate expressed from 120 
chicken anti-MPO scFv clones from pan 4. The bars highlighted in blue represent all the 
positive MPO-specific clones and the negative clones (response below the background level) 
are illustrated in red. 
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The peroxidase nature of MPO required the use of an AP-labelled anti-HA mAb for detection 
of the MPO-scFv complex as opposed to the previously used HRP conjugate. Forty-four 
MPO-specific clones were identified, showing specificity to the MPO antigen, with no non-
specific binding to bovine serum albumin. These positive clones (highlighted in blue) were 
taken forward for further analysis to determine solution-phase binding to MPO. 
 
3.4.8 Preliminary Biacore analysis 
 
The ELISA-based screening strategy employed for the murine anti-CRP scFv library (section 
4.1) proved to be both considerably labour intensive and time-consuming (see sections 3.2.8 
and 3.2.9). Additionally, this approach may lead to potential high affinity clones being 
overlooked due to poor expression. Therefore, an alternative more robust strategy was 
implemented for screening of the avian anti-MPO scFv library. A Biacore-based ‘ranking’ 
approach was decided upon, to ensure a more reliable and also high-throughput analysis of 
the positive clones. 
Anti-HA mAb
Captured anti-
MPO scFv
MPO
CM5 chip
CM dextran
 
 
 
 
 
 
 
 
Figure 3.4.8 Capture assay format used on the Biacore 3000 instrument. 
 
An off-rate ‘ranking’ approach was undertaken using the basic format illustrated in Figure 
3.4.8. Initially, anti-HA mAb (section 2.11.12) was immobilised onto flow cell 2 (FC2) of a 
CM5 sensor chip (GE Healthcare) using the standard protocol described in section 2.8.8. 
Crude bacterial lysates were prepared for each of the positive clones using the techniques 
described in section 2.9.19. A 30 nM concentration of CRP proved optimal for ‘off-rate’ 
ranking of the avian anti-CRP scFv clones, therefore, this concentration was also investigated 
for the avian anti-MPO clones. However, a significant degree of non-specific binding of 
MPO to the FC 1 (unmodified CM-dextran reference flow cell) was identified. This was 
thought to be due to the highly cationic nature of MPO, resulting in non-specific binding to 
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the CM-dextran surface. To counteract this problem, a fresh CM5 chip was coated with anti-
HA mAb described in section 2.11.12. Furthermore, the reference flow cell to be used in the 
analysis was activated using EDC/NHS chemistry and capped to reduce any potential non-
specific binding. These modified immobilisation and surface-capping protocols involved the 
use of ethylenediamine (pH 8.5) as opposed to the traditional ethanolamine as a capping 
agent. It was envisaged that the strong basic nature of ethylendiamine would make it a more 
efficient capping agent for analysis of the highly cationic MPO protein.  
 
3.4.9 Off-rate analysis of avian anti-MPO scFv clones 
 
Each of the bacterial lysates were diluted in HBS buffer to ensure an scFv capture level of 
~100 RU’s. A 3 nM concentration of MPO was found to be optimal for the analysis, which 
showed insignificant binding to the reference flow cell. A reference control was also 
incorporated into the assay for each of the clones, whereby, HBS buffer was passed across 
each of the captured scFv clones. The conditions used in the ‘off-rate’ analysis assay may be 
found in section 2.11.13. 
The ‘off-rate’ data for each of the clones was imported into the supplied BIAevaluation 
software package for analysis. Antibody/antigen complex stability (% left) was calculated for 
each of the clones by expressing the ‘stability late’ (calculated from the average response 
from 295 to 300 s after buffer injection) as a percentage of ‘stability early’ (calculated from 
the average response from the first 5 s after buffer injection), as illustrated in Figure 3.4.9. 
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Figure 3.4.9 Analysis of the percentage antibody/antigen complex remaining after 5 min 
dissociation in buffer for 25 of the MPO-specific scFv clones.  
 
Selection of the clone to be taken forward for sequencing and kinetic analysis was based on 
both the percentage of MPO retained and also the expression level. The clone showing the 
highest percentage of MPO retained was B10B, which was also found to have the highest 
level of expression (judged by dilution factor of lysate) of clones with over 85% MPO 
retained. 
 
3.4.10 Sequence analysis of Avian B10B anti-MPO scFv clone 
 
Following ‘off-rate’ ranking of the selected pool of MPO-specific scFv antibodies, the B10B 
scFv was selected for sequence analysis and more in-depth characterisation. The protein 
sequence of the B10B scFv is shown in Figure 3.4.10, with all of the key CDR regions, 
linkers and affinity tags highlighted. 
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Figure 3.4.10 Sequence of the selected avian anti-MPO scFv clone. The three CDR regions 
for both the variable light (CDR-L) and variable heavy (CDR-H) regions are highlighted in 
blue and red, respectively. A glycine-serine linker (green) fuses the variable heavy and light 
regions together (green font). To aid in the purification and characterisation of the scFv 
fragments, both a hexa-histidine tag (orange) and a HA epitope tag (pink) are incorporated at 
the carboxyl terminus of the scFv fragment. 
 
On analysis of the sequence data of the B10B scFv, the CDR regions for both the light (blue) 
and heavy chains (red) were found to be dominated by serine and glycine residues. Several 
studies have commented on the importance of these residues in providing suitable 
conformations within the CDR regions for high affinity binding (Wiesmann and Sidhu, 2004; 
Fellouse et al., 2005; Fellouse et al., 2006; Fellouse et al., 2007). The small size of both 
serine and glycine, contribute to the overall flexibility of the CDR region, which has been 
shown to be a key feature in effective antigen recognition (Mian et al., 1991; Padlan, 1994; 
Zemlin et al., 2003). Furthermore, tyrosine residues were present in four of the six CDR 
regions, which have been suggested as playing an integral role in making favourable contacts 
with the antigen in the CDR regions (Birtalan et al., 2008). The same study revealed that 
highly functional CDR-H3 loops could be derived from combinations of tyrosine, serine and 
glycine residues.  
 
3.4.11 Large-scale IMAC purification of B10B anti-MPO scFv 
 
Large-scale expression and purification of the B10B scFv was performed, as described in 
sections 2.10.3 and 2.10.4, respectively. Approximately 50 mg of purified scFv product was 
harvested from a 500 mL bacterial culture using an optimised IMAC protocol. The 
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production of 500 µg of pure scFv per ml of bacterial culture was deemed to be a 
significantly high yield.  
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Figure 3.4.11 SDS-PAGE analysis of the various fractions of an IMAC purification of a 
MPO-specific scFv fragment. The fractions were loaded as crude lysate (Lane 2), ‘flow-
through’ 1 (Lane 3), ‘flow-through’ 2 (Lane 4), wash (Lane 5), elution fraction (Lane 6) and 
buffer-exchanged fraction (Lane 7). A protein marker ladder (Fermentas) was also loaded 
alongside the samples in lane 1 and 8 for estimation of the apparent molecular weights of the 
each of the protein samples. 
 
The final scFv fraction (Lane 7 in Figure 3.4.11) was found to have a high degree of purity 
with minimal contaminant proteins evident. Several formats such as ELISA, Biacore and 
lateral flow were used to further characterise this purified scFv preparation.  
 
3.4.12 Titration and inhibition ELISA analysis of B10B anti-MPO scFv 
 
Initial characterisation of the purified MPO-specific B10B scFv was performed via ELISA to 
determine its functionality in a basic assay format. It was decided to investigate the solution-
based binding capacity of the purified B10B scFv in an inhibition-style ELISA format. 
Firstly, a titre ELISA (section 2.11.14) was performed to determine the optimal dilution of 
the purified B10B scFv to be used in the inhibition assay.  
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Figure 3.4.12 (a) Titration curve of purified avian anti-MPO B10B scFv in a direct ELISA 
format for determination of the optimal dilution factor for inhibition assay analysis. 
 
On analysis of the titration curve (Figure 3.4.12 a), a 1/500,000 dilution of the purified scFv 
was selected for incorporation into the inhibition ELISA. This value was calculated as the 
dilution of scFv corresponding to the halfway point of the slope of the titration curve. An 
explanation of the basis of an inhibition ELISA may be found in section 3.2.9. 
The inhibition ELISA involved pre-incubating varying concentrations of free MPO (5000, 
2500, 1250, 625, 312.5, 156.25, 78.13, 39.06, 19.53, 9.76, 4.88, 2.44 and 1.22 ng/mL) with 
the calculated 1/500,000 dilution of scFv, which were then applied in duplicate to a plate 
coated with MPO (See Figure 3.4.12 b for assay format used). 
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Figure 3.4.12 (b) Assay format used for inhibition ELISA. 
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Figure 3.4.12 (c) Inhibition curve of purified avian anti-MPO scFv against several selected 
concentrations of MPO. 
 
Detection of the free MPO was evident down to the low nanogram level (See Figure 3.4.12 
c). An IC50 is a useful value which may be extrapolated from an inhibition curve, which 
provides an indication of the affinity of the antibody under investigation. The IC50 value 
(also known as the half maximal inhibitory concentration) refers to the concentration of free 
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MPO (ng/mL) required to give 50% inhibition of the binding of the scFv to the immobilised 
MPO. Therefore, the IC50 value for the tested B10B scFv was approximately 90 – 100 
ng/mL. 
 
3.4.13 Kinetic analysis of B10B anti-MPO scFv clone 
 
Crude ‘scFv-rich’ lysate may be employed to obtain kinetic data on a clone (as seen in 
section 3.2.16). Nevertheless, it was decided to use purified fractions of the MPO-specific 
B10B scFv due to the large yield of purified product obtained (section 3.4.10). A HA tag 
capture-based format was used for kinetic analysis of the B10B scFv. The anti-HA mab-
immobilised CM5 chip used for kinetic analysis was prepared as described in section 2.11.12. 
Initially, serial dilutions of the purified B10B scFv were performed in HBS, ranging from 
1/100 to 1/10,000,000. Each scFv dilution, starting with the most dilute, was passed across 
flow cells 1 and 2 of the CM5 chip and their subsequent capture levels monitored. A 
1/200,000 dilution of the B10B scFv produced a capture level of approximately 100 RU’s, 
following a 2 min injection at a flow-rate of 10 µl/min. This dilution translated into an scFv 
concentration of approximately 215 ng/mL, which was employed as the optimal scFv 
concentration to be used for kinetic analysis (Figure 3.4.13). 
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Figure 3.4.13 Kinetic analysis fit of the avian B10B anti-MPO scFv using the Biacore 3000 
system. Shown is the local fit of a 1:1 interaction model (with drifting baseline) to the 
response data obtained from the Biacore 3000 with multiple analyte concentrations. The 
black lines represent the local fit, to the response data (shown as coloured lines). The six 
concentrations of MPO used in the analysis were 5000 (red), 2500 (green), 1250 (purple), 
625 (turquoise), 312.5 (grey) and 156.3 pM (blue). 
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The kinetic run consisted of initial capture of the scFv, using a 2 min injection of the 
optimised dilution across the anti-HA chip surface at a flow rate of 10 μL/min, followed by a 
stabilization period of 3 min. Next, MPO was spiked into HBS at concentrations of 5000, 
2500, 1250, 625, 312.5 and 156.3 pM and passed across the captured scFv at a flow rate of 30 
μL/min. A duplicate of the 625 pM concentration of MPO was included, in addition to a zero 
concentration, enabling double referencing in the analysis. Association and dissociation 
phases were monitored for 2 and 10 min, respectively. Sensograms for each of the MPO 
concentrations were fit globally to a 1:1 interaction model using Biacore 3000 dedicated 
software. A good fit (Figure 3.4.13) was observed for the kinetic run using the Langmuir 
equation, producing a Chi2 output value of 0.395. This 1:1 interaction model was 
subsequently used to extrapolate the relevant kinetic constants and binding affinities of the 
scFv for MPO (Table 3.4.13).  
 
Table 3.4.13 Kinetic constants and binding affinity calculated for the B10B scFv 
Kinetic parameter ka (M−1 s−1) kd (s−1) KD (M) 
Value 4.93 x 106 9.16 x 10-4 1.86 x 10-10
 
 
3.4.14 Direct detection of MPO with TMB/OPD 
 
As discussed in section 3.4.2, the peroxidase nature of MPO was considered to be a very 
useful characteristic, which may be exploited in a diagnostic assay. Therefore, it was decided 
to investigate a potential use for the enzymatic properties of MPO in an immunological assay 
format, whereby MPO itself can be used as the detection enzyme in the assay format. The 
substrates TMB and OPD, commonly used for measurement of peroxidase activity, were 
identified as two potential candidates for use in the assay. To demonstrate ‘proof of principle’ 
a basic capture-based ELISA was performed, comparing the use of either TMB or OPD as a 
detection agent. 
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Figure 3.4.14 (a) Assay format used for direct detection of MPO with TMB/OPD. 
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Figure 3.4.14 (b) Use of substrates TMB and OPD as direct detection agents of MPO in an 
ELISA-based assay.  
 
The format of the ‘proof of principle’ assay is illustrated in Figure 3.4.14 (a) and a 
description of the assay itself may be found in section 2.11.15. On analysis of the assay data 
(Figure 3.4.14 b), a good correlation was observed between both of the substrates and the 
varying concentrations of MPO used. Although both substrates produced similar results 
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(detection of MPO down to the low ng/mL range), the TMB substrate was found be slightly 
more sensitive and was, therefore, adopted for application in an alternative assay format. 
 
3.4.15 Lateral flow assay development  
 
It was decided to investigate this novel method for the rapid detection of MPO in an 
alternative more robust system. Although an ELISA-based approach proved successful for 
implementation of this novel assay format, several time-consuming steps such as hour long 
incubations and wash steps contribute to an overall poor assay turn-around-tme (TAT). 
Conversely, the employment of a lateral flow immunoassay (LFIA) – based format will allow 
for a significant improvement in assay TAT. Initially, a preliminary hybrid-type lateral 
flow/western blot format (see section 2.11.16) was employed to ensure functionality of the 
assay on the LFIA nitrocellulose membrane. MPO was spiked into 1% (w/v) milk-PBST 
solutions at concentrations of 10000, 1000, 100 and 10 ng/mL. Instead of allowing the 
samples travel up the strip via capillary action (classic lateral flow), a less stringent approach 
was utilised involving full submersion of the each of the strips in its corresponding spiked 
MPO sample. Similarly, liquid TMB substrate was applied to the test line area and allowed to 
develop (See Figure 3.4.15 a) 
 
 
 
 
 
 
 
 
      1                     2                    3                       4   
Figure 3.4.15 (a) Developed nitrocellulose membrane strips from the hybrid LFIA-western 
blot assay. Strips 1 – 4 represent detection of 10000, 1000, 100 and 10 ng/mL of MPO-spiked 
samples. 
 
Detection of the scFv-captured MPO is clearly visible in the buffer samples spiked with 
10000, 1000, and 100 ng/mL of MPO, however, the lowest concentration of MPO (10 
ng/mL) was found to produce no visible band. The main focus of this hybrid assay was to 
identify whether or not this particular direct detection format could be applied to a 
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nitrocellulose membrane. Due to the successful application of this assay format on the 
nitrocellulose membrane, the next step involved performing the assay in an authentic LFIA. 
 
The finalised protocol for the optimised LFIA may be found in section 3.12.1. An identical 
format to that shown in Figure 3.4.14 (a) was used for all subsequent LFIA experiments, 
except only TMB substrate was employed for detection of the test and control lines. In each 
assay the developed test line represents the scFv captured-MPO detected with TMB substrate 
and the control line shows the HRP-labelled Ab reacting with the TMB substrate. Prior to the 
identification of this finalised protocol, however, several preliminary LFIA experiments were 
performed involving optimisation of several components of the assay procedure such as 
spotting buffer, scFv spotting concentration, sample application and running/wash buffers 
used. One of these preliminary experiments examined the combination of various spotting 
buffers with various running buffers for use in the LFIA experiments (Figure 3.4.15 b).  
 
Table 3.4.15 Various buffer combinations used for LFIA experiments 
Label Spotting Buffer Running buffer 
A 
Borate (0.1% (w/v) BSA, 0.05% (v/v) 
Tween, 0.01% (v/v) Triton X) 
Borate (0.05% (v/v) Tween) 
B 
Borate (0.1% (w/v) BSA, 0.05% (v/v) 
Tween, 0.01% (v/v) Triton X) 
50mM sodium phosphate, pH 7.5 + 
0.05% (v/v) Tween 
C 
Borate (0.1% (w/v) BSA, 0.05% (v/v) 
Tween, 0.01% (v/v) Triton X) 
50mM sodium phosphate, pH 7.5 
D 
50mM sodium phosphate, pH 7.5 (1% (w/v) 
trehalose) 
50mM sodium phosphate, pH 7.5 + 
0.05% (v/v) Tween 
E 
50mM sodium phosphate, pH 7.5 (1% (w/v) 
trehalose) 
50mM sodium phosphate, pH 7.5 
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Figure 3.4.15 (b) Developed nitrocellulose membrane strips from LFIA optimisation 
experiments. Strips A – E represent various buffer combinations (Table 3.4.15) used for the 
LFIA experiments. Each of the strips was sprayed with a test line (purified MPO-specific 
scFv) and also a control line (HRP-labelled anti-rabbit antibody).  
 
A selected scFv spotting concentration of 500 µg/mL was applied for each strip. 
Additionally, a concentration of 1 µg/mL of MPO was used for each of the five strips in this 
comparative experiment. On analysis of each of the developed LFIA strips, it was clear that 
combination D produced the most optimal conditions. In comparison to strips A and B, a 
clear defined test line band was observed for combination D (spotting buffer - 50mM sodium 
phosphate, pH 7.5, containinmg 1% (w/v) trehalose and running buffer - 50mM sodium 
phosphate, pH 7.5 + 0.05% (v/v) Tween). Furthermore, these experiments demonstrated the 
importance of the presence of 0.05 % (v/v) Tween in the running buffer solutions. It was 
discovered that the use of a buffer without Tween resulted in unsuccessful migration of the 
MPO protein up the strip. Instead the MPO stayed at the application area (bottom of the 
nitrocellulose membrane) where it was detected with the TMB substrate.  
No ‘negative control’ had been incorporated for initial testing. Therefore, a further LFIA 
experiment was set up examining the detection of a range of MPO concentrations (1000, 500, 
250, 125, 62.5 ng/mL). In addition, a ‘negative control’ was included in the experiment 
involving the application of running buffer to one of the strips containing no spiked MPO 
(Figure 3.4.15 c). Again, the scFv spotting concentration was set at 500 µg/mL and buffer 
combination D was implemented for this assay.  
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Figure 3.4.15 (c) Developed nitrocellulose membrane strips from LFIA optimisation 
experiments. Strips 1 - 6 represent the detection of 1000, 500, 250, 125, 62.5 and 0 ng/mL of 
MPO-spiked running buffer, respectively. Each of the strips was sprayed with a test line 
(purified MPO-specific scFv) and also a control line (HRP-labelled anti-rabbit antibody). 
 
A good correlation was observed between the band strength and the concentration of MPO, 
where a clear pattern was evident. Moreover, no band was observed for the ‘negative control’ 
strip, which further validates the sensitivity and specificity of the LFIA. The final optimised 
LFIA experiment data, including a critical discussion of its potential use as a point-of-care 
(POC) assay may be found in section 3.5.4. 
 
3.4.16 Discussion of results 
 
Due to the impressive performance of the avian immune system in the generation of highly 
sensitive and specific CRP-specific scFv clones, it was decided to take advantage of this 
refined host for the generation of an MPO-specific scFv library. Avian hosts were combined 
with the use of the pComb system for construction of the MPO-specific library. As 
previously discussed, this system proved to be highly efficient in terms of both the ease of 
construction and subsequent characterisation of antibody libraries. 
As described for the screening approach of the murine scFv library, an initial preliminary 
ELISA was performed for the identification of MPO-specific clones. However, due to 
differences in antibody expression and valency, the signal intensity of such assays cannot be 
reliably linked to antibody affinity (Steukers et al., 2006). Furthermore, antibody 
concentration determinations are required prior to affinity constant determination. For this 
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reason, implementation of a complete ELISA-based screening strategy can prove to be both 
considerably labour-intensive and time-consuming. Therefore, for this library, an alternative 
more refined screening strategy was implemented, as opposed to the ELISA-based screening 
strategy employed for screening of the CRP-specific murine library (sections 3.2.8 and 3.2.9). 
A successful high-throughput screening (HTS) campaign involves ranking of promising 
candidates through a series of different screening assays that are both high-throughput and 
informative. The Biacore-based strategy employed for this library achieved both of these 
essential characteristics and enabled the identification of several high affinity MPO-specific 
scFv clones. Moreover, the off-rate approach enabled the identification of clones possessing 
high expression levels such as the B10B, which proved to be significantly advantageous for 
their purification and subsequent incorporation into the developed LFIA. Initially, obtaining 
reliable kinetic Biacore data on the MPO-specific B10B scFv proved somewhat troublesome 
due to the highly cationic nature of MPO. However, an optimised protocol was developed 
(section 2.11.12) for immobilisation of the Biacore CM5 chip. This enabled reliable kinetic 
data to be gathered on the scFv, without any interference from non-specific cationic 
interactions. An affinity of 1.86 x 10-10 M (186 pM) was extrapolated from the kinetic data of 
the B10B scFv, which was found to be well within the clinically relevant reference range. 
According to a key study by Baldus and colleagues (Baldus et al., 2003), a threshold level of 
350 ng/ml (2.33 nM) proved to be optimal in predicting cardiac risk in ACS patients. Thus, 
the isolated MPO-specific B10B scFv clone (affinity of 186 pM) has the ability to detect 
MPO well within such clinically relevant threshold levels. 
The peroxidase nature of MPO provided a unique opportunity to develop a novel assay for its 
rapid detection. Initially, a proof-of-principle’ ELISA was performed to determine the ability 
of TMB substrate to detect the B10B scFv-captured MPO, which proved successful. In terms 
of the combination of the use of TMB substrate with a capture-based immunoassay, a similar 
product is the InnoZyme™ Myeloperoxidase Activity Kit developed by Calbiochem. This kit 
is designed to measure human myeloperoxidase activity in cell lysates and biological samples 
and to screen enzyme inhibitors. This particular assay was employed by Baldus and 
colleagues (Baldus et al., 2003) in the ground-breaking study investigating the ability of 
MPO serum levels to predict risk in ACS patients. The ELISA-based approach of this assay, 
however, means several time-consuming incubation and wash steps contribute to an overall 
poor TAT for the assay. For this reason, an alternative platform was decided upon for 
incorporation of the MPO-specific assay, namely LFIA. This robust LFIA technology 
provided a cheap and efficient method for developing a rapid, sensitive and specific assay for 
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the detection of MPO. The final optimised LFIA is discussed in more detail in section 3.5.1, 
including the advantages of having a one-step POC version of this assay available in the 
clinical arena. 
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3.5 Point-of-care platforms for 
detection of CRP and MPO 
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3.5.1 Point-of-care technology 
 
Point-of-care (POC) tests are a simple, rapid and relatively inexpensive means for reducing 
hospital stay, complications and improving adherence to treatment (McDonnell et al., 2009). 
The use of POC tests can lead to a reduction in test ordering, sample transport to laboratories 
and data reporting. Several high-throughput automated systems have enabled the introduction 
of a wide range of tests to be performed simply (no requirement for highly trained personal) 
and quickly (without the need for laboratory processing). Overall, there are mixed opinions 
regarding the issue of POC implementation. For instance, several POCT investigators have 
concluded that these POC analysers could serve as an alternative to lab analysers (Wu et al., 
2004; Ordonez-Llanos et al., 2006). In contrast, other studies have questioned the accuracy of 
the technologies (Agewall, 2003; James et al., 2004; Cramer et al., 2007). Several studies 
have investigated the implementation of POCT devices in a clinical setting. For instance, a 
study by Rathore and colleagues (Rathore et al., 2008) explored the application of the ‘Triage 
Cardiac Panel’ (Biosite) in a hospital A & E department. This panel consisted of the 
simultaneous detection of the three cardiac biomarkers of creatine kinase MB (CK-MB), 
myoglobin and cardiac troponin I (cTnI). The study concluded that the POCT device had the 
potential to significantly reduce hospital admissions of patients in the low to intermediate risk 
range. A clinicians experience of using a cardiac POCT device (developed by Roche) in a 
clinical setting (Alehagen and Janzon, 2008), whereby the device was compared to the 
performance of a clinical laboratory assay, concluded the POC device to be potentially useful 
in the clinical setting, with comparable results to the central lab system. A further study by 
Apple and colleagues (Apple et al., 2006) demonstrated both the cost effectiveness and 
clinical efficacy of implementation of a POC assay by Dade Behring. Use of the POCT 
device led to a significant decrease in assay TAT compared to the central laboratory and also 
a 25% decrease in total charges, saving an estimated $4,281 per patient admission.   
The two main types of POC testing formats available in the clinical setting include small 
bench-top analysers and hand-held devices. Small bench-top analysers are basically a 
miniaturised version of the mainframe central lab equipment, except with essential 
modifications to prevent operator error and provide rapid, reproducible results. Hand-held 
devices are developed using state-of-the-art microfabrication techniques, which essentially 
integrate several key analytical steps i.e. sample clean-up, separation, analysis and data 
reporting. Devices for cardiac biomarker POC testing are predominantly based upon 
immunoassay methods. The current formats for these devices are principally 2-site 
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immunometric methods, lateral-flow technology (LFT) and flow-through immunoassay 
systems. However, rapid development in the field of antibody-based biosensors is predicted 
to lead to a new era in POCT design (Sluss, 2006). An example of this is the validation of a 
Resonant Acoustic Profiling ™ (RAP™) (McBride and Cooper, 2008) system for 
quantification of CRP levels in serum samples. Although not a prototypical POCT, this 
system is label-free and shows good correlation with a commercial hs-CRP ELISA but with a 
much reduced sample analysis time.  
 
3.5.2 Lateral flow immunoassay (LFIA) 
 
A classic POC technique which continues to be successfully applied in many fields is LFIA. 
LFIA is designed as a robust and user-friendly immunochemical method suitable for specific 
semi-quantitative detection of analytes. This technique needs only low-cost instrumentation 
and enables significant reduction of the assay duration when set against ELISAs on 
microtitration plates. Such favourable characteristics have led to the application of LFIA 
technology across a wide range of areas (Henderson and Stewart, 2000; Aldus et al., 2003; 
O'Keeffe et al., 2003; Salomone et al., 2004; Edwards and Baeumner, 2006; Koets et al., 
2006; Wang et al., 2006; Kalogianni et al., 2007; Wang et al., 2007; Corstjens et al., 2008; 
Posthuma-Trumpie et al., 2009). The lack of any specialised storage conditions such as 
refrigeration, make this technology an ideal test format for biomedical puposes in third-world 
countries. Moreover, visual interpretation of the results is often satisfactory. Large batches of 
these devices may be prepared due to their extensive shelf-life, which in turn can lead to a 
reduction in variation between batches. Another appealing characteristic of LFIA’s is their 
disposable single use design, which rules out the possibility of any contamination with 
previously tested samples. 
As discussed in section 3.4.13, the intrinsic enzymatic activity of MPO provided a unique 
opportunity for its detection in a novel assay format. The exploitation of the peroxidase 
nature of MPO, eliminated the need for the standard sandwich-based format to be used. This 
removes additional steps in the assay such as the addition of a secondary conjugate antibody, 
reducing both assay TAT and also cost. Therefore, to ensure such beneficial characteristics 
were maintained in the final MPO-specific assay, it was decided to combine this novel assay 
format with the well-established technology of LFIA.  
Following the optimisation of several parameters (section 3.14.4) of the MPO-specific LFIA, 
the detection of MPO from depleted human serum was investigated. The fully optimised 
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protocol for the LFIA may be found in section 2.12.1. As a comparison, several 
concentrations of MPO were spiked into both MPO-depleted human serum (HyTest) and also 
LFIA running buffer (50 mM sodium phosphate, pH 7.5, containing 0.05% (v/v) Tween). 
MPO was spiked into both the serum and buffer to concentrations of 500, 50 and 5 ng/mL. 
Additionally, control samples containing no spiked MPO were also prepared in both, to 
identify any non-specific background signal. Each of the serum- and buffer-spiked samples 
were prepared from an initial working-dilution of the MPO diluted in sterile filtered PBS. 
This approach was performed to avoid any potential variation between both sets of dilutions, 
which may become an issue when the dilutions are prepared from a concentrated stock of the 
analyte. Furthermore, the LFIA using both the serum and buffer methods were performed 
simultaneously to reduce any inter-assay variability. The developed LFIA strips (8 in total) 
using both methods are shown in Figure 3.5.2.  
 
     A1      A2       A3      A4     B1      B2       B3      B4   
 
 
 
 
 
 
 
 
 
 
Figure 3.5.2 Developed LFIA strips from an the fully optimized assay, performed in both 
MPO-depleted human serum (A) and 50 mM sodium phosphate, pH 7.5, containing 0.05% 
(v/v) Tween (B). MPO was spiked to final concentrations of 500, 50, 5 and 0 ng/mL (1, 2, 3 
and 4) for both methods. 
 
Detection of both the 500 and 50 ng/ml (S1, S2 and B1, B2) concentrations of MPO-spiked 
serum are evident from Figure 3.5.5, where clear defined bands may be observed at the test 
line. A lighter yet distinct band was also observed by eye for the 5 ng/ml concentration of 
MPO tested, however, the camera was unable to clearly capture the relevant band. In any 
case, detection of MPO at this range is not required as clinical studies investigating the use of 
MPO as a risk predictor have identified concentrations as high as 350 ng/ml as being 
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clinically relevant threshold values (Baldus et al., 2003). The key novel aspect of this LFIA is 
the combination of a highly specific and sensitive recombinant antibody fragment with the 
rapid reactivity of the TMB substrate with MPO.  Furthermore, the incorporation of this 
system into a lateral flow strip, allows for the highly specific and sensitive detection of MPO, 
at a patients bedside, in approximately 20 min. Considering a prototype strip would contain 
both pre-sprayed test and control lines, the turn-around-time (TAT) mentioned, refers to the 
actual performance of the assay i.e 20 min.  
As with any technology, LFIA has several limitations associated with its use. As was the case 
for the developed MPO-specific LFIA, a standard nitrocellulose material was employed. This 
mesh-like membrane is one of the most popular membranes used for LFIA devices 
(Henderson and Stewart, 2000; Paek et al., 2000; Lönnberg and Carlsson, 2001; Oku et al., 
2001; Zhu et al., 2002; Kim et al., 2003; Leung et al., 2003; O'Keeffe et al., 2003; Jin et al., 
2005; Edwards and Baeumner, 2006; Zhang et al., 2006; Kalogianni et al., 2007) and is 
available in various pore sizes ranging from 0.05 to about 12 μm. However, these pores are 
not randomly distributed because of the manufacturing process and this can lead to 
inconsistent or poor flow rates. In addition, usually the nitrocellulose material to be used for 
production of the LFIA device can be stored at ambient temperature and humidity; however, 
at low humidity, handling of the material can be difficult owing to accumulation of static 
electricity (Posthuma-Trumpie et al., 2009). Non-specific signal in nitrocellulose-based 
assays has also been highlighted as a significant problem for the diagnostic industry (Jones, 
1999). In general, LFIA’s are only capable of providing qualitative data, where the exact 
level of the detected analyte remains unknown. This characteristic is one of the main 
limitations associated with the use of LFIA in the field of diagnostics. One method used to 
circumvent this problem, is the incorporation of a dedicated fluorescent reader, which allows 
for quantitative data on the analyte to be obtained. An example of such a platform is the 
4castchip ™ developed by Åmic AB (Uppsala, Sweden). This open lateral flow (OLF) device 
was investigated for the development of a sandwich-based assay for the detection of CRP 
(next section). 
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3.5.3 Amic Open Lateral Flow (OLF) platform 
 
In addition to its ability to provide quantitative information on an analyte, the 4castchip ™ 
has several other beneficial attributes over standard lateral flow systems. This micro 
structured plastic device is composed of a highly ordered array of micro pillars (Figure 3.5.3 
a). These custom designed micro pillars drive the flow of liquid in an open channel by 
capillary action, which generates wicking capabilities far superior to that of standard 
nitrocellulose-based LFIA. The flow of liquid through the chip is controlled by both the pillar 
geometry and the channel length, made possible via an extremely reproducible manufacturing 
technology. Such is the precision of this technology that every manufactured chip possesses 
an identical surface flow rate. Moreover, the chip surface also provides a biocompatible 
surface for the attachment of capture ligands at test and control lines. Therefore, the Amic 
device offers the capacity for multiple functionality, where the pillar-defined flow path can 
act as a sample application area, reaction surface and wick. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.3 (a) The Open lateral flow 4 castchip ™ (left) and a magnified image of the 
micro-pillar structures (right). 
 
The aldehyde-functionalised surface chemistry of the 4castchip ™ allows for simple coupling 
of capture molecules to the chip. Amine groups on the capture probes react by a simple one-
step Schiff’s base reaction to couple covalently to the chip surface. This novel surface 
chemistry also leads to a reduction in background signal from non-specific binding. Also, the 
hydrophilic nature of the surface is comparable with protein surfaces such as BSA which, 
unlike conventional lateral flow matrices, obviates the requirement for any blocking steps. 
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A competition-based approach was decided as the assay format for detection of CRP (See 
Figure 3.5.3 b). The ‘in-house’ CRP-specific antibodies chosen for the assay were the four 
scFv antibodies (F8, F8, G5 and H2) from the immune avian library (See sections 3.3.4 and 
3.3.5). Two commercial anti-CRP mAb’s (M701289 and M7111422, Fitzgerald, MA) were 
also incorporated into this comparative assay. A negative control in the form of an anti-cTnI 
scFv was also used in the assay, to identify the background binding level. Finally, to ensure a 
realistic sample matrix, CRP-depleted serum was the medium employed in the assay (See 
section 2.12.2 for the full protocol). 
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Figure 3.5.3 (b) Assay format for competitive CRP assay on an open lateral flow 4castchip™ 
chip. The ‘immobilised antibody zone’ of each chip was coupled with one of the six 
antibodies discussed. A defined mixture of unlabelled and labelled CRP was applied to the 
‘sample application zone’, which travels up via capillary action towards the immobilised 
antibodies. The unlabelled CRP and the fluorescently-labelled CRP compete for binding to 
the immobilised antibodies. 
 
The assay comprised each of the 6 capture antibodies (4 anti-CRP scFv, 2 anti-CRP mAb and 
1 anti-cTnI scFv) being spotted onto individual chips. Next, CRP-depleted serum was spiked 
with seven concentrations of CRP antigen (30, 10, 3.3, 1.1, 0.55 and 0 µg/mL). CRP antigen 
labelled with a commercial fluorophore (Alexa 647) was added to each of the spiked samples 
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to a final concentration of 100 ng/mL and each mixture then applied to each of the chips in 
triplicate. The unlabelled CRP and the fluorescently-labelled CRP compete for binding to the 
strip containing the immobilised antibodies. The higher the spiked unlabelled CRP antigen 
concentration in the samples, the lower the quantity of bound labelled CRP antigen that binds 
to the immobilised antibody layer, hence, the lower the final fluorescent signal.  
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Figure 3.5.3 (c) Plotted competition ELISA data for all four purified avian anti-CRP scFv 
antibodies and two commercial CRP specific mAb’s (Fitzgerald). 
 
The plotted data for the competitive binding assay is shown in Figure 3.5.3 (c). Each of the 
plots shown were normalised to background using an unrelated anti-cardiac troponin I (cTnI) 
recombinant antibody. Comparable depletion of the labelled anti-CRP antigen was observed 
for each of the four avian anti-CRP scFv clones to that of the commercial Fitzgerald mAb’s 
and also no cross reactivity was observed for the avian anti-cTnI scFv clone. 
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As previously discussed, the 4castchip™ offers a superior alternative to that of standard 
nitrocellulose-based LFIA’s. However, the requirement for chips to be handled individually 
could be considered a drawback from a processing standpoint, by contrast with the ability of 
materials such as nitrocellulose to be processed in-line. Additionally, application of the test 
sample (spiked CRP-depleted serum in this case) to the ‘sample application zone’ must be 
highly regular, reproducible and carefully controlled to ensure assay consistency. Another 
potential cause of variation in this particular assay may be caused by the wash step (section 
2.12.2) that must be performed to remove any non-specific material from the readout site 
(immobilised antibody zone).  
 
3.5.4 Parabolic chip platform 
 
One approach to circumvent the problem of ‘wash step variation’ is the employment of 
supercritical angular fluorescence (SAF) detection technology (Laib et al., 2006). The use of 
SAF confines the fluorescence detection volume strictly to the close proximity of the biochip 
surface (surface confined fluorescence), whereas collecting below the critical angle allows 
gathering of the fluorescence emitted several microns deep inside the sample. Consequently, 
the signals from surface-bound and unbound diffusing fluorescent molecules can be obtained 
simultaneously (Verdes et al., 2007). This removes the requirement for a wash step due to the 
devices ability to distinguish between the non-specific fluorescent signal in the bulk mixture 
from the specific fluorescent signal at the chip surface. In addition to a reduction in assay 
variation, the removal of wash steps may also lead to a significant decrease in the assay TAT. 
A common downfall of many diagnostic platforms is the poor signal to noise ratio associated 
with them. However, the ability of SAF technology to achieve highly specific surface 
excitation, leads to a more accurate and sensitive detection of analyte. An example of a 
biosensor employing SAF-based detection is the parabolic chip developed at the Biomedical 
diagnostic Institute (BDI) in Dublin City University (DCU), Ireland. Huge advances in 
injection moulding technology have led to the ability to mass produce novel lab-on-a-chip 
platforms (Tüdős et al., 2001; Yakovleva et al., 2002; Kim et al., 2005; Situma et al., 2006) 
possessing superior accuracies at sub-micron levels. This capability has led to the 
development of the lab-on-a-chip format such as the BDI proprietary parabolic chip. This 
novel biochip platform is composed of a low auto-fluorescence zeonex polymer (refractive 
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index 1.52). The biosensor chip (Figure 3.5.4 a) consists of a 3 x 3 annular aperture array, 
allowing for a total of nine biochemical surface reactions to be monitored in ‘real time’.  
  
 
 
Figure 3.5.4 (a) Parabolic array format of biochip together with microfluidic channel for 
sample delivery (left). Annular aperture mask for blocking non-Total Internal Reflection 
Fluorescence (TIRF) excitation and non-SAF emission (right). TIRF excitation is the 
phenomenon of total internal reflection, which occurs at the interface between optically dense 
medium, such as glass, and optically less dense medium such as water or an aqueous solution. 
At large angles of incidence, the excitation beam reflects back into the glass and generates an 
evanescent wave at the water interface. The evanescent wave has a maximum intensity at the 
surface and exponentially decays with the distance from the interface. Only molecules that 
are at the TIRF surface are excited and fluoresce, while molecules in the bulk of solution, at 
distances larger than 100-200 nm are not excited and, respectively, do not fluoresce. 
 
The enhancement of fluorescence capture, using this biosensor, is of the order of 100-fold. 
Following completion of the assay, a collimated excitation beam (Figure 3.5.4 b) is 
supercritically reflected off the edges of the paraboloid so that excitation of fluorophores on 
the polymer-liquid interface occurs due to an evanescent wave. Subsequently, light from 
surface-bound fluorophores is emitted preferentially into supercritical angles i.e. supercritical 
angle fluorescence (SAF). This emitted light is then collected again by the paraboloid edges 
and reflected into a ‘loss-free’ collimated beam towards a detector. 
 
 
172
  
Figure 3.5.4 (b) Optically engineered biosensor platform (left) that focuses collimated light 
onto surface above critical angle to produce surface-confined TIRF excitation and the same 
platform exclusively collects SAF fluorescence above the critical angle (right). 
 
The immobilisation of antibodies onto such polymer substrates requires the surface to be 
functionalised with groups capable of binding antibody structures. Amine and carboxyl 
groups within the antibody structure provide a site of attachment to the corresponding 
carboxyl group or amine groups located on the substrate. Following functionalisation of the 
chip surface using an aldehyde-activated dextran surface coating, the antibody-compatible 
surface is ready for deposition of the antibodies and commencement of the assay (section 
2.12.3).  
 
A fluorescent-based assay involving the detection of CRP from depleted human serum was 
performed on the parabolic chip platform. The fluorescent assay utilised a sandwich-based 
format involving an optimised concentration of capture antibody (purified anti-CRP pAb – 
section 3.1.4) deposition onto the functionalised paraboloids. Previously, several spotting 
concentrations of the capture pAb (ranging from 50 - 300 µg/mL) were investigated for 
determination of the most optimal coating concentration. Comparable results were observed 
for the capture Ab at concentrations of 200 µg/mL and 300 µg/mL, indicating the possibility 
of a saturation effect occurring above 200 µg/mL. Therefore, to limit both pAb stacking and 
also the quantity of pAb used, a capture concentration of 200 µg/mL was used in all 
subsequent experiments.  
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Figure 3.5.4 (c) Calibration curve for the determination of CRP levels from depleted human 
serum using a sandwich-based assay on a paraboloid chip. Purified unlabelled CRP-specific 
rabbit pAb was spotted on the parabolic chip surface (capture antibody). Various 
concentrations of CRP-spiked depleted human serum were tested for binding. Detection of 
the complex was achieved using fluorescently labelled rabbit anti-CRP pAb. The plotted 
results represent the mean response ± SD (vertical eror bars) over each of the 3 days during 
which the assay was performed. 
 
Figure 3.5.4 (c) shows a plot of 9 separate assays (performed in triplicate over 3 days) 
involving CRP antigen spiked into CRP-depleted serum at 8 different concentrations (10, 3.3, 
1.0, 0.33, 0.1, 0.033, 0.01, 0 µg/mL). Detection of the CRP-pAb complex was accomplished 
using a fluorescently labelled sample of the same anti-CRP pAb deposited on the paraboloids. 
The pentameric nature of CRP enables the capture and detection pAb, employed by the assay, 
to be identical.  
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Figure 3.5.4 (d) Calibration curve for determination of CRP levels using a sandwich-based 
assay on the parabolic chip. See legend of previous Figure (Figure 3.5.4 c) for full description 
of the assay format. The calibration curve was generated using the Biacore Biaevaluation 
software package, as described in section 3.1.7. 
 
The raw data was then subject to the same evaluation process as described for the Biacore 
pAb data in section 3.1.7. A 4-parameter equation was employed to generate a plot of the 
mean fluorescent values (F/Fo) against the spiked CRP concentrations (Figure 3.5.4 d). The 
resultant output values were then incorporated into an equation to determine the % accuracy 
values, which are shown in Table 3.5.4.  
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Table 3.5.4 Processed data from the fluorescent sandwich CRP assay on the parabolic chip 
platform using dedicated Biacore Biaevaluation software package (see section 3.1.7 for full 
description of data processing) 
S.D. – Standard Deviations 
CRP conc. (ng/mL) S.D. values Biaevaluation 
Output value 
% Accuracy value 
10000 0.54 Low - 
3333 0.38 2191.7 65.8 
1000 0.21 1112.9 111.3 
333 0.38 353.2 106.1 
100 0.22 93.7 93.7 
33 0.26 36.7 111.1 
10 0.11 8.5 84.6 
 
The output % recovery values in Table 3.5.4 demonstrated a good correlation within the 
assay. Therefore, this experiment has successfully demonstrated ‘proof of concept’ for this 
novel parabolic format for the detection of CRP. This particular platform offers many 
beneficial characteristics, particularly the incorporation of the SAF technology. As was 
discussed earlier, the use of such technology can remove the need for time-consuming wash 
steps. In the experiments shown, however, wash steps were performed prior to detection of 
the resultant fluorescent signal. This was due to further optimisation being required on the 
instruments ability to distinguish between the bulk and specific surface-bound signal on the 
chip. Although this platform is an exciting prospect for biosensors, the requirement for 
fluorescently-labelled antibody or analyte may be considered a major disadvantage. For 
instance, fluorescent labels can be vulnerable to degradation over time. Commonly used 
fluoresecent labels have been shown to be susceptible to ozone damage and also 
photobleaching (Dar et al., 2008). Several key issues must be addressed when choosing a 
fluorescent label that is compatible with the biological material being investigated. Firstly, 
the label must be conveniently excitable, without simultaneous excitation of the biological 
matrix. Secondly, that it possesses a high molar absorption coefficient at the excitation 
wavelength and a high fluorescence quantum yield (ratio of photons absorbed to photons 
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emitted through fluorescence). Thirdly, the label must be soluble in relevant buffers and also 
stable under relevant conditions used in the assays. Another important consideration includes 
the issue of steric and size-related effects of the label (Resch-Genger et al., 2008). All of 
these issues can have a detrimental effect on the overall assay efficiency and reproducibility 
if not properly addressed. The use of label-free detection systems is one technique which has 
the ability to overcome such problematic issues. Label-free based detection systems have 
been associated with major benefits such as faster assay development times, greater accuracy, 
the ability to generate high information content data and finally less interference from labels 
(Cooper, 2006). Such characteristics have led to a revolution in the development of label-free 
based detection systems such as the SPR-based Biacore™ systems. The first application of 
this breakthrough technology was more than two decades ago, yet SPR remains a central tool 
for characterizing and quantifying biomolecular interactions. Since then, SPR sensor 
technology has been commercialised by several companies and has become a leading 
technology in the field of direct real-time observation of biomolecular interactions (Homola 
et al., 1999). SPR sensors have made vast advances in terms of both development of the 
technology and its applications (Homola, 2008). The SPRSpectral® system, developed at the 
Institute Photonics and Electronics in the Czech Republic, is an example of a SPR-based 
POC device. This device was employed for the final characterisation of the re-engineered 
CRP-specific H2 avian scFv (section 3.3.6 – 3.3.8). 
 
3.5.5 SPRSpectral® platform 
 
Presently, a wide range of configurations of SPR biosensors have been applied to monitoring 
biomolecular interactions (Lukosz et al., 1991; Brandenburg and Gombert, 1993; Buckle et 
al., 1993; Cush et al., 1993; Gauglitz et al., 1993, Heideman et al., 1993; Clerc and Lukosz, 
1997; Schmitt et al., 1997; Heideman and Lambeck, 1999; Ymeti et al., 2005; Schmitt et al., 
2007). An example of some of the most popular configurations used can be found in Figure 
3.5.5 (a). Although an extensive range exists, each of the devices is based upon the same 
principle. This principle involves the measurement of refractive index changes occurring in 
the field of an electromagnetic wave supported by the optical structure of a sensor.  
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(A) 
(C) 
(B) 
Figure 3.5.5 (a) Most widely used configurations for SPR sensors: (a) prism coupler-based 
SPR system - Attenuated Total Reflection (ATR) method; (b) grating coupler-based SPR 
system and (c) optical waveguide-based SPR system. 
 
The SPRSpectral® system employed in this work falls under the category of a prism coupler-
based configuration (A). The SPRSpectral® system uses a white light source with a spectral 
distribution ranging from 390 to 1070 nm. A Gaussian profile (bell-shape curve) is produced 
by the system with a maximum output at 680 nm. The actual SPR coupling occurs in the 700-
800 nm range, with the angle between the light source and the sample remaining fixed. 
Analysis is performed in four independent test channels, each with an area of 2 x 4 mm2 and 
a height of 60 nm. The light emitted from each channel is collected on independent optic 
fibres and the resultant signals are converted for posterior analysis. The area between the gold 
film and the light beam is the PMMA substrate (18 x 32 mm2) with is coupled to the prism 
using immersion oil (Plasmon IV immersion oil type A, Cargille). Cleaning of the system 
between experiments is performed according to the following sequence: 4 min with ultra-pure 
water, 1 min with 50mM NaOH, 4 min again with ultra-pure water and finally flushing of the 
system with compressed air. 
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As discussed in section 3.3.6 to 3.3.8, the highest affinity CRP-specific H2 scFv generated 
from the immunised avian library (section 3.3) was subjected to a novel re-engineering 
strategy. This re-engineering process involved the conversion of the H2 scFv fragment to a 
scAb fragment via fusion of the scFv to a chicken Cλ chain. The resultant D9 scAb fragment 
may be directly conjugated to a gold surface via the unique cysteine residue at the terminal 
site of the fused chicken Cλ chain. A free-thiol group provided by the terminal uncoupled 
cysteine residue reacts with the gold surface forming a relatively stable covalent bond. In 
addition to the fragments ability to achieve direct conjugation to a gold surface, the terminal 
location of the reactive site allows the fragment to assume a fully-functional conformation.   
 
IMAC-purified D9 scAb (see Figure 3.3.8) was incorporated into a direct binding assay for 
CRP. To further validate the application of this assay in a clinical environment, depleted 
human serum was the sample matrix chosen for the assay (full protocol in section 2.12.4). Six 
concentrations of CRP were tested (200, 400, 600, 800, 1000 and 1200 ng/mL), as well as a 
zero concentration involving unspiked CRP-depleted serum. For each of the concentrations 
tested, a set concentration of the purified D9 scAb (15 µg/mL) was immobilised onto the gold 
surface. 
 
As was described in the full protocol in section 2.12.4, a new baseline was calculated 
following the addition of each of the experimental solutions (CRP-specific D9 scAb, 
blocking solution, CRP spiked serum/unspiked serum). Each of the new baseline levels were 
identified by passing degassed 1 x PBS across the modified test channels. In order to simplify 
the experiment, each of the solutions passed across the test channels were identified as a label 
shown below: 
 
1.  Baseline: ultra-pure water 
2. Baseline: 1 x PBS 
3. D9 scAb immobilisation 
4. Baseline: 1 x PBS 
5. Blocking reagent 
6. Baseline: 1 x PBS 
7. CRP spiked serum/unspiked serum 
8. Baseline: PBS 1x 
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Therefore, quantification of the materal absorbed on the surface was obtained from the 
calculations below: 
 
Table 3.3.5 Calculations for quantification of material absorbed onto test channels 
Step for quantification Calculation 
D9 scAb immobilisation SPR signal (4.) minus SPR signal (2.) 
Blocking solution SPR signal (6.) minus SPR signal (4.) 
CRP binding reponse SPR signal (8.) minus SPR signal (6.) 
 
Each of the concentrations tested were performed in triplicate and Figure 3.3.5 (b) shows the 
plotted average reponse for each of the six concentrations used minus the zero concentration. 
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Figure 3.3.5 (b) Plotted data for a direct binding assay using a novel CRP-specific scAb 
fragment on the SPRSpectral® platform. The average responses for each of the six 
concentrations of CRP (200, 400, 600, 800, 1000 and 1200 ng/mL) performed in triplicate are 
shown. The plotted results represent the mean response ± SD (vertical error bars), over the 3 
data points taken for each concentration (n = 3). 
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Following analysis of the final plotted data of the CRP binding reponses for each of the six 
spiked concentrations tested (Figure 3.3.5 b), a good correlation was evident with relatively 
minor standard deviations. One of the main advantages of the SPRSpectral® system was its 
enclosed flow-based format. Some of the previously discussed POC platforms, such as the 
OLF systems are lacking in this respect and, consequently, may suffer from problems such as 
sample evaporation. As previously mentioned, the antibody fragment employed in this assay 
was the product of a novel re-engineering strategy. Another major limiting feature of some 
biosensor technologies is the requirement for conjugation of the biomolecules such as 
antibodies to a gold surface. These conjugations can prove to be not only time-consuming, 
but also may also potentially degrade the biomolecule through the use of certain coupling 
chemistries. This novel fragment, however, may be directly conjugated to gold surfaces via 
its incoporated terminal cysteine residue, removing the need for potentially inefficient 
conjugation steps. The employment of such a strategy can, therefore, expedite the route from 
antibody generation to functional biosensor assay development.  
 
3.3.6 Discussion of results 
 
The main drawback associated with central lab testing (CLT) is their general poor TAT, 
which can lead to significant problems in the emergency unit setting. Consistent poor assay 
TAT can result in critical issues such as increases in unnecessary patient admissions and 
length-of-stay (Murray et al., 1999; Lee-Lewandrowski et al., 2003), inaccurate identification 
of critically ill patients and poor patient clinical outcome (McCord et al., 2001; Ng et al., 
2001). The most recent guidelines from the American Heart Association (AHA) (Gibler et 
al., 2005) regarding unstable angina/non-ST-segment elevation myocardial infarction (MI) in 
the emergency department (ED) states that a turnaround time for laboratory results should not 
exceed 1 h when central laboratory testing is used. However, a comprehensive survey by 
Novis and colleagues (Novis et al., 2004) which assessed the TAT of over 11,000 cardiac 
biomarker tests in 159 institutions discovered that on average participants reported 90% of 
their order-to-report cardiac marker results in more than 90 min. Time-consuming tasks such 
as test ordering, sample transport to laboratories and data reporting may be avoided. 
Although, central lab testing is usually well validated, the much reduced human involvement 
accompanying POC testing (POCT) can lead to a significant decrease in both inter/intra assay 
variation and human error. This section demonstrated just some of the potential POC 
platforms which may be successfully applied in the clinical arena. Some of the platforms 
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discussed take advantage of key technologies such as novel surface chemistries, high 
precision microfluidics, SAF-based detection and label-free detection. It is felt that the 
application of such technologies to the clinical arena, can have a significant impact on the 
overall efficiency of cardiac diagnostics. 
As previously discussed in section 1.6, CRP remains a key marker in the cardiac arena. 
However, in general apparently healthy individuals with a hs-CRP value >8 mg/L require the 
test to be repeated to rule out a recent response to undetected infection or tissue injury. 
Consequently, a large quantity of hs-CRP tests must be performed in most hospitals. Since 
CLT is the most commonly used approach, this can cause a massive backlog in central 
laboratories, which in turn can lead to poor TAT and even result in subsequent patient death. 
Therefore, the availability of a rapid, highly sensitive and specific test for hsCRP, such as 
those discussed, could potentially alleviate some of this backlog and significantly reduce 
TAT’s. In the case of MPO, it has been demonstrated that a single measurement of this 
marker at hospital admission can predict the risk of major adverse cardiac events for both a 
30-day and six month period (Baldus et al., 2003; Brennan et al., 2003). Therefore, a method 
for the rapid detection of MPO from human serum may prove extremely useful in the clinical 
setting. Currently, analysis of this cardiac biomarker in patients sera is performed via central 
laboratory testing (CLT), which has been the subject of much criticism. Presently, the 
CardioMPO™ assay developed by PrognostiX is the only FDA approved assay for 
determination of MPO in the clinical setting. The sandwich-based ELISA format, however, 
means that several time-consuming steps i.e. washes, incubations etc. must be performed via 
an adequately skilled central lab, resulting in a poor overall TAT. Conversely, the use of a 
point-of-care (POC) version of the LFIA assay presented in this work, would remove the 
need for skilled lab personnel, while also significantly reducing the TAT associated with 
central lab testing. Such a significant decrease in assay TAT would greatly improve the triage 
of cardiac patients and would allow for more time and resources to be focused on those 
patients identified as being at a greater risk of having a cardiac event.  
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Chapter 4 
Conclusions 
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4.0 Conclusions 
 
The principal objective of this research was the production, characterisation and application 
of antibodies for the detection of both CRP and MPO. In the case of CRP, an initial pool of 
polyclonal antibody was generated and purified from New Zealand white rabbits following an 
extensive immunization strategy. The resultant polyclonal antibody harvested from the 
rabbits proved to be a highly sensitive and useful reagent. This pAb was successfully 
incorporated into both a fluorescent sandwich ELISA and also a direct capture assay on the 
Biacore 3000 system. Although the high sensitivity of the pAb is apparent on analysis of the 
fluorescent ELISA, a more accurate indication of the true sensitivity of the pAb was provided 
by the Biacore assay. The polyclonal preparation was found to have a sensitivity in the low 
nanomolar range, making it an ideal candidate for use as a capture agent in an immunological 
assay. Consequently, the final characterisation of the polyclonal antibody involved its use as 
both a capture and detection agent in a sandwich-based fluorescent assay on a novel parabolic 
chip. The pentameric nature of CRP enabled the capture and detection pAb, employed by the 
assay, to be identical. Data evaluation packages were employed for the analysis of the overall 
performance of the polyclonal antibody in both the Biacore and parabolic chip platforms. A 
high level of accuracy and reproducibility was evident following analysis of both assays 
using statistical analysis packages. Use of the parabolic chip allowed for the major benefits of 
SAF technology to be harnessed. Implementation of such technologies allows for highly 
specific surface excitation to be achieved, therefore, leading to more accurate and sensitive 
detection of the analyte. Although, polyclonal antibody remains to be a highly utilised 
immunological agent, they have an obvious limitation in terms of their overall specificity. For 
instance, the polyclonal antibody preparation was found to react with not only the immunised 
CRP protein but also its homologue SAP. Alternatively, the homogenous nature of 
monoclonal antibodies has led to their superiority in terms of specificity over polyclonal 
antibodies. 
For this reason, state-of-the-art recombinant antibody technology was harnessed for the 
generation of monoclonal antibody fragments to CRP. Both mice and chickens were 
investigated as immune hosts in the generation of CRP-specific scFv antibodies. Several 
problems were encountered throughout construction, screening and characterisation of the 
murine library (discussed in section 3.2.17). A major hindrance associated with the final 
characterisation of the murine clones was their poor expression levels. This was further 
exacerbated by the lack of any effective affinity tag of the pAK system used for construction 
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of the library. For this reason, the best performing murine scFv antibody (C11-2) was 
subcloned into an alternative vector (pComb3X). This system provided a highly specific HA 
affinity tag, which allowed for reliable kinetic data to be obtained using the Biacore system. 
A final affinity of 2.1 × 10-8 M was extrapolated from the kinetic data for the murine C11-2 
scFv subclone. A high level of purity is required for the incorporation of these scFv 
fragments into sensitive novel assay platforms, as discussed in section 3.3.5. Unfortunately, 
in the case of the murine C11-2 subclone, the production of large quantities of purified scFv 
for incorporation into such devices was not feasible due to its extremely poor expression 
levels. Consequently, the avian immune system was investigated for the generation of scFv 
fragments specific for CRP. An alternative system was employed for construction of the 
chicken scFv library, namely the pComb system. Following an intensive screening and 
selection strategy, four scFv clones were chosen (F6, F8, G5 and H2) from the library, based 
on their affinities for the CRP antigen (2.54×10-8 M, 1.01×10-8 M, 3.52×10-9 M, 3.53×10-10 
M, respectively). Large yields of expressed scFv were obtained for each of the four fully-
characterised scFv clones, with F8 being particularly good. A 500 mL bacterial culture of the 
clone produced approximately 15.5 mg of pure scFv using a simple IMAC purification 
protocol.  All four of the clones proved to be ideal candidates for model assay development 
due to their stable expression and high level of purity. Subsequently, each of the purified 
scFv fragments were incorporated into a competition-based assay on a novel OLF device 
(4castchip™). The 4castchip™ offered a superior alternative to that of standard 
nitrocellulose-based LFIA’s and each of the recombinant fragments performances were 
comparable to that of two commercially available mAbs. Also, the highest affinity H2 scFv 
was subjected to a novel engineering process, allowing for its direct conjugation to gold 
biosensor surfaces via a terminal thiol group. Therefore, the final characterisation of the re-
engineered CRP-specific fragment involved incorporation into the SPRSpectral® system. 
The re-engineered fragment was successfully applied in this commercial platform, efficiently 
detecting a range of concentrations of CRP, showing good overall reproducibility. 
Consequently, this platform was able to take advantage of the novel engineering process 
administered on the avian H2 scFv, which validates this novel strategy as an alternative 
approach to bioconjugation of antibodies to such platforms.  
Due to the impressive performance of the avian immune system in the generation of highly 
sensitive and specific CRP-specific scFv clones, it was decided to take advantage of this 
refined host for the generation of an MPO-specific scFv library. Avian hosts were combined 
with the use of the pComb system for construction of the MPO-specific library. As 
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previously discussed, this system proved to be highly efficient in terms of both the ease of 
construction and subsequent characterisation of antibody libraries. Using an optimised ‘off-
rate’ ranking strategy, B10B was identified as the highest affinity clone. Following kinetic 
data analysis on the scFv an affinity of 1.86 x 10-10 M (186 pM) was extrapolated. This value 
was found to be well within the clinically relevant reference range. The peroxidase nature of 
MPO provided a unique opportunity to develop a novel assay for its rapid detection. Initially, 
a ‘proof-of-principle’ ELISA was performed to determine the ability of TMB substrate to 
detect the B10B scFv-captured MPO, which proved successful. This was then successfully 
transferred to a novel LFIA format, which allowed for the highly specific and sensitive 
detection of MPO. Considering a prototype strip would contain both pre-sprayed test and 
control lines, the turn-around-time (TAT) for the assay could be as little as 20 min. 
Spiked samples of depleted human serum were employed in each of the assay platforms, thus 
validating their performance in a clinically representative sample matrix. It is confidently 
anticipated that each of these systems will be successfully deployed in the clinical arena. 
Furthermore, some of the antibodies and platforms developed in this thesis are currently 
being evaluated by several companies with respect to their commercial potential. Recently, 
Biosurfit have exercised a licensing option on the developed CRP-specific scAb for use in 
their proprietary Lab-on-a-CD SPR-based platform. Also, Åmic (now part of Johnson and 
Johnson) are in the process of commercialising a cardiac test on their propietary OLF 
platform, using the protocols partially optimised in this research. The work herein also 
demonstrates the first working assay performed on BDI-patented SAF technology on a 
parabolic substrate. 
The primary location where some of the developed POC assays would be most beneficial 
would be in the coronary care unit (CCU) of hospitals, which specialises in the care of 
patients with heart attacks, unstable angina and various other cardiac conditions that require 
continuous monitoring. The POC format of the assay negates the need for skilled lab 
personnel, as nursing staff may perform the assay, following sufficient training on the correct 
use of the device. In fact, the previously mentioned study by Allehagen and colleagues 
(Alehagen and Janzon, 2008) investigated use of a POC device by nurses in the CCU, who 
found the assay easy to learn and the device simple to operate, without any impairment of the 
results obtained. Implementation of the device could, therefore, lead to a more efficient 
patient discharge system, which could lead to an increase in both effective use of bed 
capacity and minimise the need for patient admission to those with real problems. 
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Furthermore, a secondary location where use of the device may be required is in local GP 
practices, whereby discharged cardiac patients may be regularly monitored. This could 
significantly reduce the number of unnecessary patient admissions to hospitals, leading to a 
significant improvement in the use of scarce hospital resources. Inappropriate use of hospitals 
can result in lengthy discharge and admission cycles, emergency room (ED) over-crowding, 
higher ambulance diversion and potentially critical patients leaving without being seen. 
Therefore, delegation of some of the responsibility to GP practices could help to alleviate 
some of these potentially life-threatening situations. 
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7.0 Appendix 
7.1 Vector maps 
Several bacterial vectors were employed in this research to provide a means for efficient 
cloning, phage display and bacterial expression. The pComb3X vector was found to be the 
most robust vector for achieving each of these functions. 
7.1.1 pComb3XSS vector 
pComb3xSS
4973 bp
bla res
SD
OmpA leader peptide
hexa-histidine tail
HA tag
amber stop codon
Gene III
 
 
SfiI (283)
 
 
 
 
 
 
 
 
 
Xho I (1579)
XbaI (1472) 
 
 
 
 
SfiI (1955) 
 
 
 
 
 
 
 
 
Figure 7.1.1 The pComb3 phagemid vectors are designed to express antibody fragments and 
other proteins on the surface of filamentous phage or to express them as soluble proteins. The 
antibody fragments are fused to the carboxy-terminal domain of the minor coat protein (coat 
protein III). An amber codon has been inserted between the 3´ SfiI restriction site and the 5´ 
end of gene III. This allows for soluble protein expression in nonsuppressor strains of 
bacteria without excising the gene III fragment. A 6x histidine (HIS) tag has been inserted 
carboxy-terminal to the Fd fragment for universal protein purification. A hemagglutinin (HA) 
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decapeptide tag has been inserted at the 3´ end of the HIS tag for universal detection using an 
anti-HA antibody. This vector allows the expression of Fab, scFv, diabody, or other proteins. 
 
7.2 Process schematics 
 
7.2.1 Phage panning/selection process 
 
 
 
Figure 7.2.1 Phage selection strategy. Iterative selection shown here is a multistep process. V 
gene assembly by PCR allows cloning of the recombinant antibody (scFv is shown) library 
into E. coli cells. Subsequent rescue by helper phage allows for the propagation of the phage 
antibody library. Antigen presentation is a key consideration and there are many modes of 
antigen-phage antibody interaction. Serially increasing the stringency of washing after 
antigen presentation selects those phage displaying antibodies with highly specific binding 
properties. Elution strategies are also illustrated. 
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7.3 Tables 
 
7.3.1 Biochemical markers of the acute coronary syndromes 
 
Biochemical markers now play a fundamental role in the diagnosis, prognosis, monitoring 
and risk stratification of patients with acute coronary syndromes (ACS). The table below 
shows some of the most widely used cardiac biomarkers and their characteristics. 
 
Marker Structure Implications Utility 
Myoglobin 
18 kDa (single chain globular 
protein) 
Early acute 
myocardial infarction 
Re-infarction diagnosis 
Creatine-kinase MB 85 kDa 
Acute myocardial 
infarction 
Re-infarction diagnosis 
Myeloperoxidase 150 kDa (Dimeric enzyme) 
Inflammation/plaque 
rupture 
Short-term risk stratifier 
C-reactive protein 
125 kDa (pentameric form) 
25 kDa (monomeric form) 
Inflammation Long-term risk stratifier 
Brain natriuretic 
peptide 
17 kDa 
Ventricular 
overload/heart failure 
Infarct 
sizing/prognosticator 
Cardiac troponin I 
23.5 kDa (subunit of a ternary 
regulatory protein) 
Myocardial infarction Benchmark for MI 
diagnosis 
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